Subject Index to Volume 53

A

Acetazolamide
new CACNA1A gene mutation in acetazolamide-responsive familial hemiplegic migraine and ataxia (Battistini et al) 1999;53:38

Acetylcholine
chromosome 17p-linked myasthenias stem from defects in the acetylcholine receptor ε-subunit gene (Middleton et al) 1999;53:1076

Adolescents
changes of serum sICAM-1 and MMP-9 induced by rIFNβ-1b treatment in relapsing-remitting MS (Trojano et al) 1999;53:1402
MRI volumes of amygdala and hippocampus in non-mentally retarded autistic adolescents and adults (Aylward et al) 1999;53:2145
pseudoseizures and other nonepileptic paroxysmal disorders in children and adolescents (Andriola and Ettinger) (Sept, suppl 2) 1999;53:S89

Adrenergic receptors
astrocytes in MS lack beta-2 adrenergic receptors (De Keyser et al) 1999;53:1628

Age. *See also specific age groups*
evidence for the GluR6 gene associated with younger onset age of Huntington's disease (MacDonald et al) 1999;53:1330

Aging. *See also* **Geriatric population**
APOE-ε4 count predicts age when prevalence of AD increases, then declines: the Cache County Study (Breitner et al) 1999;53:321
critical decline in fine motor hand movements in human aging (Smith et al) 1999;53:1458
relation of education to brain size in normal aging: implications for the reserve hypothesis (Coffey et al) 1999;53:189

Aldose reductase
effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy (Greene et al) 1999;53:580

Allergy
allergies to multiple antiseizure medications: a relationship to ANA and SSA (Attarian et al) 1999;53:434

Alzheimer's disease. *See also* **Apolipoprotein E, Dementia**
altered brain activation in cognitively intact individuals at high risk for Alzheimer's disease (Smith et al) 1999;53:1391
clinicopathologic correlates of dementia with Lewy bodies in comparison to Alzheimer's disease (Gómez-Isla et al) 1999;53:2003
differentiation of vascular dementia from AD on neuropsychological tests (Looi and Sachdev) (Views & Reviews) 1999;53:670
double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease (Scharf et al) 1999;53:197
elevated CSF prostaglandin E_2 levels in patients with probable AD (Montine et al) 1999;53:1495
error behaviors associated with loss of competency in Alzheimer's disease (Marson et al) 1999;53:1983
failure to detect *Chlamydia pneumoniae* in brain tissues of Alzheimer's disease (Nochlin et al) 1999;53:1888
faster memory decline in AD patients with higher educational or occupational attainment: cognitive reserve? (Stern et al) 1999;53:1942
gender differences in the relation between comorbidity and mortality of patients with Alzheimer's disease (Gambassi et al) 1999;53:508
head trauma and risk of dementia and Alzheimer's disease. The Rotterdam Study (Mehta et al) 1999;53:1959
marital status and risk of Alzheimer's disease: a French population-based cohort study (Helmer et al) 1999;53:1953
motor dysfunction in mildly demented AD individuals without extrapyramidal signs (Goldman et al) 1999;53:956
no association of alpha-2 macroglobulin gene five-nucleotide deletion with AD in Taiwan Chinese (Hu et al) 1999;53:642
no association of paraoxonase gene polymorphism with atherosclerosis or Alzheimer's disease (Sodeyama et al) 1999;53:1146
practical method to predict rate of cognitive decline in mild to moderate Alzheimer's disease (Matsui et al) 1999;53:2208
regional cerebral blood flow difference between dementia with Lewy bodies and AD (Ishii et al) 1999;53:413
sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample (Andreasen et al) 1999;53:1488
sex differences in the incidence of Alzheimer's and vascular dementia (Andersen et al) 1999;53:1992

Amantadine
amantadine-induced peripheral neuropathy (Shulman et al) 1999;53:1862

L-Amino acid decarboxylase deficiency
clinical and therapeutic observations in aromatic L-amino acid decarboxylase deficiency (Swoboda et al) 1999;53:1205

Amnesia
perfusion- and diffusion-weighted magnetic resonance imaging in transient global amnesia (Budson et al) (Letter); (Furie and Ay) (Reply) 1999;53:239
postencephalitic focal retrograde amnesia after bilateral anterior temporal lobe damage (Tanaka et al) 1999;53:344

Amputation
reorganization of motor cortex outputs after arm amputation (Röricht et al) 1999;53:106

Amygdala
MRI volumes of amygdala and hippocampus in non-mentally retarded autistic adolescents and adults (Aylward et al) 1999;53:2145

Amyloid
aggressive familial amyloidotic polyneuropathy caused by a new variant transthyretin Lys 54 (Togashi et al) 1999;53:637
cerebral amyloid angiopathy with unilateral hemorrhages, mass effect, and meningeal enhancement (Morton-Bours et al) 1999;53:233
MRI detection of new hemorrhages: potential marker of progression in cerebral amyloid angiopathy (Greenberg et al) 1999;53:1135
transthyretin amyloidosis and superficial siderosis of the CNS (Mascalchi et al) 1999;53:1498

Amyotrophic lateral sclerosis
algorithm for ALS diagnosis and management (Swash) 1999;53:S58
clustering of ALS patients in central Italy due to the occurrence of the L84F SOD1 gene mutation (Ceroni et al) 1999;53:1064
cognitive impairment in ALS (Strong et al) 1999;53:1665
conceptual approach to diagnostic delay in ALS: a United States perspective (Gelinas) 1999;53:S17
current treatment pathways in ALS: a European perspective (Dengler) 1999;53:S4
current treatment pathways in ALS: a South American perspective (Dubrovsky and Sica) 1999;53:S11
defining optimal management in ALS: from first symptoms to announcement (Brooks) (Nov, suppl 5) 1999;53:S1
defining optimal management in ALS: group discussion 1 1999;53:S20
defining optimal management in ALS: group discussion 2 1999;53:S35
defining optimal management in ALS: group discussion 3 1999;53:S40
defining optimal management in ALS: group discussion 4 1999;53:S55
defining optimal management in ALS: group discussion 5 1999;53:S67
detection and cellular localization of enterovirus RNA sequences in spinal cord of ALS patients (Berger et al) 1999;53:1998
diagnostic challenges in ALS (Belsh) 1999;53:S26
diffusion tensor MRI assesses corticospinal tract damage in ALS (Ellis et al) 1999;53:1051
do the benefits of currently available treatments justify earlier diagnosis and treatment of amyotrophic lateral sclerosis? (Ludolph and Reipe) (Arguments Against); (Cashman) (Arguments For) 1999;53:S46
earlier is better: the benefits of early diagnosis (Brooks) 1999;53:S53
^{1}H-MRS evidence of neurodegeneration and excess glutamate + glutamine in ALS medulla (Pioro et al) 1999;53:71
honesty and hope: announcement of diagnosis in ALS (Silani and Borasio) 1999;53:S37
integrating the algorithm into community practice (Smithson) 1999;53:S63
melatonin and painful gynecomastia (De Bleecker et al) 1999;53:435
nutritional status is a prognostic factor for survival in ALS (Desport et al) 1999;53:1059
patient choices in ALS: life-sustaining treatment versus palliative care? (Mitsumoto) 1999;53:248
presentation of ALS to the otolaryngologist/head and neck surgeon: getting to the neurologist (Hillel et al) 1999;53:S22
prospective study of preferences and actual treatment choices in ALS (Albert et al) 1999;53:278
safety and factors related to survival after percutaneous endoscopic gastrostomy in ALS (Chiò et al) 1999;53:1123
simplifying the approach: what can we do? (Strong) 1999;53:S31
SOD1 gene mutation in a patient with slowly progressing familial ALS (Penco et al) 1999;53:404
tongue and limb myokymia in amyotrophic lateral sclerosis (Sander et al) 1999;53:1889
what are the implications of early diagnosis? maintaining optimal health as long as possible (Brooks) 1999;53:S43

July 13 issue, pp 1–246; July 22 issue, pp 247–442; August issue, pp 443–660; September 11 issue, pp 661–896; September 22 issue, pp 897–1162; September, Supplement 1, pp S1–S48; September, Supplement 2, pp S1–S100; September, Supplement 3, pp S1–S53; October 12 issue, pp 1163–1378; October 22 issue, pp 1379–1612; October, Supplement 4, pp S1–S37; November issue, pp 1613–1898; November, Supplement 5, pp S1–S72; December issue, pp 1899–2246

Subject Index to Volume 53

A

Acetazolamide
new CACNA1A gene mutation in acetazolamide-responsive familial hemiplegic migraine and ataxia (Battistini et al) 1999;53:38

Acetylcholine
chromosome 17p-linked myasthenias stem from defects in the acetylcholine receptor ε-subunit gene (Middleton et al) 1999;53:1076

Adolescents
changes of serum sICAM-1 and MMP-9 induced by rIFNβ-1b treatment in relapsing-remitting MS (Trojano et al) 1999;53:1402
MRI volumes of amygdala and hippocampus in non-mentally retarded autistic adolescents and adults (Aylward et al) 1999;53:2145
pseudoseizures and other nonepileptic paroxysmal disorders in children and adolescents (Andriola and Ettinger) (Sept, suppl 2) 1999;53:S89

Adrenergic receptors
astrocytes in MS lack beta-2 adrenergic receptors (De Keyser et al) 1999;53:1628

Age. *See also specific age groups*
evidence for the GluR6 gene associated with younger onset age of Huntington's disease (MacDonald et al) 1999;53:1330

Aging. *See also* **Geriatric population**
APOE-ε4 count predicts age when prevalence of AD increases, then declines: the Cache County Study (Breitner et al) 1999;53:321
critical decline in fine motor hand movements in human aging (Smith et al) 1999;53:1458
relation of education to brain size in normal aging: implications for the reserve hypothesis (Coffey et al) 1999;53:189

Aldose reductase
effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy (Greene et al) 1999;53:580

Allergy
allergies to multiple antiseizure medications: a relationship to ANA and SSA (Attarian et al) 1999;53:434

Alzheimer's disease. *See also* **Apolipoprotein E, Dementia**
altered brain activation in cognitively intact individuals at high risk for Alzheimer's disease (Smith et al) 1999;53:1391
clinicopathologic correlates of dementia with Lewy bodies in comparison to Alzheimer's disease (Gómez-Isla et al) 1999;53:2003
differentiation of vascular dementia from AD on neuropsychological tests (Looi and Sachdev) (Views & Reviews) 1999;53:670
double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease (Scharf et al) 1999;53:197
elevated CSF prostaglandin E_2 levels in patients with probable AD (Montine et al) 1999;53:1495
error behaviors associated with loss of competency in Alzheimer's disease (Marson et al) 1999;53:1983
failure to detect *Chlamydia pneumoniae* in brain tissues of Alzheimer's disease (Nochlin et al) 1999;53:1888
faster memory decline in AD patients with higher educational or occupational attainment: cognitive reserve? (Stern et al) 1999;53:1942
gender differences in the relation between comorbidity and mortality of patients with Alzheimer's disease (Gambassi et al) 1999;53:508
head trauma and risk of dementia and Alzheimer's disease. The Rotterdam Study (Mehta et al) 1999;53:1959
marital status and risk of Alzheimer's disease: a French population-based cohort study (Helmer et al) 1999;53:1953
motor dysfunction in mildly demented AD individuals without extrapyramidal signs (Goldman et al) 1999;53:956
no association of alpha-2 macroglobulin gene five-nucleotide deletion with AD in Taiwan Chinese (Hu et al) 1999;53:642
no association of paraoxonase gene polymorphism with atherosclerosis or Alzheimer's disease (Sodeyama et al) 1999;53:1146
practical method to predict rate of cognitive decline in mild to moderate Alzheimer's disease (Matsui et al) 1999;53:2208
regional cerebral blood flow difference between dementia with Lewy bodies and AD (Ishii et al) 1999;53:413
sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample (Andreasen et al) 1999;53:1488
sex differences in the incidence of Alzheimer's and vascular dementia (Andersen et al) 1999;53:1992

Amantadine
amantadine-induced peripheral neuropathy (Shulman et al) 1999;53:1862

L-Amino acid decarboxylase deficiency
clinical and therapeutic observations in aromatic L-amino acid decarboxylase deficiency (Swoboda et al) 1999;53:1205

Amnesia
perfusion- and diffusion-weighted magnetic resonance imaging in transient global amnesia (Budson et al) (Letter); (Furie and Ay) (Reply) 1999;53:239
postencephalitic focal retrograde amnesia after bilateral anterior temporal lobe damage (Tanaka et al) 1999;53:344

Amputation
reorganization of motor cortex outputs after arm amputation (Röricht et al) 1999;53:106

Amygdala
MRI volumes of amygdala and hippocampus in non-mentally retarded autistic adolescents and adults (Aylward et al) 1999;53:2145

Amyloid
aggressive familial amyloidotic polyneuropathy caused by a new variant transthyretin Lys 54 (Togashi et al) 1999;53:637
cerebral amyloid angiopathy with unilateral hemorrhages, mass effect, and meningeal enhancement (Morton-Bours et al) 1999;53:233
MRI detection of new hemorrhages: potential marker of progression in cerebral amyloid angiopathy (Greenberg et al) 1999;53:1135
transthyretin amyloidosis and superficial siderosis of the CNS (Mascalchi et al) 1999;53:1498

Amyotrophic lateral sclerosis
algorithm for ALS diagnosis and management (Swash) 1999;53:S58
clustering of ALS patients in central Italy due to the occurrence of the L84F SOD1 gene mutation (Ceroni et al) 1999;53:1064
cognitive impairment in ALS (Strong et al) 1999;53:1665
conceptual approach to diagnostic delay in ALS: a United States perspective (Gelinas) 1999;53:S17
current treatment pathways in ALS: a European perspective (Dengler) 1999;53:S4
current treatment pathways in ALS: a South American perspective (Dubrovsky and Sica) 1999;53:S11
defining optimal management in ALS: from first symptoms to announcement (Brooks) (Nov, suppl 5) 1999;53:S1
defining optimal management in ALS: group discussion 1 1999;53:S20
defining optimal management in ALS: group discussion 2 1999;53:S35
defining optimal management in ALS: group discussion 3 1999;53:S40
defining optimal management in ALS: group discussion 4 1999;53:S55
defining optimal management in ALS: group discussion 5 1999;53:S67
detection and cellular localization of enterovirus RNA sequences in spinal cord of ALS patients (Berger et al) 1999;53:1998
diagnostic challenges in ALS (Belsh) 1999;53:S26
diffusion tensor MRI assesses corticospinal tract damage in ALS (Ellis et al) 1999;53:1051
do the benefits of currently available treatments justify earlier diagnosis and treatment of amyotrophic lateral sclerosis? (Ludolph and Reipe) (Arguments Against); (Cashman) (Arguments For) 1999;53:S46
earlier is better: the benefits of early diagnosis (Brooks) 1999;53:S53
^{1}H-MRS evidence of neurodegeneration and excess glutamate + glutamine in ALS medulla (Pioro et al) 1999;53:71
honesty and hope: announcement of diagnosis in ALS (Silani and Borasio) 1999;53:S37
integrating the algorithm into community practice (Smithson) 1999;53:S63
melatonin and painful gynecomastia (De Bleecker et al) 1999;53:435
nutritional status is a prognostic factor for survival in ALS (Desport et al) 1999;53:1059
patient choices in ALS: life-sustaining treatment versus palliative care? (Mitsumoto) 1999;53:248
presentation of ALS to the otolaryngologist/head and neck surgeon: getting to the neurologist (Hillel et al) 1999;53:S22
prospective study of preferences and actual treatment choices in ALS (Albert et al) 1999;53:278
safety and factors related to survival after percutaneous endoscopic gastrostomy in ALS (Chiò et al) 1999;53:1123
simplifying the approach: what can we do? (Strong) 1999;53:S31
SOD1 gene mutation in a patient with slowly progressing familial ALS (Penco et al) 1999;53:404
tongue and limb myokymia in amyotrophic lateral sclerosis (Sander et al) 1999;53:1889
what are the implications of early diagnosis? maintaining optimal health as long as possible (Brooks) 1999;53:S43

July 13 issue, pp 1–246; July 22 issue, pp 247–442; August issue, pp 443–660; September 11 issue, pp 661–896; September 22 issue, pp 897–1162; September, Supplement 1, pp S1–S48; September, Supplement 2, pp S1–S100; September, Supplement 3, pp S1–S53; October 12 issue, pp 1163–1378; October 22 issue, pp 1379–1612; October, Supplement 4, pp S1–S37; November issue, pp 1613–1898; November, Supplement 5, pp S1–S72; December issue, pp 1899–2246

Analgesics
effect of simple analgesics on quantitative sensation test threshold (Wang et al) 1999;53:1865
Aneurysms
aneurysms in relatives of patients with subarachnoid hemorrhage: frequency and risk factors (Raaymakers and the MARS Study Group) 1999;53:982
long-term follow-up of aneurysms developed during extracranial internal carotid artery dissection (Guillon et al) 1999;53:117
Angiitis
brain biopsy in primary angiitis of the central nervous system (Alrawi et al) 1999;53:858
Angiopathy
cerebral amyloid angiopathy with unilateral hemorrhages, mass effect, and meningeal enhancement (Morton-Bours et al) 1999;53:233
Anorgasmia
gabapentin-induced anorgasmia (Clark and Elliott) 1999;53:2209
Anosognosia
pontine anosognosia for hemiplegia (Evyapan and Kumral) 1999;53:647
Antibodies. *See also* **Monoclonal antibodies**
antibodies to prothrombin in patients with Sneddon's syndrome (Kalashnikova et al) 1999;53:223
antiphosphatidyl serine antibodies are independently associated with ischemic stroke (Tuhrim et al) 1999;53:1523
effect of anti-α4 integrin antibody on brain lesion activity in MS (Tubridy et al) 1999;53:466
Guillain-Barré syndrome with anti-GalNAc antibodies (Ang et al) 1999;53:2122
humoral response to oligodendrocyte-specific protein in MS: a potential molecular mimic (Bronstein et al) 1999;53:154
inverse correlation of HTLV-1 viral load in CSF and intrathecal synthesis of HTLV-1 antibodies in TSP/HAM (Puccioni-Sohler et al) 1999;53:1335
marginally improved detection of GM1 antibodies by Covalink ELISA in multifocal motor neuropathy (Carpo et al) 1999;53:2206
myasthenia, thymoma, presynaptic antibodies, and a continuum of neuromuscular hyperexcitability (Vernino et al) 1999;53:1233
neonatal Guillain-Barré syndrome: blocking antibodies transmitted from mother to child (Buchwald et al) 1999;53:1246
novel antineuronal antibody in a motor neuron syndrome associated with breast cancer (Ferracci et al) 1999;53:852
to test or not to test? (Holloway and Feasby) (Editorial) 1999;53:1905
Anticipation
preliminary evidence for anticipation in genetic E200K Creutzfeldt-Jakob disease (Rosenmann et al) 1999;53:1328
repeats may not be everything in anticipation (Ashizawa and Conneally) (Editorial) 1999;53:1164
Antiepileptic drugs
allergies to multiple antiseizure medications: a relationship to ANA and SSA (Attarian et al) 1999;53:434
brief AED withdrawal prolongs next seizure (Laowattana et al) 1999;53:1736
cost-effectiveness model of adjunctive lamotrigine for the treatment of epilepsy (Heaney and Sander) (Letter); (Markowitz et al) (Reply) 1999;53:657
guideline for discontinuing antiepileptic drugs in seizure-free patients (Wilkins) (Letter); (Franklin et al) (Reply) 1999;53:239
positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders (Ketter et al) (Sept, suppl 2) 1999;53:S53
serum leptin changes in epileptic patients who gain weight after therapy with valproic acid (Verrotti et al) 1999;53:230
vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects (Kälviäinen et al) 1999;53:922
Antioxidants
radical reactions from missing ceruloplasmin: the importance of a ferroxidase as an endogenous antioxidant (Graf and Noetzel) (Editorial) 1999;53:446
Antiphosphatidyl serine antibodies
antiphosphatidyl serine antibodies are independently associated with ischemic stroke (Tuhrim et al) 1999;53:1523
Antiplatelet therapy
antiplatelet therapy: foundations for optimal treatment decisions (Albers and Tijssen) (Sept, suppl 4) 1999;53:S25
antiplatelet therapy: views from the experts (Easton et al) (Sept, suppl 4) 1999;53:S32
antiplatelet treatment does not reduce the severity of subsequent stroke (Sivenius et al) 1999;53:825
Antiretroviral therapy
highly active antiretroviral therapy reverses brain metabolite abnormalities in mild HIV dementia (Chang et al) 1999;53:782
Antiseizure drugs. *See* **Antiepileptic drugs**
Anxiety disorders
cluster headaches: association with anxiety disorders and memory deficits (Jorge et al) 1999;53:543
Aphasia
making sense out of jargon: a neurolinguistic and computational account of jargon aphasia (Hillis et al) 1999;53:1813
Apolipoprotein E
APOE ε2-4 and -491 polymorphisms are not associated with MS (Ferri et al) 1999;53:888
APOE-ε4 count predicts age when prevalence of AD increases, then declines: the Cache County Study (Breitner et al) 1999;53:321
APOE genotype as a risk factor for ischemic cerebrovascular disease: a meta-analysis (McCarron et al) 1999;53:1308
ApoE genotype in relation to AD and cholesterol: a study of 2,326 Chinese adults (Liu et al) 1999;53:962
APOE-ε4 is associated with less frontal and more medial temporal atrophy in AD (Geroldi et al) 1999;53:1825
APOE-491 promoter polymorphism is a risk factor for late-onset Alzheimer's disease (Casadei et al) 1999;53:1888
effect of *APOE* on dementia is not through atherosclerosis: The Rotterdam Study (Slooter et al) 1999;53:1593
impaired olfaction as a marker for cognitive decline: interaction with apolipoprotein E ε4 status (Borenstein Graves et al) 1999;53:1480
influence of *APOE* genotype on familial aggregation of AD in an urban population (Devi et al) 1999;53:789
intracerebral hemorrhage outcome: apolipoprotein E genotype, hematoma, and edema volumes (McCarron et al) 1999;53:2176
metrifonate treatment of AD: influence of apolipoprotein E genotype (Farlow et al) 1999;53:2010
preclinical memory decline in cognitively normal apolipoprotein E-ε4 homozygotes (Caselli et al) 1999;53:201
Apoptosis
is apoptotic death of the oligodendrocyte a critical event in the pathogenesis of multiple sclerosis? (Rodriguez and Lucchinetti) (Editorial) 1999;53:1615
βAPP
cultured inclusion-body myositis muscle fibers do not accumulate βAPP and can be innervated (McFerrin et al) 1999;53:2184
Apraxia
cerebral lateralization: relationship of language and ideomotor praxis (Meador et al) 1999;53:2028
ptosis, blepharospasm, and apraxia of eyelid opening secondary to putaminal hemorrhage (Verghese et al) 1999;53:652
Arteriosclerosis
brain arteriosclerosis and hemodynamic disturbance may induce leukoaraiosis (Yamauchi et al) 1999;53:1833
Astrocytes
astrocytes in MS lack beta-2 adrenergic receptors (De Keyser et al) 1999;53:1628
Ataxia
CACNA1A mutations: hemiplegic migraine, episodic ataxia type 2, and the others (Tournier-Lasserve) (Editorial) 1999;53:3
cerebellar ataxia associated with subclinical celiac disease responding to gluten-free diet (Pellecchia et al) 1999;53:1606
clinical and MRI findings in spinocerebellar ataxia type 5 (Stevanin et al) 1999;53:1355
cognitive impairments in patients with congenital nonprogressive cerebellar ataxia (Steinlin et al) 1999;53:966
maculopathy in spinocerebellar ataxia type 7 (Morrow et al) (*NeuroImages*) 1999;53:244
medullary syndrome characterized by wild arm ataxia (Currier and Bebin) 1999;53:1608
neuroimaging study in autosomal dominant cerebellar ataxia, deafness, and narcolepsy (Melberg et al) 1999;53:2190
new CACNA1A gene mutation in acetazolamide-responsive familial hemiplegic migraine and ataxia (Battistini et al) 1999;53:38
nonpathogenic GAAGGA repeat in the Friedrich gene: implications for pathogenesis (Ohshima et al) 1999;53:1854
novel nonsense mutation in CACNA1A causes episodic ataxia and hemiplegia (Jen et al) 1999;53:34
Atherosclerosis
atherosclerosis is not implicated in association of *APOE* ε4 with AD (Itoh et al) 1999;53:236
effect of *APOE* on dementia is not through atherosclerosis: The Rotterdam Study (Slooter et al) 1999;53:1593
no association of paraoxonase gene polymorphism with atherosclerosis or Alzheimer's disease (Sodeyama et al) 1999;53:1146
Attention
impairments of attention after cingulotomy (Cohen et al) 1999;53:819
rightward bias of defective attention in left unilateral neglect (Bartolomeo and Chokron) 1999;53:2023
Austrian population
MRI white matter hyperintensities: three-year follow-up of the Austrian Stroke Prevention Study (Schmidt et al) 1999;53:132
Autism
MRI volumes of amygdala and hippocampus in non-mentally retarded autistic adolescents and adults (Aylward et al) 1999;53:2145

Autoantibodies
immunoglobulin G and complement immunoreactivity in the cerebral cortex of patients with Rasmussen's encephalitis (Whitney et al) 1999;53:699
Axons
diagnostic value of myotatic reflexes in axonal and demyelinating polyneuropathy (van Dijk et al) 1999;53:1573
mice lacking cytosolic copper/zinc superoxide dismutase display a distinctive motor axonopathy (Shefner et al) 1999;53:1239

B

Babinski reflex
Babinski reflex hammer (Lanska) (Neuro*Images*) 1999;53:647
Bacille-Calmette-Guèrin
use of Bacille-Calmette-Guèrin (BCG) in multiple sclerosis (Ristori et al) 1999;53:1588
Balloon occlusion
dysarthria during basilar artery balloon occlusion (Hartmann et al) 1999;53:421
Band heterotopia
association of trisomy 9p and band heterotopia (Federico et al) 1999; 53:430
Basilar artery
dysarthria during basilar artery balloon occlusion (Hartmann et al) 1999;53:421
Behavioral problems. *See* **Psychiatric issues**
Biopterin
striatal biopterin and tyrosine hydroxylase protein reduction in dopa-responsive dystonia (Furukawa et al) 1999;53:1032
Blepharospasm
ptosis, blepharospasm, and apraxia of eyelid opening secondary to putaminal hemorrhage (Verghese et al) 1999;53:652
Blink reflex
role of the blink reflex in the evaluation of sensory neuronopathy (Auger et al) 1999;53:407
Blood pressure. *See* **Hypertension; Hypotension**
Bolivia
prevalence of epilepsy in rural Bolivia. a door-to-door survey (Nicoletti et al) 1999;53:2064
Book and media reviews
An Atlas of Multiple Sclerosis, by Poser (Calabresi) 1999;53:1377
Case studies in Neuroscience, by Jozefowicz and Halloway (Hirsch) 1999;53:1896
Clinical Companion to the Molecular and Genetic Basis of Neurological Disease, 2nd edition, edited by Rosenberg et al (Conneally) 1999; 53:245
Clinical Diagnosis and Management of Alzheimer's Disease, Second Edition, by Gauthier and Dunitz (Papka) 1999;53:1377
Clinical Neurocardiology, by Caplan et al (Oppenheimer) 1999;53:1896
Clinical Neuroimmunology, edited by Antel et al (Cross) 1999;53:1378
Fifty Neurological Cases From The National Hospital, by Wills and Marsden (Joynt) 1999;53:1896
The Genesis of Neuroscience, by Walker (Goldblatt) 1999;53:245
Genetics of Mental Disorders: A Guide for Students, Clinicians, and Researchers, by Faraone et al (Silverman) 1999;53:2217
Introduction to Neuropathic Pain Assessment and Examination, edited by Backonja (Kanazi) 1999;53:245
Magnetic Resonance Techniques in Clinical Trials in Multiple Sclerosis, edited by Filippi et al (Schwid) 1999;53:1162
Meniere's Disease: What You Need to Know, by Haybach (Harris) 1999; 53:245
Neurology in the Tropics, by Chopra and Sawhney (Roos) 1999;53:1162
Parkinson's Disease—The Treatment Options, by Oertel and LeWitt (Counihan) 1999;53:1377
Stroke and Alzheimer's disease, edited by Leys et al (Lopez) 1999;53: 2217
Borrelia burgdorferi
absence of *Borrelia burgdorferi*-specific immune complexes in chronic fatigue syndrome (Schutzer and Natelson) 1999;53:1340
Botulinum toxin
botulinum toxin A in patients with oromandibular dystonia: long term follow-up (Tan et al) 1999;53:2102
historical aspects of botulinum toxin: Justinius Kerner (1786–1862) and the "sausage poison" (Erbguth and Naumann) (Historical Neurology) 1999;53:1850
safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia (Brin et al) 1999;53:1431
safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia (Brashear et al) 1999;53:1439
Botulism
adult-onset "infant" botulism: an unusual case of weakness in the intensive care unit (Li et al) 1999;53:891
Bradykinin
bradykinin B_1 receptor expression and function on T lymphocytes in active multiple sclerosis (Prat et al) 1999;53:2087
Brain. *See also* **Traumatic brain injury;** *specific areas of brain*
altered brain activation in cognitively intact individuals at high risk for Alzheimer's disease (Smith et al) 1999;53:1391
alternative splicing patterns of *CYP2D* genes in human brain and neurodegenerative disorders (Woo et al) 1999;53:1570
brain activation during working memory 1 month after mild traumatic brain injury: a functional MRI study (McAllister et al) 1999;53:1300
brain arteriosclerosis and hemodynamic disturbance may induce leukoaraiosis (Yamauchi et al) 1999;53:1833
brain biopsy in primary angiitis of the central nervous system (Alrawi et al) 1999;53:858
brain morphometry in reading-disabled twins (Pennington et al) 1999; 53:723
brain processing of capsaicin-induced secondary hyperalgesia: a functional MRI study (Baron et al) 1999;53:548
brain size, head size, and intelligence quotient in monozygotic twins (Anderson) (Letter); (Tramo and Gazzaniga) (Reply) 1999;53:242
early-life seizures in rats increase susceptibility to seizure-induced brain injury in adulthood (Koh et al) 1999;53:915
effects of neonatal seizures on subsequent seizure-induced brain injury (Schmid et al) 1999;53:1754
failure to detect *Chlamydia pneumoniae* in brain tissues of Alzheimer's disease (Nochlin et al) 1999;53:1888
hereditary ceruloplasmin deficiency increases advanced glycation end products in the brain (Tajima et al) 1999;53:619
highly active antiretroviral therapy reverses brain metabolite abnormalities in mild HIV dementia (Chang et al) 1999;53:782
increased brain serotonin synthesis in migraine (Chugani et al) 1999; 53:1473
leukoencephalopathy and raised brain lactate from heroin vapor inhalation ("chasing the dragon") (Kriegstein et al) 1999;53:1765
longitudinal study of brain atrophy in relapsing multiple sclerosis (Simon et al) 1999;53:139
reduced brain creatine in gyrate atrophy of the choroid and retina with hyperornithinemia (Näntö-Salonen) 1999;53:303
relation of education to brain size in normal aging: implications for the reserve hypothesis (Coffey et al) 1999;53:189
structural and functional brain asymmetries in human situs inversus totalis (Kennedy et al) 1999;53:1260
use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS (Rudick et al) 1999;53:1698
Brain death
chronic "brain death": meta-analysis and conceptual consequences (López-Navidad) (Letter); (Wijdicks and Bernat) (Letter); (Crisci) (Letter); (Lang) (Letter); (Shewmon) (Reply) 1999;53:1359
Brainstem
adult brainstem gliomas (Chamberlain) (Letter); (De Angelis and Landolfi) (Reply) 1999;53:437
brainstem tuberculoma mimicking glaucoma (Mak and Cheung) (Letter); (Fong et al) (Reply) 1999;53:1894
hypertensive brainstem encephalopathy: three cases presenting with severe brainstem edema (Chang and Keane) 1999;53:652
superior oblique palsies with brainstem lesions (Thömke and Ringel) 1999;53:1126
Brain stimulation. *See also* **Transcranial magnetic stimulation**
bilateral thalamic stimulation for the treatment of essential tremor (Pahwa et al) 1999;53:1447
brief bursts of pulse stimulation terminate afterdischarges due to cortical stimulation (Lesser et al) 1999;53:2073
chronic thalamic stimulation for the tremor of multiple sclerosis (Montgomery Jr. et al) 1999;53:625
comparative effects of unilateral and bilateral subthalamic nucleus deep brain stimulation (Kumar et al) 1999;53:561
globus pallidus deep brain stimulation for generalized dystonia: clinical and PET investigation (Kumar et al) 1999;53:871
neuropsychological and quality of life outcome after thalamic stimulation for essential tremor (Tröste et al) 1999;53:1774
Breast cancer
novel antineuronal antibody in a motor neuron syndrome associated with breast cancer (Ferracci et al) 1999;53:852
Bromocriptine
3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease (Korczyn et al) 1999;53:364
Brumlik, Joel
Joel Brumlik (Boshes) (In Memoriam) 1999;53:12

C

CACNA1A gene
CACNA1A mutations: hemiplegic migraine, episodic ataxia type 2, and the others (Tournier-Lasserve) (Editorial) 1999;53:3
genetic heterogeneity in Italian families with familial hemiplegic migraine (Carrera et al) 1999;53:26
new CACNA1A gene mutation in acetazolamide-responsive familial hemiplegic migraine and ataxia (Battistini et al) 1999;53:38
novel nonsense mutation in CACNA1A causes episodic ataxia and hemiplegia (Jen et al) 1999;53:34

CADASIL
cerebrospinal fluid findings in CADASIL (Dichgans et al) 1999;53:233
Calcification
edema associated with calcified lesions in neurocysticercosis (Nash and Patronas) 1999;53:777
Canadian population
mortality in elderly Canadians with and without dementia: a 5-year follow-up (Ostbye et al) 1999;53:521
Cannabis
suppression of pendular nystagmus by smoking cannabis in a patient with multiple sclerosis (Harte et al) 1999;53:2209
Capillary leak syndrome
lethal capillary leak syndrome after a single administration of interferon beta-1b (Schmidt et al) 1999;53:220
Carbamazepine
carbamazepine in comparative trials: pharmacokinetic characteristics too often forgotten (Arroyo and Sander) (Views & Reviews) 1999;53:1170
Carbidopa
immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study (Koller et al) 1999;53:1012
Cardiovascular disease. *See* **Stroke**
Carotid arteries
acute isolated monocular blindness and painless carotid artery dissection (Lee et al) 1999;53:1155
antithrombotic treatment of ischemic stroke among patients with occlusion or severe stenosis of the internal carotid artery: a report of the Trial of Organization 10172 in Acute Stroke Treatment (TOAST) (Adams Jr. et al) 1999;53:122
carotid artery dissection due to elongated styloid process (Zuber et al) 1999;53:1886
long-term follow-up of aneurysms developed during extracranial internal carotid artery dissection (Guillon et al) 1999;53:117
orthostatic limb shaking from carotid hypoperfusion (Zaidat et al) 1999;53:650
Carpal tunnel syndrome
assessment of carpal tunnel syndrome (Padua et al) 1999;53:1654
Catalepsy
catalepsy after stroke (Saposnik et al) 1999;53:1132
Catamenial epilepsy
catamenial epilepsy: clinical aspects (Zahn) (Sept, suppl 1) 1999;53:S34
epilepsy in women: the science of why it is special (Morrell) (Sept, suppl 1) 1999;53:S42
hormonal contraception and epilepsy (Guberman) (Sept, suppl 1) 1999;53:S38
CCNU
neoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma (Paleologos et al) 1999;53:1141
Celiac disease
cerebellar ataxia associated with subclinical celiac disease responding to gluten-free diet (Pellecchia et al) 1999;53:1606
Cerebellar ataxia
cerebellar ataxia associated with subclinical celiac disease responding to gluten-free diet (Pellecchia et al) 1999;53:1606
cognitive impairments in patients with congenital nonprogressive cerebellar ataxia (Steinlin et al) 1999;53:966
neuroimaging study in autosomal dominant cerebellar ataxia, deafness, and narcolepsy (Melberg et al) 1999;53:2190
Cerebellum
cerebellar hemorrhage presenting as orthostatic headache: two case reports (Chen et al) 1999;53:1887
effect of hyperventilation in downbeat nystagmus in cerebellar disorders (Walker and Zee) 1999;53:1576
superficial siderosis of the CNS: a late complication of cerebellar tumors (Kassubek et al) (Letter); (Anderson) (Reply) 1999;53:1893
Cerebral blood flow
effect of vigabatrin on cerebral blood flow and metabolism (Spanaki et al) 1999;53:1518
reduced cerebral blood flow and impaired visual-spatial function in proximal myotonic myopathy (Meola et al) 1999;53:1042
regional cerebral blood flow difference between dementia with Lewy bodies and AD (Ishii et al) 1999;53:413
Cerebral cortex
brief bursts of pulse stimulation terminate afterdischarges due to cortical stimulation (Lesser et al) 1999;53:2073
clinical and imaging features of cortical malformations in childhood (Leventer et al) 1999;53:715
cortical activation patterns during voluntary blinks and voluntary saccades (Bodis-Wollner et al) 1999;53:1800
cortical excitability and recovery curve analysis in generalized epilepsy (Brodtmann et al) 1999;53:1347
immunoglobulin G and complement immunoreactivity in the cerebral cortex of patients with Rasmussen's encephalitis (Whitney et al) 1999;53:699
mechanisms and clinical features of posterior border-zone infarcts (Belden et al) 1999;53:1312
menstrual cycle effects on cortical excitability (Smith et al) 1999;53:2069
sensory symptoms restricted to proximal body parts in small cortical infarction (Kim) 1999;53:889
Cerebral embolism
potential source of cerebral embolism in migraine with aura: a transcranial Doppler study (Cheng) (Letter); (Anzola et al) (Reply) 1999;53:2213
Cerebral lateralization
cerebral lateralization: relationship of language and ideomotor praxis (Meador et al) 1999;53:2028
Cerebral metabolism
effect of vigabatrin on cerebral blood flow and metabolism (Spanaki et al) 1999;53:1518
longitudinal study of cerebral glucose metabolism, MRI, and disability in patients with MS (Blinkenberg et al) 1999;53:149
Cerebral veins
isolated intracranial hypertension as the only sign of cerebral venous thrombosis (Biousse et al) 1999;53:1537
Cerebrospinal fluid
absence of human herpesvirus 6 and 7 from spinal fluid and serum of multiple sclerosis patients (Mirandola et al) 1999;53:1367
absent pachymeningeal gadolinium enhancement on cranial MRI despite symptomatic CSF leak (Mokri et al) 1999;53:402
cerebrospinal fluid findings in CADASIL (Dichgans et al) 1999;53:233
cerebrospinal fluid isoprostane shows oxidative stress in patients with multiple sclerosis (Greco et al) 1999;53:1876
clinical outcome in pneumococcal meningitis correlates with CSF lipoteichoic acid concentrations (Schneider et al) 1999;53:1584
elevated CSF prostaglandin E_2 levels in patients with probable AD (Montine et al) 1999;53:1495
inverse correlation of HTLV-1 viral load in CSF and intrathecal synthesis of HTLV-1 antibodies in TSP/HAM (Puccioni-Sohler et al) 1999;53:1335
nitric oxide metabolites in cerebrospinal fluid of patients with MS are related to a clinical disease course (Svenningsson et al) 1999;53:1880
relevance of glutamate levels in the CSF of patients with HIV-1-associated dementia complex (Espey et al) 1999;53:1144
sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample (Andreasen et al) 1999;53:1488
serum and CSF neuron-specific enolase in patients with West syndrome (Suzuki et al) 1999;53:1761
Cerebrovascular disease. *See* **Ischemic stroke; Stroke**
Cerebrum
cerebral hemodynamic impairment: methods of measurement and association with stroke risk (Derdeyn et al) (Views & Reviews) 1999;53:251
Ceruloplasmin
estimation of the gene frequency of aceruloplasminemia in Japan (Mayajima et al) 1999;53:617
hereditary ceruloplasmin deficiency increases advanced glycation end products in the brain (Tajima et al) 1999;53:619
radical reactions from missing ceruloplasmin: the importance of a ferroxidase as an endogenous antioxidant (Graf and Noetzel) (Editorial) 1999;53:446
Charcot-Marie-Tooth neuropathy
myelin uncompaction in Charcot-Marie-Tooth neuropathy type 1A with a point mutation of peripheral myelin protein-22 (Fabrizi et al) 1999;53:846
Chiari malformations
pediatric Chiari I malformations: do clinical and radiologic features correlate? (Wu et al) 1999;53:1271
Children
autosomal-recessive juvenile parkinsonism in a Jewish Yemenite kindred: mutation of *Parkin* gene (Nisipeanu et al) 1999;53:1602
behavioral issues in pediatric epilepsy (Dunn and Austin) (Sept, suppl 2) 1999;53:S96
benign acute childhood myositis: laboratory and clinical features (Mackay et al) 1999;53:2127
childhood-onset epilepsy with and without preceding febrile seizures (Berg et al) 1999;53:1742
clinical and imaging features of cortical malformations in childhood (Leventer et al) 1999;53:715
clinical correlations of occipital epileptiform discharges in children (Libenson et al) 1999;53:265
corpus callosum measurements in girls with Tourette syndrome (Mostofsky et al) 1999;53:1345
eliminating institutional child abuse: a road too well traveled (Percy) 1999;53:1617
juvenile Parkinson's disease with REM sleep behavior disorder, sleepiness, and daytime REM onset (Rye et al) 1999;53:1868
multiple sclerosis in children under 6 years of age (Ruggieri et al) 1999;53:478
neurologic complications of pediatric lung transplantation (Wong et al) 1999;53:1542

pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q (Rajput) (Letter); (Mori) (Reply) 1999;53:1375
pediatric Chiari I malformations: do clinical and radiologic features correlate? (Wu et al) 1999;53:1271
placebo-controlled trial of lamotrigine add-on therapy for partial seizures in children (Duchowny et al) 1999;53:1724
pseudoseizures and other nonepileptic paroxysmal disorders in children and adolescents (Andriola and Ettinger) (Sept, suppl 2) 1999;53:S89
stroke after zoster ophthalmicus in a 12-year-old girl with protein C deficiency (Cadavid et al) 1999;53:1128

Chinese population
ApoE genotype in relation to AD and cholesterol: a study of 2,326 Chinese adults (Liu et al) 1999;53:962
no association of alpha-2 macroglobulin gene five-nucleotide deletion with AD in Taiwan Chinese (Hu et al) 1999;53:642

Chlamydia pneumoniae
failure to detect *Chlamydia pneumoniae* in brain tissues of Alzheimer's disease (Nochlin et al) 1999;53:1888

Cholesterol
ApoE genotype in relation to AD and cholesterol: a study of 2,326 Chinese adults (Liu et al) 1999;53:962

Choroid
reduced brain creatine in gyrate atrophy of the choroid and retina with hyperornithinemia (Näntö-Salonen) 1999;53:303

Chromosomes
genetic localization of a new locus for recessive familial spastic paraparesis to 15q13-15 (Martínez Murillo et al) 1999;53:50
phenotypic analysis of autosomal dominant hereditary spastic paraplegia linked to chromosome 8q (Hedera et al) 1999;53:44

Clinical trials
influence of lamotrigine on progression of early Huntington disease: a randomized clinical trial (Kremer et al) 1999;53:1000
magnetization transfer imaging to monitor clinical trials in multiple sclerosis (Richert and Frank) (Sept, suppl 3) 1999;53:S29
need for safety monitoring committees for clinical trials (Cramer) (Letter); (Schachter) (Reply) 1999;53:2211
why drugs fail in postpolio syndrome: lessons from another clinical trial (Dalakas) (Editorial) 1999;53:1166

Cluster headaches
cluster headaches: association with anxiety disorders and memory deficits (Jorge et al) 1999;53:543
cognitive processing is involved in cluster headache but not in chronic paroxysmal hemicrania (Evers et al) 1999;53:357
topiramate-treated cluster headache (Wheeler and Carranza) 1999;53:234

Cognitive function. *See also* **Mental retardation**
brain size, head size, and intelligence quotient in monozygotic twins (Anderson) (Letter); (Tramo and Gazzaniga) (Reply) 1999;53:242
cognitive and magnetic resonance imaging aspects of corticobasal degeneration and progressive supranuclear palsy (Soliveri et al) 1999;53:502
cognitive consequences of coexisting temporal lobe developmental malformations and hippocampal sclerosis (Martin et al) 1999;53:709
cognitive correlates of ^{1}H MRSI detected hippocampal abnormalities in temporal lobe epilepsy (Martin et al) 1999;53:2052
cognitive decline in individuals with high blood pressure: a longitudinal study in the elderly (Tzourio et al) 1999;53:1948
cognitive deficits in epilepsy and contribution to psychopathology (Perrine and Kiolbasa) (Sept, suppl 2) 1999;53:S49
cognitive impairment in ALS (Strong et al) 1999;53:1665
cognitive impairments in patients with congenital nonprogressive cerebellar ataxia (Steinlin et al) 1999;53:966
cognitive processing is involved in cluster headache but not in chronic paroxysmal hemicrania (Evers et al) 1999;53:357
error behaviors associated with loss of competency in Alzheimer's disease (Marson et al) 1999;53:1983
facilitation of picture naming after repetitive transcranial magnetic stimulation (Mottaghy et al) 1999;53:1806
faster memory decline in AD patients with higher educational or occupational attainment: cognitive reserve? (Stern et al) 1999;53:1942
impaired olfaction as a marker for cognitive decline: interaction with apolipoprotein E ε4 status (Borenstein Graves et al) 1999;53:1480
impairments of attention after cingulotomy (Cohen et al) 1999;53:819
lifetime cognitive function and timing of the natural menopause (Richards et al) 1999;53:308
metabolic abnormalities detected by ^{1}H-MRS in dyscalculia and dysgraphia (Levy et al) 1999;53:639
practical method to predict rate of cognitive decline in mild to moderate Alzheimer's disease (Matsui et al) 1999;53:2208
randomized trial of the platelet-activating factor antagonist lexipafant in HIV-associated cognitive impairment (Schifitto et al) 1999;53:391

Complement
immunoglobulin G and complement immunoreactivity in the cerebral cortex of patients with Rasmussen's encephalitis (Whitney et al) 1999;53:699

Confusional states
psychosis and peri-ictal confusional states (Lancman) (Sept, suppl 2) 1999;53:S33

Consent
consent issues in the management of cerebrovascular diseases: a position paper of the American Academy of Neurology Ethics and Humanities Subcommittee 1999;53:9

Corpus callosum
corpus callosum measurements in girls with Tourette syndrome (Mostofsky et al) 1999;53:1345

Corrections
to: bilineal transmission in Tourette syndrome 1999;53:1612
to: hippocampal sclerosis studies in identical twins 1999;53:246
to: new metabolite contributing to *N*-acetyl signal in ^{1}H MRS of the brain in Salla disease 1999;53:1162
to: randomized, placebo-controlled study of topiramate in primary generalized tonic-clonic seizures 1999;53:1162
to: stroke and intracranial venous thrombosis during pregnancy and puerperium 1999;53:1612
to: 3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease 1999;53:1162

Corticobasal degeneration
cognitive and magnetic resonance imaging aspects of corticobasal degeneration and progressive supranuclear palsy (Soliveri et al) 1999;53:502
dementia as the most common presentation of cortical-basal ganglionic degeneration (Grimes et al) 1999;53:1969
pathologic heterogeneity in clinically diagnosed corticobasal degeneration (Boeve et al) 1999;53:795

Corticospinal tract
diffusion tensor MRI assesses corticospinal tract damage in ALS (Ellis et al) 1999;53:1051

Creatine
creatin' news (Ross and Kaye) (Editorial) 1999;53:249
reduced brain creatine in gyrate atrophy of the choroid and retina with hyperornithinemia (Näntö-Salonen) 1999;53:303

Creutzfeldt-Jakob disease
incubation period of Creutzfeldt-Jakob disease in human growth hormone recipients in France (d'Aignaux et al) 1999;53:1197
multiple prion types in the same brain (Dickson and Brown) (Editorial) 1999;53:1903
preliminary evidence for anticipation in genetic E200K Creutzfeldt-Jakob disease (Rosenmann et al) 1999;53:1328
relative risk of Creutzfeldt-Jakob disease with cadaveric dura transplantation in Japan (Nakamura et al) 1999;53:218
sporadic Creutzfeldt-Jakob disease: co-occurrence of different types of PrP^{Sc} in the same brain (Puoti et al) 1999;53:2173

Cueing
ipsilesional intentional neglect and the effect of cueing (Schwartz et al) 1999;53:2017

Cyclophosphamide
pulse cyclophosphamide therapy in CIDP (Ikeda et al) (Letter); (Good et al) (Reply) 1999;53:894

Cysticercosis
heavy nonencephalitic cerebral cysticercosis in tapeworm carriers (García et al) 1999;53:1582

D

Dancing mania
relicts of dancing mania: the Dancing Procession of Echternach (Krack) (Historical Neurology) 1999;53:2169

Deafness
neuroimaging study in autosomal dominant cerebellar ataxia, deafness, and narcolepsy (Melberg et al) 1999;53:2190

Death and dying. *See also* **Mortality**
end-of-life care: a survey of US neurologists' attitudes, behavior, and knowledge (Carver et al) 1999;53:284

Degenerative disorders
accuracy of four clinical diagnostic criteria for the diagnosis of neurodegenerative dementias (Lopez et al) 1999;53:1292
alternative splicing patterns of *CYP2D* genes in human brain and neurodegenerative disorders (Woo et al) 1999;53:1570
cognitive and magnetic resonance imaging aspects of corticobasal degeneration and progressive supranuclear palsy (Soliveri et al) 1999;53:502
dementia as the most common presentation of cortical-basal ganglionic degeneration (Grimes et al) 1999;53:1969
familial multisystem degeneration with parkinsonism associated with the 11778 mitochondrial DNA mutation (Simon et al) 1999;53:1787
frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria (Faber) (Letter); (Neary) (Reply) 1999;53:1159
high prevalence of neurovascular instability in neurodegenerative dementias (Idiaquez and Sandoval) (Letter) 1999;53:1610

mutation in the microtubule-associated protein tau in pallido-nigro-luysian degeneration (Yasuda et al) 1999;53:864
neurodegenerative diseases of Guam: analysis of *TAU* (Pérez-Tur et al) 1999;53:411
pathologic heterogeneity in clinically diagnosed corticobasal degeneration (Boeve et al) 1999;53:795
study of five candidate genes in Parkinson's disease and related neurodegenerative disorders (Nicholl et al) 1999;53:1415
Wallerian degeneration of the pyramidal tract does not affect stroke rehabilitation outcome (Seitz and Binkofski) (Letter); (Miyai et al) (Reply) 1999;53:1375

Dementia. *See also* **Alzheimer's disease**
accuracy of four clinical diagnostic criteria for the diagnosis of neurodegenerative dementias (Lopez et al) 1999;53:1292
characterization of risk factors for vascular dementia: The Honolulu-Asia Aging Study (Ross et al) 1999;53:337
clinical and quantitative pathologic correlates of dementia with Lewy bodies (Gómez-Tortosa et al) 1999;53:1284
clinicopathologic correlates of dementia with Lewy bodies in comparison to Alzheimer's disease (Gómez-Isla et al) 1999;53:2003
dementia as the most common presentation of cortical-basal ganglionic degeneration (Grimes et al) 1999;53:1969
diabetes and dementia—is the brain another site of end-organ damage? (Lovestone) (Editorial) 1999;53:1907
diabetes mellitus and the risk of dementia: The Rotterdam Study (Ott et al) 1999;53:1937
differentiation of vascular dementia from AD on neuropsychological tests (Looi and Sachdev) (Views & Reviews) 1999;53:670
effect of *APOE* on dementia is not through atherosclerosis: The Rotterdam Study (Slooter et al) 1999;53:1593
head trauma and risk of dementia and Alzheimer's disease. The Rotterdam Study (Mehta et al) 1999;53:1959
highly active antiretroviral therapy reverses brain metabolite abnormalities in mild HIV dementia (Chang et al) 1999;53:782
high prevalence of neurovascular instability in neurodegenerative dementias (Idiaquez and Sandoval) (Letter) 1999;53:1610
mortality in elderly Canadians with and without dementia: a 5-year follow-up (Ostbye et al) 1999;53:521
prevalence and severity of dementia among northern Italian centenarians (Ravaglia et al) 1999;53:416
randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia (De Deyn et al) 1999;53:946
regional cerebral blood flow difference between dementia with Lewy bodies and AD (Ishii et al) 1999;53:413
relevance of glutamate levels in the CSF of patients with HIV-1-associated dementia complex (Espey et al) 1999;53:1144
report of the second dementia with Lewy body international workshop: diagnosis and treatment (McKeith et al) (Views & Reviews) 1999;53:902
sex differences in the incidence of Alzheimer's and vascular dementia (Andersen et al) 1999;53:1992
validity of clinical criteria for the diagnosis of dementia with Lewy bodies (Verghese et al) 1999;53:1974

Demyelinating disorders. *See also specific disorders*
diagnostic value of myotatic reflexes in axonal and demyelinating polyneuropathy (van Dijk et al) 1999;53:1573
diagnostic value of sural nerve T cells in chronic inflammatory demyelinating polyneuropathy (Bosboom et al) 1999;53:837
interferon-β1 in chronic inflammatory demyelinating polyneuropathy (Kuntzer et al) 1999;53:1364
matrix metalloproteinases in inflammatory demyelination: targets for treatment (Kieseier et al) (Views & Reviews) 1999;53:20
matrix metalloproteinase upregulation in chronic inflammatory demyelinating polyneuropathy and nonsystemic vasculitic neuropathy (Leppert et al) 1999;53:62
pulse cyclophosphamide therapy in CIDP (Ikeda et al) (Letter); (Good et al) (Reply) 1999;53:894
quantitative MRI in patients with clinically isolated syndromes suggestive of demyelination (Tenser) (Letter); (Miller et al) (Reply) 1999;53:1893
randomized trial of interferon β-1a in chronic inflammatory demyelinating polyradiculopathy (Hadden et al) 1999;53:57

Depression
co-morbid psychiatric disorder in chronic epilepsy: recognition and etiology of depression (Wiegartz et al) (Sept, suppl 2) 1999;53:S3
depressive disorders in epilepsy (Kanner and Nieto) (Sept, suppl 2) 1999;53:S26
postexercise motor evoked potentials in depressed patients, recovered depressed patients, and controls (Shajahan et al) 1999;53:644

Devic's syndrome
clinical course of neuromyelitis optica (Devic's syndrome) (Wingerchuk et al) 1999;53:1107
MRI and magnetization transfer imaging changes in Devic's neuromyelitis optica (Filippi et al) 1999;53:1705

Diabetes mellitus
diabetes and dementia—is the brain another site of end-organ damage? (Lovestone) (Editorial) 1999;53:1907
diabetes mellitus and the risk of dementia: The Rotterdam Study (Ott et al) 1999;53:1937
effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy (Greene et al) 1999;53:580
microvasculitis and ischemia in diabetic lumbosacral radiculoplexus neuropathy (Dyck et al) 1999;53:2113
most diabetic third nerve palsies are peripheral (Thömke et al) (Letter); (Keane and Ahmadi) (Reply) 1999;53:894

Dichloroacetate
dichloroacetate stabilizes the mutant E1α subunit in pyruvate dehydrogenase deficiency (Morten et al) 1999;53:612

Diclofenac
double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease (Scharf et al) 1999;53:197

Diffusion mapping
diffusion mapping applied to mesial temporal lobe epilepsy: preliminary observations (Hugg et al) 1999;53:173

Diplegia
brachial amyotrophic diplegia: a slowly progressive motor neuron disorder (Katz et al) 1999;53:1071

Disability
longitudinal study of cerebral glucose metabolism, MRI, and disability in patients with MS (Blinkenberg et al) 1999;53:149

Disequilibrium
neuropathology in older people with disequilibrium of unknown cause (Whitman et al) 1999;53:375

DNA
autosomal dominant progressive external ophthalmoplegia: distribution of multiple mitochondrial DNA deletions (Moslemi et al) 1999;53:79
DNA analysis of Huntington's disease: five years of experience in Germany, Austria, and Switzerland (Laccone et al) 1999;53:801
familial multisystem degeneration with parkinsonism associated with the 11778 mitochondrial DNA mutation (Simon et al) 1999;53:1787

L-Dopa
striatal biopterin and tyrosine hydroxylase protein reduction in dopa-responsive dystonia (Furukawa et al) 1999;53:1032
time course of frontal somatosensory evoked potentials: relation to L-dopa plasma levels and motor performance (Ulivelli et al) 1999;53:1451

Dopamine
cerebral dopamine concentrations during levodopa treatment (Cumming et al) (Letter) (Contin et al) (Reply) 1999;53:1374
dopamine agonists reorient visual exploration away from the neglected hemispace (Barrett) (Letter); (Geminiani) (Letter); (Grujic) (Reply) 1999;53:1610
dopamine D_2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD (Oliveri et al) 1999;53:1425

Down syndrome
APOE genotype and gender effects on Alzheimer's disease in 100 adults with Down syndrome (Lai et al) 1999;53:331

Drug abuse
prevalence of peripheral neuropathy in injection drug users (Berger et al) 1999;53:592

Dura
relative risk of Creutzfeldt-Jakob disease with cadaveric dura transplantation in Japan (Nakamura et al) 1999;53:218

Dysarthria
dysarthria during basilar artery balloon occlusion (Hartmann et al) 1999;53:421

Dyscalculia
metabolic abnormalities detected by ^{1}H-MRS in dyscalculia and dysgraphia (Levy et al) 1999;53:639

Dysferlin
dysferlin is a surface membrane-associated protein that is absent in Miyoshi myopathy (Matsuda et al) 1999;53:1119

Dysgraphia
metabolic abnormalities detected by ^{1}H-MRS in dyscalculia and dysgraphia (Levy et al) 1999;53:639

Dyskinesia
dopamine D_2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD (Oliveri et al) 1999;53:1425
mirtazapine treats resting tremor, essential tremor, and levodopa-induced dyskinesias (Pact and Giduz) 1999;53:1154

Dyslexia
brain morphometry in reading-disabled twins (Pennington et al) 1999;53:723
caudal infrasylvian surface in dyslexia: novel magnetic resonance imaging-based findings (Green et al) 1999;53:974

Dystonia
abnormal perception of vibration-induced illusion of movement in dystonia (Rome and Grünewald) 1999;53:1794
botulinum toxin A in patients with oromandibular dystonia: long term follow-up (Tan et al) 1999;53:2102
globus pallidus deep brain stimulation for generalized dystonia: clinical and PET investigation (Kumar et al) 1999;53:871

safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-resistant cervical dystonia (Brin et al) 1999;53:1431
safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia (Brashear et al) 1999;53:1439
sex-related influences on the frequency and age of onset of primary dystonia (Epidemiologic Study of Dystonia in Europe [ESDE] Collaborative Group) 1999;53:1871
soleus H-reflex tests in causalgia-dystonia compared with dystonia and mimicked dystonic posture (Koelman et al) 1999;53:2196
striatal biopterin and tyrosine hydroxylase protein reduction in dopa-responsive dystonia (Furukawa et al) 1999;53:1032

E

Economics
analysis of the costs of ischemic stroke in an Italian stroke unit (Mamoli et al) 1999;53:112
cost-effectiveness model of adjunctive lamotrigine for the treatment of epilepsy (Heaney and Sander) (Letter); (Markowitz et al) (Reply) 1999;53:657

Edema
edema associated with calcified lesions in neurocysticercosis (Nash and Patronas) 1999;53:777
hypertensive brainstem encephalopathy: three cases presenting with severe brainstem edema (Chang and Keane) 1999;53:652
optic nerve edema as a consequence of respiratory disease (O'Halloran et al) 1999;53:2204
vasogenic edema on MELAS: a serial study with diffusion-weighted MR imaging (Yoneda et al) 1999;53:2182

Education. *See also* **Medical education**
relation of education to brain size in normal aging: implications for the reserve hypothesis (Coffey et al) 1999;53:189

Elderly persons. *See* **Geriatric population**

Electroencephalography
cortical motor reorganization after paraplegia: an EEG study (Green et al) 1999;53:736
EEG checkerboard pattern of bruxism (Hirsch and Crispin) (Neuro*Images*) 1999;53:669
focal akinetic seizures as documented by electroencephalography and video recordings (Noachtar and Lüders) 1999;53:427

Electrophysiology
visual dysfunction in patients receiving vigabatrin: clinical and electrophysiologic findings (Miller et al) 1999;53:2082

Encephalitis
bilateral substantia nigra changes on MRI in a patient with encephalitis lethargica (Kun et al) 1999;53:1860
[^{11}C](*R*)-PK11195 PET imaging of activated microglia in vivo in Rasmussen's encephalitis (Banati et al) 1999;53:2199
encephalitis after hepatitis B vaccination: recurrent disseminated encephalitis or MS? (Tourbah et al) 1999;53:396
immunoglobulin G and complement immunoreactivity in the cerebral cortex of patients with Rasmussen's encephalitis (Whitney et al) 1999;53:699
parkinsonism due to predominant involvement of substantia nigra in Japanese encephalitis (Pradhan et al) 1999;53:1781
postencephalitic focal retrograde amnesia after bilateral anterior temporal lobe damage (Tanaka et al) 1999;53:344

Encephalomyelitis
clinical outcome of anti-Hu-associated encephalomyelitis after a tumor (Keime-Gilbert et al) 1999;53:1719

Encephalopathy
does HIV-8 have a protective role on the development of HIV encephalopathy? (Dorrucci et al) 1999;53:2032
encephalopathy in scleromyxedema (Johkura et al) 1999;53:1138
hypertensive brainstem encephalopathy: three cases presenting with severe brainstem edema (Chang and Keane) 1999;53:652
nonvasculitic autoimmune inflammatory meningoencephalitis (NAIM): a reversible form of encephalopathy (Caselli et al) 1999;53:1579

Endolymphatic sac tumors
VHL gene inactivation in an endolymphatic sac tumor associated with von Hippel-Lindau disease (Kawahara et al) 1999;53:208

Enteroviruses
detection and cellular localization of enterovirus RNA sequences in spinal cord of ALS patients (Berger et al) 1999;53:1998

Enzyme-linked immunosorbent assay
marginally improved detection of GM1 antibodies by Covalink ELISA in multifocal motor neuropathy (Carpo et al) 1999;53:2206
to test or not to test? (Holloway and Feasby) (Editorial) 1999;53:1905

Epilepsy. *See also* **Antiepileptic drugs; Temporal lobe epilepsy**
behavioral issues in pediatric epilepsy (Dunn and Austin) (Sept, suppl 2) 1999;53:S96
childhood-onset epilepsy with and without preceding febrile seizures (Berg et al) 1999;53:1742
clinical correlations of occipital epileptiform discharges in children (Libenson et al) 1999;53:265
coexistence of temporal lobe and idiopathic generalized epilepsies (Koutroumanidis et al) 1999;53:490
cognitive deficits in epilepsy and contribution to psychopathology (Perrine and Kiolbasa) (Sept, suppl 2) 1999;53:S49
co-morbid psychiatric disorder in chronic epilepsy: recognition and etiology of depression (Wiegartz et al) (Sept, suppl 2) 1999;53:S3
cortical excitability and recovery curve analysis in generalized epilepsy (Brodtmann et al) 1999;53:1347
cost-effectiveness model of adjunctive lamotrigine for the treatment of epilepsy (Heaney and Sander) (Letter); (Markowitz et al) (Reply) 1999;53:657
de novo status epilepticus due to multiple cerebral hamartomas (Greenfield et al) 1999;53:2237
depressive disorders in epilepsy (Kanner and Nieto) (Sept, suppl 2) 1999;53:S26
do early seizures beget epilepsy? (Theodore and Wasterlain) (Editorial) 1999;53:898
genetic localization of the familial adult myoclonic epilepsy *(FAME)* gene to chromosome 8q24 (Plaster et al) 1999;53:1180
immunoglobulin G and complement immunoreactivity in the cerebral cortex of patients with Rasmussen's encephalitis (Whitney et al) 1999;53:699
is the underlying cause of epilepsy a major prognostic factor for recurrence? (Benbadis) (Letter); (Semah) (Reply) 1999;53:440
long-term treatment with vagus nerve stimulation in patients with refractory epilepsy (Morris, III et al) 1999;53:1731
management issues for women with epilepsy (Liporace) (Letter); (Galus) (Letter); (Zahn et al) (Reply) 1999;53:656
management of migraine and epilepsy throughout the reproductive cycle (Edmeads) (Sept, suppl 1) 1999;53:S1
methodological issues in assessing risk factors for epilepsy in an epidemiological study in India (Pal et al) 1999;53:2058
mutation of *CHRNA4* responsible for autosomal dominant frontal lobe epilepsy (Hirose et al) 1999;53:1749
photosensitive epilepsies and pathophysiologic mechanisms of the photoparoxysmal response (Takahashi et al) 1999;53:926
postictal heart rate oscillations in partial epilepsy (Al-Aweel et al) 1999;53:1590
postictal in situ MRS brain lactate in the rat kindling model (Maton et al) 1999;53:2045
prevalence of epilepsy in rural Bolivia. a door-to-door survey (Nicoletti et al) 1999;53:2064
psychosis and peri-ictal confusional states (Lancman) (Sept, suppl 2) 1999;53:S33
quality of life assessment in clinical practice (Cramer) (Sept, suppl 2) 1999;53:S49
reassessment: vagus nerve stimulation for epilepsy: a report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology (Fisher and Handforth) 1999;53:666
risk factors for seizure-related motor vehicle crashes in patients with epilepsy (McAbee and Madison) (Letter); (Drachman) (Letter); (Krauss et al) (Reply) 1999;53:2214
seizure frequency and the health-related quality of life of adults with epilepsy (Leidy) 1999;53:162
serum leptin changes in epileptic patients who gain weight after therapy with valproic acid (Verrotti et al) 1999;53:230

Epley's procedure
modified Epley's procedure for self-treatment of benign paroxysmal positional vertigo (Radtke et al) 1999;53:1358

Estradiol
short-term effects of high-dose 17β-estradiol in postmenopausal Parkinson's disease patients: a crossover study (Blanchet et al) 1999;53:91

Europe
current treatment pathways in ALS: a European perspective (Dengler) 1999;53:S4

Evoked potentials
postexercise motor evoked potentials in depressed patients, recovered depressed patients, and controls (Shajahan et al) 1999;53:644
time course of frontal somatosensory evoked potentials: relation to L-dopa plasma levels and motor performance (Ulivelli et al) 1999;53:1451

Exercise
postexercise motor evoked potentials in depressed patients, recovered depressed patients, and controls (Shajahan et al) 1999;53:644

Eyelids
ptosis, blepharospasm, and apraxia of eyelid opening secondary to putaminal hemorrhage (Verghese et al) 1999;53:652

F

Familial hemiplegic migraine
CACNA1A mutations: hemiplegic migraine, episodic ataxia type 2, and the others (Tournier-Lasserve) (Editorial) 1999;53:3
genetic heterogeneity in Italian families with familial hemiplegic migraine (Carrera et al) 1999;53:26
new CACNA1A gene mutation in acetazolamide-responsive familial hemiplegic migraine and ataxia (Battistini et al) 1999;53:38

Fatigue
absence of *Borrelia burgdorferi*-specific immune complexes in chronic fatigue syndrome (Schutzer and Natelson) 1999;53:1340
enhanced fatigue during motor performance in patients with PD (Friedman) (Letter); (Ziv and Melamed) (Reply) 1999;53:438
fatigue immune-mediated polyneuropathies (Merkies et al) 1999;53: 1648
quantitative assessment of motor fatigue and strength in MS (Schwid et al) 1999;53:743
Ferroxidases
radical reactions from missing ceruloplasmin: the importance of a ferroxidase as an endogenous antioxidant (Graf and Noetzel) (Editorial) 1999;53:446
Finnish population
founder mutations and the high prevalence of myotonia congenita in northern Finland (Papponen et al) 1999;53:297
Flumazenil
glucose and [^{11}C]flumazenil PET abnormalities of thalamic nuclei in temporal lobe epilepsy (Juhász et al) 1999;53:2037
transient and falsely lateralizing flumazenil-PET asymmetries in temporal lobe epilepsy (Ryvlin et al) 1999;53:1882
Fornix
quantitative MRI in temporal lobe epilepsy: evidence for fornix atrophy (Kuzniecky et al) 1999;53:496
Fractures
alternative to vitamin D supplementation to prevent fractures in patients with MS (Sato et al) (Letter); (Cosman) (Reply) 1999;53: 437
French, Joseph H.
Joseph H. French, 1928–1999 (Rapin and Moshé) (In Memoriam) 1999: 53:1168
French population
incubation period of Creutzfeldt-Jakob disease in human growth hormone recipients in France (d'Aignaux et al) 1999;53:1197
marital status and risk of Alzheimer's disease: a French population-based cohort study (Helmer et al) 1999;53:1953
Friedrich ataxia
nonpathogenic GAAGGA repeat in the Friedrich gene: implications for pathogenesis (Ohshima et al) 1999;53:1854
Frontal lobes
APOE-ε4 is associated with less frontal and more medial temporal atrophy in AD (Geroldi et al) 1999;53:1825
facilitory paratonia and frontal lobe functioning (Agid and Lhermitte) (Letter); (Beversdorf and Heilman) (Reply) 1999;53:241
time course of frontal somatosensory evoked potentials: relation to L-dopa plasma levels and motor performance (Ulivelli et al) 1999;53: 1451
Frontotemporal lobe
frontotemporal lobar degeneration: a consensus on clinical diagnostic criteria (Faber) (Letter); (Neary) (Reply) 1999;53:1159

G

Gabapentin
gabapentin-induced anorgasmia (Clark and Elliott) 1999;53:2209
Gangliosides
Guillain-Barré syndrome with anti-GaINAc antibodies (Ang et al) 1999;53:2122
marginally improved detection of GM1 antibodies by Covalink ELISA in multifocal motor neuropathy (Carpo et al) 1999;53:2206
Gastrostomy
safety and factors related to survival after percutaneous endoscopic gastrostomy in ALS (Chiò et al) 1999;53:1123
Gender. *See also* **Sex; Women**
APOE genotype and gender effects on Alzheimer's disease in 100 adults with Down syndrome (Lai et al) 1999;53:331
gender differences in the relation between comorbidity and mortality of patients with Alzheimer's disease (Gambassi et al) 1999;53:508
Gene therapy
gene therapy using viral vectors for acute neurological insults (Sapolsky and Steinberg) (Editorial) 1999;53:1922
Genetics. *See also* **Apolipoprotein E; CACNA1A gene**
alternative splicing patterns of *CYP2D* genes in human brain and neurodegenerative disorders (Woo et al) 1999;53:1570
autosomal dominant progressive external ophthalmoplegia: distribution of multiple mitochondrial DNA deletions (Moslemi et al) 1999;53:79
autosomal dominant spastic paraplegia: refined SPG8 locus and additional genetic heterogeneity (Reid et al) 1999;53:1844
autosomal-recessive juvenile parkinsonism in a Jewish Yemenite kindred: mutation of *Parkin* gene (Nisipeanu et al) 1999;53:1602
bilineal transmission in Tourette syndrome (Hanna et al) 1999;53:813
brain size, head size, and intelligence quotient in monozygotic twins (Anderson) (Letter); (Tramo and Gazzaniga) (Reply) 1999;53:242
candidate genes and Parkinson's disease: where to next? (Markopoulou and Langston) (Editorial) 1999;53:1382
case-control study of the ubiquitin carboxy-terminal hydrolase L1 gene in Parkinson's disease (Maraganore et al) 1999;53:1858
chromosome 17p-linked myasthenias stem from defects in the acetylcholine receptor ε-subunit gene (Middleton et al) 1999;53:1076
clustering of ALS patients in central Italy due to the occurrence of the L84F SOD1 gene mutation (Ceroni et al) 1999;53:1064
differences in the gyral pattern distinguish chromosome 17-linked and X-linked lissencephaly (Dobyns et al) 1999;53:270
distinctive autosomal dominant vacuolar neuromyopathy linked to 19p13 (Servidei et al) 1999;53:830
DNA analysis of Huntington's disease: five years of experience in Germany, Austria, and Switzerland (Laccone et al) 1999;53:801
dopamine D_2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD (Oliveri et al) 1999;53:1425
estimation of the gene frequency of aceruloplasminemia in Japan (Mayajima et al) 1999;53:617
evidence for the GluR6 gene associated with younger onset age of Huntington's disease (MacDonald et al) 1999;53:1330
familial multisystem degeneration with parkinsonism associated with the 11778 mitochondrial DNA mutation (Simon et al) 1999;53:1787
genetic localization of a new locus for recessive familial spastic paraparesis to 15q13-15 (Martínez Murillo et al) 1999;53:50
genetic localization of the familial adult myoclonic epilepsy *(FAME)* gene to chromosome 8q24 (Plaster et al) 1999;53:1180
inherited prion disease with a PrP P105L mutation: clinicopathologic and PrP heterogeneity (Yamada et al) 1999;53:181
mapping of autosomal dominant progressive external ophthalmoplegia to a 7 cM critical region on 10q24 (Li et al) 1999;53:1265
moyamoya disease in Italian monozygotic twins (Andreone et al) 1999; 53:1332
mutational analysis of the tau gene in progressive supranuclear palsy (Higgins et al) 1999;53:1421
mutation of *CHRNA4* responsible for autosomal dominant frontal lobe epilepsy (Hirose et al) 1999;53:1749
myelin uncompaction in Charcot-Marie-Tooth neuropathy type 1A with a point mutation of peripheral myelin protein-22 (Fabrizi et al) 1999;53:846
myophosphorylase gene transfer in McArdle's disease myoblasts in vitro (Pari et al) 1999;53:1352
neurodegenerative diseases of Guam: analysis of *TAU* (Pérez-Tur et al) 1999;53:411
no association between Glu/Aso polymorphism of *NOS3* gene and ischemic stroke (MacLeod et al) 1999;53:418
no association of alpha-2 macroglobulin gene five-nucleotide deletion with AD in Taiwan Chinese (Hu et al) 1999;53:642
no association of paraoxonase gene polymorphism with atherosclerosis or Alzheimer's disease (Sodeyama et al) 1999;53:1146
nonpathogenic GAAGGA repeat in the Friedrich gene: implications for pathogenesis (Ohshima et al) 1999;53:1854
Parkinson's disease in twins: a follow-up study (Vieregge et al) 1999; 53:566
pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q (Rajput) (Letter); (Mori) (Reply) 1999;53:1375
PET studies of parkinsonism associated with mutation in the α-synuclein gene (Samii et al) 1999;53:2097
phenotypic analysis of autosomal dominant hereditary spastic paraplegia linked to chromosome 8q (Hedera et al) 1999;53:44
preimplantation genetic diagnosis for spinal muscular atrophy type 1 (Fallon et al) 1999;53:1087
preliminary evidence for anticipation in genetic E200K Creutzfeldt-Jakob disease (Rosenmann et al) 1999;53:1328
primary association of a TNF gene polymorphism with susceptibility to multiple sclerosis (Fernandez-Arquero et al) 1999;53:1361
relative role of genetic and environmental factors in migraine without aura (Gervil et al) 1999;53:995
repeats may not be everything in anticipation (Ashizawa and Conneally) (Editorial) 1999;53:1164
SOD1 gene mutation in a patient with slowly progressing familial ALS (Penco et al) 1999;53:404
study of five candidate genes in Parkinson's disease and related neurodegenerative disorders (Nicholl et al) 1999;53:1415
VHL gene inactivation in an endolymphatic sac tumor associated with von Hippel-Lindau disease (Kawahara et al) 1999;53:208
Von Hippel-Lindau disease: how does one gene cause multiple tumors? (Roach) (Editorial) 1999;53:7
Geriatric population
cognitive decline in individuals with high blood pressure: a longitudinal study in the elderly (Tzourio et al) 1999;53:1948
neuropathology in older people with disequilibrium of unknown cause (Whitman et al) 1999;53:375
prevalence and severity of dementia among northern Italian centenarians (Ravaglia et al) 1999;53:416
small head size is related to low Mini-Mental State Examination scores in a community sample of nondemented older adults (Reynolds et al) 1999;53:228
Gliomas
adult brainstem gliomas (Chamberlain) (Letter); (De Angelis and Landolfi) (Reply) 1999;53:437

transient MRI enhancement in a patient with seizures and previously resected glioma: use of MRS (Quan et al) 1999;53:211
Globus pallidus
globus pallidus deep brain stimulation for generalized dystonia: clinical and PET investigation (Kumar et al) 1999;53:871
Glucose
glucose and [^{11}C]flumazenil PET abnormalities of thalamic nuclei in temporal lobe epilepsy (Juhász et al) 1999;53:2037
longitudinal study of cerebral glucose metabolism, MRI, and disability in patients with MS (Blinkenberg et al) 1999;53:149
Glutamate
^{1}H-MRS evidence of neurodegeneration and excess glutamate + glutamine in ALS medulla (Pioro et al) 1999;53:71
relevance of glutamate levels in the CSF of patients with HIV-1-associated dementia complex (Espey et al) 1999;53:1144
Glutamine
^{1}H-MRS evidence of neurodegeneration and excess glutamate + glutamine in ALS medulla (Pioro et al) 1999;53:71
Guam
neurodegenerative diseases of Guam: analysis of *TAU* (Pérez-Tur et al) 1999;53:411
Guillain-Barré syndrome
Guillain-Barré syndrome with anti-GalNAc antibodies (Ang et al) 1999;53:2122
matrix metalloproteinase-9 is increased and correlates with severity in GBS (Créange et al) 1999;53:1683
neonatal Guillain-Barré syndrome: blocking antibodies transmitted from mother to child (Buchwald et al) 1999;53:1246
prognostic factors of Guillain-Barré syndrome after intravenous immunoglobulin or plasma exchange (Visser et al) 1999;53:598
residual physical outcome and daily living 3 to 6 years after Guillain-Barré syndrome (Bernsen et al) 1999;53:409
SIADH as the first symptom of Guillain-Barré syndrome (Hoffmann et al) 1999;53:1365
Gustatory function
bilateral gustatory disturbance caused by a unilateral pontine lesion (Hoshino et al) (Letter); (Uesaka et al) (Reply) 1999;53:1160
Gynecomastia
autosomal dominant familial spinal and bulbar muscular atrophy with gynecomastia (Ikezoe et al) 1999;53:2187
melatonin and painful gynecomastia (De Bleecker et al) 1999;53:435
Gypsy population
common mutation (ε1267delG) in congenital myasthenic patients of Gypsy ethnic origin (Abicht et al) 1999;53:1564

H

Haloperidol
randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia (De Deyn et al) 1999;53:946
Hamartomas
de novo status epilepticus due to multiple cerebral hamartomas (Greenfield et al) 1999;53:2237
Headache. *See also* **Cluster headaches; Familial hemiplegic migraine; Menstrual migraine; Migraine**
cerebellar hemorrhage presenting as orthostatic headache: two case reports (Chen et al) 1999;53:1887
impact of headache education program in the workplace (Mannix et al) 1999;53:868
sneezer's headache (Kurita et al) 1999;53:654
Head and neck cancer
trigeminal neuropathy secondary to perineural invasion of head and neck carcinomas (Boerman et al) 1999;53:213
Head size
brain size, head size, and intelligence quotient in monozygotic twins (Anderson) (Letter); (Tramo and Gazzaniga) (Reply) 1999;53:242
small head size is related to low Mini-Mental State Examination scores in a community sample of nondemented older adults (Reynolds et al) 1999;53:228
Health care
health care utilization in MS (Sander and Masdeu) (Letter); (Stolp-Smith et al) (Reply) 1999;53:892
Heart
cardiac uptake of [^{123}I]MIBG separates Parkinson's disease from multiple system atrophy (Braune et al) 1999;53:1020
Heart rate
postictal heart rate oscillations in partial epilepsy (Al-Aweel et al) 1999;53:1590
Hemicrania
cognitive processing is involved in cluster headache but not in chronic paroxysmal hemicrania (Evers et al) 1999;53:357
Hemifacial spasm
case-controlled MRI/MRA study of neurovascular contact in hemifacial spasm (Ho et al) 1999;53:2132
Hemiplegia. *See also* **Familial hemiplegic migraine**
novel nonsense mutation in CACNA1A causes episodic ataxia and hemiplegia (Jen et al) 1999;53:34
pontine anosognosia for hemiplegia (Evyapan and Kumral) 1999;53:647
Hemodynamics
brain arteriosclerosis and hemodynamic disturbance may induce leukoaraiosis (Yamauchi et al) 1999;53:1833
cerebral hemodynamic impairment: methods of measurement and association with stroke risk (Derdeyn et al) (Views & Reviews) 1999;53:251
Hemorrhage. *See also* **Intracerebral hemorrhage**
aneurysms in relatives of patients with subarachnoid hemorrhage: frequency and risk factors (Raaymakers and the MARS Study Group) 1999;53:982
cerebellar hemorrhage presenting as orthostatic headache: two case reports (Chen et al) 1999;53:1887
cerebral amyloid angiopathy with unilateral hemorrhages, mass effect, and meningeal enhancement (Morton-Bours et al) 1999;53:233
major bleeding during anticoagulation after cerebral ischemia: patterns and risk factors (Gorter) 1999;53:1319
MRI detection of new hemorrhages: potential marker of progression in cerebral amyloid angiopathy (Greenberg et al) 1999;53:1135
ptosis, blepharospasm, and apraxia of eyelid opening secondary to putaminal hemorrhage (Verghese et al) 1999;53:652
Hepatitis
encephalitis after hepatitis B vaccination: recurrent disseminated encephalitis or MS? (Tourbah et al) 1999;53:396
neurologic complications associated with hepatitis C virus infection (Tembl et al) 1999;53:861
Heroin
leukoencephalopathy and raised brain lactate from heroin vapor inhalation ("chasing the dragon") (Kriegstein et al) 1999;53:1765
Herpesviruses
absence of human herpesvirus 6 and 7 from spinal fluid and serum of multiple sclerosis patients (Mirandola et al) 1999;53:1367
Hippocampus
cognitive consequences of coexisting temporal lobe developmental malformations and hippocampal sclerosis (Martin et al) 1999;53:709
cognitive correlates of ^{1}H MRSI detected hippocampal abnormalities in temporal lobe epilepsy (Martin et al) 1999;53:2052
MRI volumes of amygdala and hippocampus in non-mentally retarded autistic adolescents and adults (Aylward et al) 1999;53:2145
Human growth hormone
incubation period of Creutzfeldt-Jakob disease in human growth hormone recipients in France (d'Aignaux et al) 1999;53:1197
Human immunodeficiency virus
distinct light microscopic changes in HIV-associated nemaline myopathy (Miró et al) (Letter); (Feinberg et al) (Reply) 1999;53:241
does HIV-8 have a protective role on the development of HIV encephalopathy? (Dorrucci et al) 1999;53:2032
highly active antiretroviral therapy reverses brain metabolite abnormalities in mild HIV dementia (Chang et al) 1999;53:782
prevalence of peripheral neuropathy in injection drug users (Berger et al) 1999;53:592
randomized trial of the platelet-activating factor antagonist lexipafant in HIV-associated cognitive impairment (Schifitto et al) 1999;53:391
relevance of glutamate levels in the CSF of patients with HIV-1-associated dementia complex (Espey et al) 1999;53:1144
Human leukocyte antigens
HLA-DQ1 associated with reflex sympathetic dystrophy (Kemler et al) 1999;53:1350
Human T-cell lymphotrophic virus type 1
inverse correlation of HTLV-1 viral load in CSF and intrathecal synthesis of HTLV-1 antibodies in TSP/HAM (Puccioni-Sohler et al) 1999;53:1335
quantitative assessment of subclinical spasticity in human T-cell lymphotrophic virus type 1 infection (Zunt et al) 1999;53:386
Huntington's disease
clinical correlation of striatal ^{1}H MRS changes in Huntington's disease (Sánchez-Pernaute et al) 1999;53:806
DNA analysis of Huntington's disease: five years of experience in Germany, Austria, and Switzerland (Laccone et al) 1999;53:801
evidence for the GluR6 gene associated with younger onset age of Huntington's disease (MacDonald et al) 1999;53:1330
influence of lamotrigine on progression of early Huntington disease: a randomized clinical trial (Kremer et al) 1999;53:1000
long-lasting improvement following (-)-OSU6162 in a patient with Huntington's disease (Tedroff et al) 1999;53:1605
Hyperalgesia
brain processing of capsaicin-induced secondary hyperalgesia: a functional MRI study (Baron et al) 1999;53:548
Hyperornithinemia
reduced brain creatine in gyrate atrophy of the choroid and retina with hyperornithinemia (Näntö-Salonen) 1999;53:303
Hypertension. *See also* **Intracranial hypertension**
cognitive decline in individuals with high blood pressure: a longitudinal study in the elderly (Tzourio et al) 1999;53:1948

hypertensive brainstem encephalopathy: three cases presenting with severe brainstem edema (Chang and Keane) 1999;53:652
Hyperventilation
effect of hyperventilation in downbeat nystagmus in cerebellar disorders (Walker and Zee) 1999;53:1576
hyperventilation-induced nystagmus in patients with vestibular schwannoma (Minor et al) 1999;53:2158
Hypotension
treatment of neurogenic orthostatic hypotension with 3,4-DL-threo-dihydroxyphenylserine (Freeman et al) 1999;53:2151
Hypothalamo-pituitary-adrenal axis
dysregulation of the hypothalamo-pituitary-adrenal axis is related to the clinical course of MS (Then Bergh et al) 1999;53:772
Hypoxia
no evidence of hypoxic tissue on ^{18}F-fluoromisonidazole PET following intracerebral hemorrhage (Hirano et al) 1999;53:2179

I

Immune complexes
absence of *Borrelia burgdorferi*-specific immune complexes in chronic fatigue syndrome (Schutzer and Natelson) 1999;53:1340
Immune function
fatigue immune-mediated polyneuropathies (Merkies et al) 1999;53:1648
Immunoglobulins
immunoglobulin G and complement immunoreactivity in the cerebral cortex of patients with Rasmussen's encephalitis (Whitney et al) 1999;53:699
prognostic factors of Guillain-Barré syndrome after intravenous immunoglobulin or plasma exchange (Visser et al) 1999;53:598
Immunotherapy
targeting immunotherapy in multiple sclerosis: a near hit and a clear miss (Schwid and Noseworthy) (Editorial) 1999;53:444
Indian population
methodological issues in assessing risk factors for epilepsy in an epidemiological study in India (Pal et al) 1999;53:2058
Inflammatory disorders
diagnostic value of sural nerve T cells in chronic inflammatory demyelinating polyneuropathy (Bosboom et al) 1999;53:837
interferon-gamma-inducing factor and interferon-gamma in inflammatory CNS diseases (Fassbender et al) 1999;53:1104
matrix metalloproteinases in inflammatory demyelination: targets for treatment (Kieseier et al) (Views & Reviews) 1999;53:20
matrix metalloproteinase upregulation in chronic inflammatory demyelinating polyneuropathy and nonsystemic vasculitic neuropathy (Leppert et al) 1999;53:62
randomized trial of interferon β-1a in chronic inflammatory demyelinating polyradiculopathy (Hadden et al) 1999;53:57
Insulin
insulin acts in hypokalemic periodic paralysis by reducing inward rectifier K^+ current (Ruff) 1999;53:1556
Intensive care unit
withdrawal of life support in the neurologic intensive care unit (Pullicino and Burke) (Letter); (Mayer and Kossoff) (Reply) 1999;53:2215
Intercellular adhesion molecules
changes in serum levels of ICAM and TNF-R correlate with disease activity in multiple sclerosis (Khoury et al) 1999;53:758
changes of serum sICAM-1 and MMP-9 induced by rIFNβ-1b treatment in relapsing-remitting MS (Trojano et al) 1999;53:1402
Interferon
changes of serum sICAM-1 and MMP-9 induced by rIFNβ-1b treatment in relapsing-remitting MS (Trojano et al) 1999;53:1402
enhanced spasticity in primary progressive MS patients treated with interferon beta-1b (Frese) (Letter); (Bramanti et al) (Reply) 1999;53:1892
evidence of interferon β-1a dose response in relapsing-remitting MS: the OWIMS study 1999;53:679
interferon beta induces T-helper 2 immune deviation in MS (Kozovska et al) 1999;53:1692
interferon-gamma-inducing factor and interferon-gamma in inflammatory CNS diseases (Fassbender et al) 1999;53:1104
interferon-β1 in chronic inflammatory demyelinating polyneuropathy (Kuntzer et al) 1999;53:1364
lethal capillary leak syndrome after a single administration of interferon beta-1b (Schmidt et al) 1999;53:220
MS: side effects of IFNβ therapy (Walther and Hohlfeld) (Views & Reviews) 1999;53:1622
pilot study of MRI activity before and during interferon beta-1a therapy (Waubant et al) 1999;53:874
randomized trial of interferon β-1a in chronic inflammatory demyelinating polyradiculopathy (Hadden et al) 1999;53:57
subacute thyroiditis in a patient with MS treated with interferon beta-1a (Kreiss et al) 1999;53:1606
Intracerebral hemorrhage
artificial neural networks improve the prediction of mortality in intracerebral hemorrhage (Edwards et al) 1999;53:351
intracerebral hemorrhage outcome: apolipoprotein E genotype, hematoma, and edema volumes (McCarron et al) 1999;53:2176
no evidence of hypoxic tissue on ^{18}F-fluoromisonidazole PET following intracerebral hemorrhage (Hirano et al) 1999;53:2179
reduction of intracerebral hemorrhaging in a rabbit embolic stroke model (Hu et al) 1999;53:2140
Intracranial hypertension
isolated intracranial hypertension as the only sign of cerebral venous thrombosis (Biousse et al) 1999;53:1537
serum vitamin A concentration is elevated in idiopathic intracranial hypertension (Jacobson et al) 1999;53:1114
Ischemia. *See also* **Ischemic stroke**
microvasculitis and ischemia in diabetic lumbosacral radiculoplexus neuropathy (Dyck et al) 1999;53:2113
Ischemic stroke
analysis of the costs of ischemic stroke in an Italian stroke unit (Mamoli et al) 1999;53:112
antiphosphatidyl serine antibodies are independently associated with ischemic stroke (Tuhrim et al) 1999;53:1523
antithrombotic treatment of ischemic stroke among patients with occlusion or severe stenosis of the internal carotid artery: a report of the Trial of Organization 10172 in Acute Stroke Treatment (TOAST) (Adams Jr. et al) 1999;53:122
APOE genotype as a risk factor for ischemic cerebrovascular disease: a meta-analysis (McCarron et al) 1999;53:1308
comparison of population-based models of risk factors for TIA and ischemic stroke (Whisnant et al) 1999;53:532
ischemic penumbra: operationally defined by diffusion and perfusion MRI (Schlaug et al) 1999;53:1528
major bleeding during anticoagulation after cerebral ischemia: patterns and risk factors (Gorter) 1999;53:1319
no association between Glu/Aso polymorphism of *NOS3* gene and ischemic stroke (MacLeod et al) 1999;53:418
thrombolysis in acute ischemic stroke: controlled trials and clinical experience (Hacke et al) (Sept, suppl 4) 1999;53:S3
Isoprostane
cerebrospinal fluid isoprostane shows oxidative stress in patients with multiple sclerosis (Greco et al) 1999;53:1876
Italian population
analysis of the costs of ischemic stroke in an Italian stroke unit (Mamoli et al) 1999;53:112
clustering of ALS patients in central Italy due to the occurrence of the L84F SOD1 gene mutation (Ceroni et al) 1999;53:1064
genetic heterogeneity in Italian families with familial hemiplegic migraine (Carrera et al) 1999;53:26
lack of sodium channel mutations in an Italian family with paramyotonia congenita (Sampaolo et al) 1999;53:1549
moyamoya disease in Italian monozygotic twins (Andreone et al) 1999;53:1332
prevalence and severity of dementia among northern Italian centenarians (Ravaglia et al) 1999;53:416

J

Japanese population
estimation of the gene frequency of aceruloplasminemia in Japan (Mayajima et al) 1999;53:617
relative risk of Creutzfeldt-Jakob disease with cadaveric dura transplantation in Japan (Nakamura et al) 1999;53:218
Jewish Yemenite kindred
autosomal-recessive juvenile parkinsonism in a Jewish Yemenite kindred: mutation of *Parkin* gene (Nisipeanu et al) 1999;53:1602

K

Kinases
aberrant expression of cyclin-dependent kinase 5 in inclusion body myositis (Nakano et al) 1999;53:1671

L

Lactate
leukoencephalopathy and raised brain lactate from heroin vapor inhalation ("chasing the dragon") (Kriegstein et al) 1999;53:1765
postictal in situ MRS brain lactate in the rat kindling model (Maton et al) 1999;53:2045
Lactic acidosis
fulminant neuropathy and lactic acidosis associated with nucleoside analog therapy (Verma et al) 1999;53:1365
Lamotrigine
cost-effectiveness model of adjunctive lamotrigine for the treatment of epilepsy (Heaney and Sander) (Letter); (Markowitz et al) (Reply) 1999;53:657
influence of lamotrigine on progression of early Huntington disease: a randomized clinical trial (Kremer et al) 1999;53:1000
lamotrigine adjunctive therapy in painful phenomena in MS: preliminary observations (Cianchetti et al) 1999;53:433
multisystem hypersensitivity reaction to lamotrigine (Sarris and Wong) 1999;53:1367
placebo-controlled trial of lamotrigine add-on therapy for partial seizures in children (Duchowny et al) 1999;53:1724

possible usefulness of lamotrigine in the treatment of SUNCT syndrome (D'Andrea et al) 1999;53:1609
Language function
cerebral lateralization: relationship of language and ideomotor praxis (Meador et al) 1999;53:2028
cessation of stuttering after bilateral thalamic infarction (Muroi et al) 1999;53:890
effects of anomalous language representation on neuropsychological performance in temporal lobe epilepsy (Loring et al) 1999;53:260
language dominance determined by magnetic source imaging: a comparison with the Wada procedure (Breier et al) 1999;53:938
making sense out of jargon: a neurolinguistic and computational account of jargon aphasia (Hillis et al) 1999;53:1813
Learning disabilities
brain morphometry in reading-disabled twins (Pennington et al) 1999; 53:723
Leptin
serum leptin changes in epileptic patients who gain weight after therapy with valproic acid (Verrotti et al) 1999;53:230
Leptomeningeal metastases
presenting features and value of diagnostic procedures in leptomeningeal metastases (van Oostenbrugge and Twijnstra) 1999;53:382
Leukoaraiosis
brain arteriosclerosis and hemodynamic disturbance may induce leukoaraiosis (Yamauchi et al) 1999;53:1833
Leukoencephalopathy
leukoencephalopathy and raised brain lactate from heroin vapor inhalation ("chasing the dragon") (Kriegstein et al) 1999;53:1765
phenotypic variation in leukoencephalopathy with vanishing white matter (Rodriguez and Gelot) (Letter); (van der Knaap and Kamphorst) (Reply) 1999;53:1373
posterior leukoencephalopathy without severe hypertension: utility of diffusion-weighted MRI (Obeid and Awada) (Letter); (Ay et al) (Reply) 1999;53:1372
Levodopa
cerebral dopamine concentrations during levodopa treatment (Cumming et al) (Letter); (Contin et al) (Reply) 1999;53:1374
dopamine D_2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD (Oliveri et al) 1999;53:1425
fluoroDOPA PET shows the nondopaminergic as well as dopaminergic destinations of levodopa (Brown et al) 1999;53:1212
immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study (Koller et al) 1999;53:1012
mirtazapine treats resting tremor, essential tremor, and levodopa-induced dyskinesias (Pact and Giduz) 1999;53:1154
pharmacodynamics of the long-duration response to levodopa in PD (Zappia et al) 1999;53:557
Lewy bodies
clinical and quantitative pathologic correlates of dementia with Lewy bodies (Gómez-Tortosa et al) 1999;53:1284
validity of clinical criteria for the diagnosis of dementia with Lewy bodies (Verghese et al) 1999;53:1974
Lexipafant
randomized trial of the platelet-activating factor antagonist lexipafant in HIV-associated cognitive impairment (Schifitto et al) 1999;53: 391
Life support
withdrawal of life support in the neurologic intensive care unit (Pullicino and Burke) (Letter); (Mayer and Kossoff) (Reply) 1999; 53:2215
Lipids
APOE genotype, plasma lipids, lipoproteins, and AD in community elderly (Romas et al) 1999;53:517
Lipoproteins
APOE genotype, plasma lipids, lipoproteins, and AD in community elderly (Romas et al) 1999;53:517
Lipoteichoic acid
clinical outcome in pneumococcal meningitis correlates with CSF lipoteichoic acid concentrations (Schneider et al) 1999;53:1584
Lissencephaly
differences in the gyral pattern distinguish chromosome 17-linked and X-linked lissencephaly (Dobyns et al) 1999;53:270
Lumbosacral spine
microvasculitis and ischemia in diabetic lumbosacral radiculoplexus neuropathy (Dyck et al) 1999;53:2113
Lung transplantation
neurologic complications of pediatric lung transplantation (Wong et al) 1999;53:1542

M

McArdle's disease
myophosphorylase gene transfer in McArdle's disease myoblasts in vitro (Pari et al) 1999;53:1352
Maculopathy
maculopathy in spinocerebellar ataxia type 7 (Morrow et al) (*NeuroImages*) 1999;53:244
Magnetic resonance angiography
case-controlled MRI/MRA study of neurovascular contact in hemifacial spasm (Ho et al) 1999;53:2132
Magnetic resonance imaging
absent pachymeningeal gadolinium enhancement on cranial MRI despite symptomatic CSF leak (Mokri et al) 1999;53:402
bilateral substantia nigra changes on MRI in a patient with encephalitis lethargica (Kun et al) 1999;53:1860
brain processing of capsaicin-induced secondary hyperalgesia: a functional MRI study (Baron et al) 1999;53:548
case-controlled MRI/MRA study of neurovascular contact in hemifacial spasm (Ho et al) 1999;53:2132
caudal infrasylvian surface in dyslexia: novel magnetic resonance imaging-based findings (Green et al) 1999;53:974
clinical and MRI findings in spinocerebellar ataxia type 5 (Stevanin et al) 1999;53:1355
cognitive and magnetic resonance imaging aspects of corticobasal degeneration and progressive supranuclear palsy (Soliveri et al) 1999;53:502
contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis (Fazekas et al) (Views & Reviews) 1999;53:448
correlation between magnetization transfer metrics and other magnetic resonance imaging abnormalities in muscle (Rouvaris et al) 1999;53:S40
diffusion tensor MRI assesses corticospinal tract damage in ALS (Ellis et al) 1999;53:1051
fatigue in multiple sclerosis: cross-sectional correlation with brain MRI findings in 71 patients (Bakshi et al) 1999;53:1151
ischemic penumbra: operationally defined by diffusion and perfusion MRI (Schlaug et al) 1999;53:1528
longitudinal study of cerebral glucose metabolism, MRI, and disability in patients with MS (Blinkenberg et al) 1999;53:149
motor cortex localization using functional MRI and transcranial magnetic stimulation (Macdonell et al) 1999;53:1462
MRI and magnetization transfer imaging changes in Devic's neuromyelitis optica (Filippi et al) 1999;53:1705
MRI detection of new hemorrhages: potential marker of progression in cerebral amyloid angiopathy (Greenberg et al) 1999;53:1135
MRI in multiple sclerosis during the menstrual cycle: relationship with sex hormone patterns (Pozzilli et al) 1999;53:622
MRI volumes of amygdala and hippocampus in non-mentally retarded autistic adolescents and adults (Aylward et al) 1999;53:2145
MRI white matter hyperintensities: three-year follow-up of the Austrian Stroke Prevention Study (Schmidt et al) 1999;53:132
multisequence MRI in clinically isolated syndromes and the early development of MS (Brex et al) 1999;53:1184
perceptual processing of stereopsis in humans: high-field (3.0-tesla) functional MRI study (Kwee et al) 1999;53:1599
perfusion- and diffusion-weighted magnetic resonance imaging in transient global amnesia (Budson et al) (Letter); (Furie and Ay) (Reply) 1999;53:239
pilot study of MRI activity before and during interferon beta-1a therapy (Waubant et al) 1999;53:874
posterior leukoencephalopathy without severe hypertension: utility of diffusion-weighted MRI (Obeid and Awada) (Letter); (Ay et al) (Reply) 1999;53:1372
quantitative MRI in patients with clinically isolated syndromes suggestive of demyelination (Tenser) (Letter); (Miller et al) (Reply) 1999;53:1893
quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H (Paolillo et al) 1999;53:751
quantitative MRI in temporal lobe epilepsy: evidence for fornix atrophy (Kuzniecky et al) 1999;53:496
serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis (Waubant et al) 1999;53:1397
silent functional magnetic resonance demonstrates focal activation in REM sleep (Lövblad et al) 1999;53:2193
transient MRI enhancement in a patient with seizures and previously resected glioma: use of MRS (Quan et al) 1999;53:211
vasogenic edema on MELAS: a serial study with diffusion-weighted MR imaging (Yoneda et al) 1999;53:2182
Magnetic resonance spectroscopy
cognitive correlates of ^{1}H MRSI detected hippocampal abnormalities in temporal lobe epilepsy (Martin et al) 1999;53:2052
localized proton magnetic resonance spectroscopy in relapsing remitting versus secondary progressive multiple sclerosis (Tourbah et al) 1999;53:1091
metabolic abnormalities detected by ^{1}H-MRS in dyscalculia and dysgraphia (Levy et al) 1999;53:639
postictal in situ MRS brain lactate in the rat kindling model (Maton et al) 1999;53:2045
predictive value of ^{1}H MRSI for outcome in temporal lobectomy (Kuzniecky et al) 1999;53:694
transient MRI enhancement in a patient with seizures and previously resected glioma: use of MRS (Quan et al) 1999;53:211

Magnetic source imaging
language dominance determined by magnetic source imaging: a comparison with the Wada procedure (Breier et al) 1999;53:938
Magnetic stimulation. *See* **Transcranial magnetic stimulation**
Magnetization transfer imaging
application of magnetization transfer imaging to multiple sclerosis (Grossman) (Sept, suppl 3) 1999;53:S8
correlation between magnetization transfer metrics and other magnetic resonance imaging abnormalities in muscle (Rouvaris et al) 1999;53:S40
magnetization transfer contrast: its utility as a technique and its application to central nervous system pathology (Bagley et al) (Sept, suppl 3) 1999;53:S49
magnetization transfer imaging methodology: its clinical and neuropsychological correlates (van Buchem et al) (Sept, suppl 3) 1999;53:S23
magnetization transfer imaging of the spinal cord and optic nerve in patients with multiple sclerosis (van Waesberghe and Barkhof) (Sept, suppl 3) 1999;53:S46
magnetization transfer imaging to monitor clinical trials in multiple sclerosis (Richert and Frank) (Sept, suppl 3) 1999;53:S29
magnetization transfer imaging to monitor the evolution of individual multiple sclerosis lesions (Filippi) (Sept, suppl 3) 1999;53:S18
MRI and magnetization transfer imaging changes in Devic's neuromyelitis optica (Filippi et al) 1999;53:1705
pathological correlated of magnetization transfer imaging abnormalities in animal models and humans with multiple sclerosis (Brochet and Dousset) (Sept, suppl 3) 1999;53:S12
physical basis of magnetization transfer imaging (McGovern) (Sept, suppl 3) 1999;53:S3
standardization of magnetization transfer imaging for multicenter studies (Sept, suppl 3) 1999;53:S33
Major histocompatibility complex
major histocompatibility complex class II alleles and the course and outcome of MS (McDonnell and Hawkins) (Letter); (Weinshenker) (Reply) 1999;53:893
Malignancies. *See also specific malignancies*
meningeal metastases from malignant melanoma presenting with gaze-evoked tinnitus (Caraceni et al) 1999;53:2207
mortality cancer risk in parkinsonian patients: a population-based study (Riggs) (Letter); (Vanacore et al) (Reply) 1999;53:1158
neoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma (Paleologos et al) 1999;53:1141
novel antineuronal antibody in a motor neuron syndrome associated with breast cancer (Ferracci et al) 1999;53:852
trigeminal neuropathy secondary to perineural invasion of head and neck carcinomas (Boerman et al) 1999;53:213
Marital status
marital status and risk of Alzheimer's disease: a French population-based cohort study (Helmer et al) 1999;53:1953
Matrix metalloproteinases
changes of serum sICAM-1 and MMP-9 induced by rIFNβ-1b treatment in relapsing-remitting MS (Trojano et al) 1999;53:1402
matrix metalloproteinase-9 is increased and correlates with severity in GBS (Créange et al) 1999;53:1683
matrix metalloproteinases in inflammatory demyelination: targets for treatment (Kieseier et al) (Views & Reviews) 1999;53:20
matrix metalloproteinases in multiple sclerosis: targets of therapy or markers of injury? (Bever and Rosenberg) (Editorial) 1999;53:1380
matrix metalloproteinase upregulation in chronic inflammatory demyelinating polyneuropathy and nonsystemic vasculitic neuropathy (Leppert et al) 1999;53:62
serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis (Waubant et al) 1999;53:1397
Medical education
changing face of academic neurology: implications for neurologic education at the millennium (Pedley) 1999;53:906
federal funding for graduate medical education (Weinrish) 1999;53:1175
Medulla
cervical cord and dorsal medullary infarction presenting with retro-orbital pain (de la Sayette et al) 1999;53:632
^{1}H-MRS evidence of neurodegeneration and excess glutamate + glutamine in ALS medulla (Pioro et al) 1999;53:71
medullary syndrome characterized by wild arm ataxia (Currier and Bebin) 1999;53:1608
Megalencephaly
primary megalencephaly at birth and low intelligence level (Petersson et al) 1999;53:1254
Melanoma
meningeal metastases from malignant melanoma presenting with gaze-evoked tinnitus (Caraceni et al) 1999;53:2207
MELAS
vasogenic edema on MELAS: a serial study with diffusion-weighted MR imaging (Yoneda et al) 1999;53:2182
Melatonin
melatonin and painful gynecomastia (De Bleecker et al) 1999;53:435
Memory
brain activation during working memory 1 month after mild traumatic brain injury: a functional MRI study (McAllister et al) 1999;53:1300
cluster headaches: association with anxiety disorders and memory deficits (Jorge et al) 1999;53:543
faster memory decline in AD patients with higher educational or occupational attainment: cognitive reserve? (Stern et al) 1999;53:1942
preclinical memory decline in cognitively normal apolipoprotein E-ε4 homozygotes (Caselli et al) 1999;53:201
subjective versus objective memory change after temporal lobe epilepsy surgery (Sawrie et al) 1999;53:1511
Meninges
cerebral amyloid angiopathy with unilateral hemorrhages, mass effect, and meningeal enhancement (Morton-Bours et al) 1999;53:233
meningeal metastases from malignant melanoma presenting with gaze-evoked tinnitus (Caraceni et al) 1999;53:2207
Meningitis
clinical outcome in pneumococcal meningitis correlates with CSF lipoteichoic acid concentrations (Schneider et al) 1999;53:1584
Menopause
epilepsy in the menopause (Lee) (Sept, suppl 1) 1999;53:S41
lifetime cognitive function and timing of the natural menopause (Richards et al) 1999;53:308
migraine in the menopause (Fettes) (Sept, suppl 1) 1999;53:S29
short-term effects of high-dose 17β-estradiol in postmenopausal Parkinson's disease patients: a crossover study (Blanchet et al) 1999;53:91
Menstrual cycle
management of migraine and epilepsy throughout the reproductive cycle (Edmeads) (Sept, suppl 1) 1999;53:S1
menstrual cycle effects on cortical excitability (Smith et al) 1999;53:2069
MRI in multiple sclerosis during the menstrual cycle: relationship with sex hormone patterns (Pozzilli et al) 1999;53:622
sex hormones and headache 1999 (menstrual migraine) (Silberstein and Merriam) (Sept, suppl 1) 1999;53:S3
Menstrual migraine
management of migraine and epilepsy throughout the reproductive cycle (Edmeads) (Sept, suppl 1) 1999;53:S1
sex hormones and headache 1999 (menstrual migraine) (Silberstein and Merriam) (Sept, suppl 1) 1999;53:S3
use of oral contraceptives in patients with menstrual migraine (Becker) (Sept, suppl 1) 1999;53:S19
Mental retardation
APOE genotype and gender effects on Alzheimer's disease in 100 adults with Down syndrome (Lai et al) 1999;53:331
primary megalencephaly at birth and low intelligence level (Petersson et al) 1999;53:1254
Metabolism
effect of vigabatrin on cerebral blood flow and metabolism (Spanaki et al) 1999;53:1518
longitudinal study of cerebral glucose metabolism, MRI, and disability in patients with MS (Blinkenberg et al) 1999;53:149
metabolic abnormalities detected by ^{1}H-MRS in dyscalculia and dysgraphia (Levy et al) 1999;53:639
Metastatic disease
presenting features and value of diagnostic procedures in leptomeningeal metastases (van Oostenbrugge and Twijnstra) 1999;53:382
Metrifonate
metrifonate treatment of AD: influence of apolipoprotein E genotype (Farlow et al) 1999;53:2010
MIBG
cardiac uptake of [^{123}I]MIBG separates Parkinson's disease from multiple system atrophy (Braune et al) 1999;53:1020
Microglia
[^{11}C]*(R)*-PK11195 PET imaging of activated microglia in vivo in Rasmussen's encephalitis (Banati et al) 1999;53:2199
Midbrain
compression of the midbrain (Chalela and Kasner) (Neuro*Images*) 1999;53:423
Migraine. *See also* **Familial hemiplegic migraine; Menstrual migraine**
increased brain serotonin synthesis in migraine (Chugani et al) 1999;53:1473
increasing incidence of medically recognized migraine headache in a Unites States population (Rozen et al) 1999;53:1468
international study to assess reliability of the Migraine Disability Assessment (MIDAS) score (Stewart et al) 1999;53:988
migraine in pregnancy (Aubé) (Sept, suppl 1) 1999;53:S26
migraine in the menopause (Fettes) (Sept, suppl 1) 1999;53:S29
potential source of cerebral embolism in migraine with aura: a transcranial Doppler study (Cheng) (Letter); (Anzola et al) (Reply) 1999;53:2213

prevalence and characteristics of migraine in a population-based cohort: The GEM Study (Launer et al) 1999;53:537
relative role of genetic and environmental factors in migraine without aura (Gervil et al) 1999;53:995
Mini-Mental State Examination
norms for the Mini-Mental State Examination in a healthy population (Grigoletto et al) 1999;53:315
small head size is related to low Mini-Mental State Examination scores in a community sample of nondemented older adults (Reynolds et al) 1999;53:228
Minnesota
autopsy patterns for Parkinson's disease and related disorders in Olmsted County, Minnesota (Maraganore et al) 1999;53:1342
Mirtazapine
mirtazapine treats resting tremor, essential tremor, and levodopa-induced dyskinesias (Pact and Giduz) 1999;53:1154
Misoprostol
double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease (Scharf et al) 1999;53:197
Mitochondria
age and cause of death in mitochondrial diseases (Klopstock et al) 1999;53:855
familial multisystem degeneration with parkinsonism associated with the 11778 mitochondrial DNA mutation (Simon et al) 1999;53:1787
Monoamine oxidase
Parkinson's disease, MOAB, and smoking (Mellick et al) (Letter) 1999;53:658
Monoclonal antibodies
quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H (Paolillo et al) 1999;53:751
Morphometry
effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy (Greene et al) 1999;53:580
Mortality. *See also* **Death and dying**
age and cause of death in mitochondrial diseases (Klopstock et al) 1999;53:855
artificial neural networks improve the prediction of mortality in intracerebral hemorrhage (Edwards et al) 1999;53:351
gender differences in the relation between comorbidity and mortality of patients with Alzheimer's disease (Gambassi et al) 1999;53:508
mortality cancer risk in parkinsonian patients: a population-based study (Riggs) (Letter); (Vanacore et al) (Reply) 1999;53:1158
mortality in elderly Canadians with and without dementia: a 5-year follow-up (Ostbye et al) 1999;53:521
study of mortality after temporal lobe epilepsy surgery (Hennessy et al) 1999;53:1276
Motor cortex
changes in excitability of motor cortical circuitry in primary restless legs syndrome (Entezari-Taher et al) 1999;53:1201
cortical motor reorganization after paraplegia: an EEG study (Green et al) 1999;53:736
deficient activation of the motor cortical network in patients with writer's cramp (Ibáñez et al) 1999;53:96
inhibition in the human motor cortex is reduced just before a voluntary contraction (Reynolds and Ashby) 1999;53:730
long-term reorganization of motor cortex outputs after arm amputation (Röricht et al) 1999;53:106
motor cortex localization using functional MRI and transcranial magnetic stimulation (Macdonell et al) 1999;53:1462
releasing the brakes before pressing the gas pedal (Floeter and Rothwell) (Editorial) 1999;53:664
Motor evoked potentials
postexercise motor evoked potentials in depressed patients, recovered depressed patients, and controls (Shajahan et al) 1999;53:644
Motor function
cerebral lateralization: relationship of language and ideomotor praxis (Meador et al) 1999;53:2028
critical decline in fine motor hand movements in human aging (Smith et al) 1999;53:1458
enhanced fatigue during motor performance in patients with PD (Friedman) (Letter); (Ziv and Melamed) (Reply) 1999;53:438
mice lacking cytosolic copper/zinc superoxide dismutase display a distinctive motor axonopathy (Shefner et al) 1999;53:1239
motor dysfunction in mildly demented AD individuals without extrapyramidal signs (Goldman et al) 1999;53:956
robot training enhanced motor outcome in patients with stroke maintained over 3 years (Volpe et al) 1999;53:1874
time course of frontal somatosensory evoked potentials: relation to L-dopa plasma levels and motor performance (Ulivelli et al) 1999;53:1451
Motor neurons
brachial amyotrophic diplegia: a slowly progressive motor neuron disorder (Katz et al) 1999;53:1071
novel antineuronal antibody in a motor neuron syndrome associated with breast cancer (Ferracci et al) 1999;53:852
transcranial magnetic stimulation identifies upper motor neuron involvement in motor neuron disease (Triggs et al) 1999;53:605
Motor vehicle crashes
risk factors for seizure-related motor vehicle crashes in patients with epilepsy (McAbee and Madison) (Letter); (Drachman) (Letter); (Krauss et al) (Reply) 1999;53:2214
Movement disorders. *See also specific disorders*
orthostatic limb shaking from carotid hypoperfusion (Zaidat et al) 1999;53:650
relicts of dancing mania: the Dancing Procession of Echternach (Krack) 1999;53:2169
Moyamoya disease
moyamoya disease in Italian monozygotic twins (Andreone et al) 1999;53:1332
Multiple sclerosis
absence of human herpesvirus 6 and 7 from spinal fluid and serum of multiple sclerosis patients (Mirandola et al) 1999;53:1367
alternative to vitamin D supplementation to prevent fractures in patients with MS (Sato et al) (Letter); (Cosman) (Reply) 1999;53:437
APOE ε2-4 and -491 polymorphisms are not associated with MS (Ferri et al) 1999;53:888
application of magnetization transfer imaging to multiple sclerosis (Grossman) (Sept, suppl 3) 1999;53:S8
association of MS with thyroid disorders (Karni and Abramsky) 1999;53:883
astrocytes in MS lack beta-2 adrenergic receptors (De Keyser et al) 1999;53:1628
bradykinin B_1 receptor expression and function on T lymphocytes in active multiple sclerosis (Prat et al) 1999;53:2087
cerebrospinal fluid isoprostane shows oxidative stress in patients with multiple sclerosis (Greco et al) 1999;53:1876
changes in serum levels of ICAM and TNF-R correlate with disease activity in multiple sclerosis (Khoury et al) 1999;53:758
changes of serum sICAM-1 and MMP-9 induced by rIFNβ-1b treatment in relapsing-remitting MS (Trojano et al) 1999;53:1402
chronic thalamic stimulation for the tremor of multiple sclerosis (Montgomery Jr. et al) 1999;53:625
clinical and laboratory features of primary progressive and secondary progressive MS (Bashir and Whitaker) 1999;53:765
contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis (Fazekas et al) (Views & Reviews) 1999;53:448
correlation between magnetization transfer metrics and other magnetic resonance imaging abnormalities in muscle (Rouvaris et al) 1999;53:S40
does a shift in the T-cell receptor repertoire precede the onset of MS? (Haegert et al) 1999;53:485
dysregulation of the hypothalamo-pituitary-adrenal axis is related to the clinical course of MS (Then Bergh et al) 1999;53:772
effect of anti-α4 integrin antibody on brain lesion activity in MS (Tubridy et al) 1999;53:466
encephalitis after hepatitis B vaccination: recurrent disseminated encephalitis or MS? (Tourbah et al) 1999;53:396
enhanced spasticity in primary progressive MS patients treated with interferon beta-1b (Frese) (Letter); (Bramanti et al) (Reply) 1999;53:1892
evidence of interferon β-1a dose response in relapsing-remitting MS: the OWIMS study (The Once Weekly Interferon for MS Study Group) 1999;53:679
fatigue in multiple sclerosis: cross-sectional correlation with brain MRI findings in 71 patients (Bakshi et al) 1999;53:1151
gastric tolerance of high dose pulse oral prednisone in multiple sclerosis (Metz et al) 1999;53:2093
general neurologist and subspecialist care for multiple sclerosis: patients' perceptions (Vickrey et al) 1999;53:1190
health care utilization in MS (Sander and Masdeu) (Letter); (Stolp-Smith et al) (Reply) 1999;53:892
humoral response to oligodendrocyte-specific protein in MS: a potential molecular mimic (Bronstein et al) 1999;53:154
interferon beta induces T-helper 2 immune deviation in MS (Kozovska et al) 1999;53:1692
is apoptotic death of the oligodendrocyte a critical event in the pathogenesis of multiple sclerosis? (Rodriguez and Lucchinetti) (Editorial) 1999;53:1615
isolated trochlear nerve palsy in patients with multiple sclerosis (Jacobson et al) 1999;53:877
lamotrigine adjunctive therapy in painful phenomena in MS: preliminary observations (Cianchetti et al) 1999;53:433
localized proton magnetic resonance spectroscopy in relapsing remitting versus secondary progressive multiple sclerosis (Tourbah et al) 1999;53:1091
longitudinal study of brain atrophy in relapsing multiple sclerosis (Simon et al) 1999;53:139
longitudinal study of cerebral glucose metabolism, MRI, and disability in patients with MS (Blinkenberg et al) 1999;53:149
magnetization transfer imaging of the spinal cord and optic nerve in patients with multiple sclerosis (van Waesberghe and Barkhof) (Sept, suppl 3) 1999;53:S46

magnetization transfer imaging to monitor clinical trials in multiple sclerosis (Richert and Frank) (Sept, suppl 3) 1999;53:S29
magnetization transfer imaging to monitor the evolution of individual multiple sclerosis lesions (Filippi) (Sept, suppl 3) 1999;53:S18
major histocompatibility complex class II alleles and the course and outcome of MS (McDonnell and Hawkins) (Letter); (Weinshenker) (Reply) 1999;53:893
matrix metalloproteinases in multiple sclerosis: targets of therapy or markers of injury? (Bever and Rosenberg) (Editorial) 1999;53:1380
Mayo Clinic-Canadian cooperative trial of sulfasalazine in active multiple sclerosis (Paty) (Letter) 1999;53:437
MRI in multiple sclerosis during the menstrual cycle: relationship with sex hormone patterns (Pozzilli et al) 1999;53:622
MS: side effects of IFNβ therapy (Walther and Hohlfeld) (Views & Reviews) 1999;53:1622
MS in two studies of US women (Hernán et al) 1999;53:1711
multiple sclerosis in children under 6 years of age (Ruggieri et al) 1999;53:478
multisequence MRI in clinically isolated syndromes and the early development of MS (Brex et al) 1999;53:1184
nitric oxide metabolites in cerebrospinal fluid of patients with MS are related to a clinical disease course (Svenningsson et al) 1999;53:1880
olfactory dysfunction in multiple sclerosis: relation to longitudinal changes in plaque numbers in central olfactory structures (Doty et al) 1999;53:880
optic neuritis as onset manifestation of multiple sclerosis: a nationwide, long-term survey (Sorensen et al) 1999;53:473
pathological correlated of magnetization transfer imaging abnormalities in animal models and humans with multiple sclerosis (Brochet and Dousset) (Sept, suppl 3) 1999;53:S12
primary association of a TNF gene polymorphism with susceptibility to multiple sclerosis (Fernandez-Arquero et al) 1999;53:1361
quality of life in multiple sclerosis: measuring the disease effects more broadly (Nortvedt et al) 1999;53:1098
quantitative assessment of motor fatigue and strength in MS (Schwid et al) 1999;53:743
quantitative MRI in patients with secondary progressive MS treated with monoclonal antibody Campath 1H (Paolillo et al) 1999;53:751
serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis (Waubant et al) 1999;53:1397
shedding of TNF receptors in multiple sclerosis patients (Jurewicz et al) 1999;53:1409
subacute thyroiditis in a patient with MS treated with interferon beta-1a (Kreiss et al) 1999;53:1606
suppression of pendular nystagmus by smoking cannabis in a patient with multiple sclerosis (Harte et al) 1999;53:2209
targeting immunotherapy in multiple sclerosis: a near hit and a clear miss (Schwid and Noseworthy) (Editorial) 1999;53:444
TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study (Lenercept Multiple Sclerosis Study Group and University of British Columbia MS/MRI Analysis Group) 1999;53:457
up-regulated $p75^{NTR}$ neurotrophin receptor on glial cells in MS plaques (Dowling et al) 1999;53:1676
use of Bacille-Calmette-Guèrin (BCG) in multiple sclerosis (Ristori et al) 1999;53:1588
use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS (Rudick et al) 1999;53:1698

Multiple system atrophy
cardiac uptake of $[^{123}]$MIBG separates Parkinson's disease from multiple system atrophy (Braune et al) 1999;53:1020

Muscle afferent block
treatment of spasticity with muscle afferent block (Mezaki et al) 1999;53:1156

Muscle atrophy
autosomal dominant familial spinal and bulbar muscular atrophy with gynecomastia (Ikezoe et al) 1999;53:2187

Muscle contraction
inhibition in the human motor cortex is reduced just before a voluntary contraction (Reynolds and Ashby) 1999;53:730

Muscle fibers
cultured inclusion-body myositis muscle fibers do not accumulate βAPP and can be innervated (McFerrin et al) 1999;53:2184

Muscle strength
quantitative assessment of motor fatigue and strength in MS (Schwid et al) 1999;53:743

Muscle weakness
adult-onset "infant" botulism: an unusual case of weakness in the intensive care unit (Li et al) 1999;53:891

Myasthenia
chromosome 17p-linked myasthenias stem from defects in the acetylcholine receptor ε-subunit gene (Middleton et al) 1999;53:1076
common mutation (ε1267delG) in congenital myasthenic patients of Gypsy ethnic origin (Abicht et al) 1999;53:1564
myasthenia, thymoma, presynaptic antibodies, and a continuum of neuromuscular hyperexcitability (Vernino et al) 1999;53:1233

Myasthenia gravis
repetitive phrenic nerve stimulation in myasthenia gravis (Zifko et al) 1999;53:1083

Myelin
myelin uncompaction in Charcot-Marie-Tooth neuropathy type 1A with a point mutation of peripheral myelin protein-22 (Fabrizi et al) 1999;53:846

Myelinosis
asymptomatic central pontine myelinosis (Strub et al) (Neuro*Images*) 1999;53:914

Myelopathy
inverse correlation of HTLV-1 viral load in CSF and intrathecal synthesis of HTLV-1 antibodies in TSP/HAM (Puccioni-Sohler et al) 1999;53:1335

Myoblasts
myophosphorylase gene transfer in McArdle's disease myoblasts in vitro (Pari et al) 1999;53:1352

Myokymia
tongue and limb myokymia in amyotrophic lateral sclerosis (Sander et al) 1999;53:1889

Myopathy
distinctive autosomal dominant vacuolar neuromyopathy linked to 19p13 (Servidei et al) 1999;53:830
distinct light microscopic changes in HIV-associated nemaline myopathy (Miró et al) (Letter); (Feinberg et al) (Reply) 1999;53:241
dysferlin is a surface membrane-associated protein that is absent in Miyoshi myopathy (Matsuda et al) 1999;53:1119
reduced cerebral blood flow and impaired visual-spatial function in proximal myotonic myopathy (Meola et al) 1999;53:1042

Myositis
aberrant expression of cyclin-dependent kinase 5 in inclusion body myositis (Nakano et al) 1999;53:1671
benign acute childhood myositis: laboratory and clinical features (Mackay et al) 1999;53:2127
cultured inclusion-body myositis muscle fibers do not accumulate βAPP and can be innervated (McFerrin et al) 1999;53:2184
inclusion body myositis in twins (Naumann and Toyka) (Letter); (Amato and Shebert) (Reply) 1999;53:659

Myotatic reflexes
diagnostic value of myotatic reflexes in axonal and demyelinating polyneuropathy (van Dijk et al) 1999;53:1573

Myotonia
founder mutations and the high prevalence of myotonia congenita in northern Finland (Papponen et al) 1999;53:297
reduced cerebral blood flow and impaired visual-spatial function in proximal myotonic myopathy (Meola et al) 1999;53:1042

N

Narcolepsy
neuroimaging study in autosomal dominant cerebellar ataxia, deafness, and narcolepsy (Melberg et al) 1999;53:2190

Neglect
ipsilesional intentional neglect and the effect of cueing (Schwartz et al) 1999;53:2017
line bisection performance of normal adults: two subgroups with opposite biases (Braun and Kirk) 1999;53:527
rightward bias of defective attention in left unilateral neglect (Bartolomeo and Chokron) 1999;53:2023

Nemaline myopathy
distinct light microscopic changes in HIV-associated nemaline myopathy (Miró et al) (Letter); (Feinberg et al) (Reply) 1999;53:241

Neonates
effects of neonatal seizures on subsequent seizure-induced brain injury (Schmid et al) 1999;53:1754
neonatal Guillain-Barré syndrome: blocking antibodies transmitted from mother to child (Buchwald et al) 1999;53:1246
primary megalencephaly at birth and low intelligence level (Petersson et al) 1999;53:1254

Neoplastic disease. *See also* **Malignancies; Metastatic disease;** *specific neoplasms*
cerebral amyloid angiopathy with unilateral hemorrhages, mass effect, and meningeal enhancement (Morton-Bours et al) 1999;53:233
cerebroretinal vasculopathy mimicking a brain tumor: a case of a rare hereditary syndrome (Weil et al) 1999;53:629
clinical outcome of anti-Hu-associated encephalomyelitis after a tumor (Keime-Gilbert et al) 1999;53:1719
superficial siderosis of the CNS: a late complication of cerebellar tumors (Kassubek et al) (Letter); (Anderson) (Reply) 1999;53:1893
transient MRI enhancement in a patient with seizures and previously resected glioma: use of MRS (Quan et al) 1999;53:211
VHL gene inactivation in an endolymphatic sac tumor associated with von Hippel-Lindau disease (Kawahara et al) 1999;53:208
Von Hippel-Lindau disease: how does one gene cause multiple tumors? (Roach) (Editorial) 1999;53:7

Nerve biopsies
pathologic findings in nerve and muscle biopsies from 47 women with silicone breast implants (Vogel) 1999;53:293
Nerve conduction
effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy (Greene et al) 1999;53:580
Nerve fibers
epidural nerve fiber density and sural nerve morphometry in peripheral neuropathies (Herrmann et al) 1999;53:1634
Neural networks
artificial neural networks improve the prediction of mortality in intracerebral hemorrhage (Edwards et al) 1999;53:351
Neurobiology
new developments in the neurobiology of the tuberous sclerosis complex (Crino and Henske) (Views & Reviews) 1999;53:1384
Neurocysticercosis
edema associated with calcified lesions in neurocysticercosis (Nash and Patronas) 1999;53:777
Neuro*Images*
arteriovenous malformation of the cervical cord (Ikeda et al) (Neuro*Images*) 1999;53:812
asymptomatic central pontine myelinosis (Strub et al) (Neuro*Images*) 1999;53:914
Babinski reflex hammer (Lanska) (Neuro*Images*) 1999;53:647
Charles Karsner Mills' "patella-tractor" (Lanska) (Neuro*Images*) 1999;53:1891
compression of the midbrain (Chalela and Kasner) (Neuro*Images*) 1999;53:423
EEG checkerboard pattern of bruxism (Hirsch and Crispin) (Neuro*Images*) 1999;53:669
Hallervordern Spatz disease and acanthocytes (Muthane et al) (Neuro*Images*) 1999;53:32A
maculopathy in spinocerebellar ataxia type 7 (Morrow et al) (Neuro*Images*) 1999;53:244
one-month-old girl with incontinentia pigmenti (Yoshikawa et al) (Neuro*Images*) 1999;53:1633
Neuroimaging. *See also specific modalities*
clinical and imaging features of cortical malformations in childhood (Leventer et al) 1999;53:715
neuroimaging study in autosomal dominant cerebellar ataxia, deafness, and narcolepsy (Melberg et al) 1999;53:2190
Neurologists
end-of-life care: a survey of US neurologists' attitudes, behavior, and knowledge (Carver et al) 1999;53:284
general neurologist and subspecialist care for multiple sclerosis: patients' perceptions (Vickrey et al) 1999;53:1190
presentation of ALS to the otolaryngologist/head and neck surgeon: getting to the neurologist (Hillel et al) 1999;53:S22
Webster's Dictionary: Websites for neurologists (Brooke) 1999;53:441
Neurology
changing face of academic neurology: implications for neurologic education at the millennium (Pedley) 1999;53:906
practicing neurology: a delicate balance (Schmidley) (Letter); (Ringer) (Reply) 1999;53:2216
Neurology
new features in *Neurology* (Griggs) (Editorial) 1999;53:2
Neuromuscular function
myasthenia, thymoma, presynaptic antibodies, and a continuum of neuromuscular hyperexcitability (Vernino et al) 1999;53:1233
Neuromyelitis optica
clinical course of neuromyelitis optica (Devic's syndrome) (Wingerchuk et al) 1999;53:1107
MRI and magnetization transfer imaging changes in Devic's neuromyelitis optica (Filippi et al) 1999;53:1705
Neuromyopathy
distinctive autosomal dominant vacuolar neuromyopathy linked to 19p13 (Servidei et al) 1999;53:830
Neuronopathy
role of the blink reflex in the evaluation of sensory neuronopathy (Auger et al) 1999;53:407
Neuron-specific enolase
serum and CSF neuron-specific enolase in patients with West syndrome (Suzuki et al) 1999;53:1761
Neuropathology
neuropathology in older people with disequilibrium of unknown cause (Whitman et al) 1999;53:375
Neuropathy. *See also* **Peripheral neuropathy; Polyneuropathy**
effect of aldose reductase inhibition on nerve conduction and morphometry in diabetic neuropathy (Greene et al) 1999;53:580
fulminant neuropathy and lactic acidosis associated with nucleoside analog therapy (Verma et al) 1999;53:1365
marginally improved detection of GM1 antibodies by Covalink ELISA in multifocal motor neuropathy (Carpo et al) 1999;53:2206
microvasculitis and ischemia in diabetic lumbosacral radiculoplexus neuropathy (Dyck et al) 1999;53:2113
painful sensory neuropathy: prospective evaluation using skin biopsy (Periquet et al) 1999;53:1641
pulse cyclophosphamide therapy in CIDP (Ikeda et al) (Letter); (Good et al) (Reply) 1999;53:894
to test or not to test? (Holloway and Feasby) (Editorial) 1999;53:1905
total neuropathy score: validation and reliability (Cornblath et al) 1999;53:1660
trigeminal neuropathy secondary to perineural invasion of head and neck carcinomas (Boerman et al) 1999;53:213
Neuropsychology
cognitive consequences of coexisting temporal lobe developmental malformations and hippocampal sclerosis (Martin et al) 1999;53:709
differentiation of vascular dementia from AD on neuropsychological tests (Looi and Sachdev) (Views & Reviews) 1999;53:670
effects of anomalous language representation on neuropsychological performance in temporal lobe epilepsy (Loring et al) 1999;53:260
functional anatomy of neuropsychological deficits after severe traumatic brain injury (Fontaine et al) 1999;53:1963
magnetization transfer imaging methodology: its clinical and neuropsychological correlates (van Buchem et al) (Sept, suppl 3) 1999;53:S23
neuropsychological and quality of life outcome after thalamic stimulation for essential tremor (Tröste et al) 1999;53:1774
neuropsychological deficits in neuroborreliosis (Primavera et al) (Letter); (Treib et al) (Reply) 1999;53:895
Neurotrophin
up-regulated $p75^{NTR}$ neurotrophin receptor on glial cells in MS plaques (Dowling et al) 1999;53:1676
Neurovascular instability
high prevalence of neurovascular instability in neurodegenerative dementias (Idiaquez and Sandoval) (Letter) 1999;53:1610
Nigrostriatal system
vulnerability of nigrostriatal system as detected by transcranial ultrasound (Berg et al) 1999;53:1026
Nitric oxide
nitric oxide metabolites in cerebrospinal fluid of patients with MS are related to a clinical disease course (Svenningsson et al) 1999;53:1880
Nucleoside analogs
fulminant neuropathy and lactic acidosis associated with nucleoside analog therapy (Verma et al) 1999;53:1365
Nutrition
nutritional status is a prognostic factor for survival in ALS (Desport et al) 1999;53:1059
Nystagmus
effect of hyperventilation in downbeat nystagmus in cerebellar disorders (Walker and Zee) 1999;53:1576
hyperventilation-induced nystagmus in patients with vestibular schwannoma (Minor et al) 1999;53:2158
suppression of pendular nystagmus by smoking cannabis in a patient with multiple sclerosis (Harte et al) 1999;53:2209

O

Older persons. *See* **Geriatric population**
Olfactory function
impaired olfaction as a marker for cognitive decline: interaction with apolipoprotein E ε4 status (Borenstein Graves et al) 1999;53:1480
olfactory dysfunction in multiple sclerosis: relation to longitudinal changes in plaque numbers in central olfactory structures (Doty et al) 1999;53:880
Oligodendrocytes
is apoptotic death of the oligodendrocyte a critical event in the pathogenesis of multiple sclerosis? (Rodriguez and Lucchinetti) (Editorial) 1999;53:1615
Oligodendroma
neoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma (Paleologos et al) 1999;53:1141
Ophthalmoplegia
autosomal dominant progressive external ophthalmoplegia: distribution of multiple mitochondrial DNA deletions (Moslemi et al) 1999;53:79
mapping of autosomal dominant progressive external ophthalmoplegia to a 7 cM critical region on 10q24 (Li et al) 1999;53:1265
Optic nerve
magnetization transfer imaging of the spinal cord and optic nerve in patients with multiple sclerosis (van Waesberghe and Barkhof) (Sept, suppl 3) 1999;53:S46
optic nerve edema as a consequence of respiratory disease (O'Halloran et al) 1999;53:2204
optic neuritis as onset manifestation of multiple sclerosis: a nationwide, long-term survey (Sorensen et al) 1999;53:473
Oral contraceptives
hormonal contraception and epilepsy (Guberman) (Sept, suppl 1) 1999;53:S38
use of oral contraceptives in patients with menstrual migraine (Becker) (Sept, suppl 1) 1999;53:S19

Oromandibular dystonia
botulinum toxin A in patients with oromandibular dystonia: long term follow-up (Tan et al) 1999;53:2102
Outcomes
baseline NIH Stroke Scale score strongly predicts outcome after stroke: a report of the Trial of Organization 172 in Acute Stroke Treatment (TOAST) (Adams Jr. et al) 1999;53:126
clinical outcome in pneumococcal meningitis correlates with CSF lipoteichoic acid concentrations (Schneider et al) 1999;53:1584
clinical outcome of anti-Hu-associated encephalomyelitis after a tumor (Keime-Gilbert et al) 1999;53:1719
getting oriented to patient-oriented outcomes (Vickrey) (Editorial) 1999;53:662
intracerebral hemorrhage outcome: apolipoprotein E genotype, hematoma, and edema volumes (McCarron et al) 1999;53:2176
major histocompatibility complex class II alleles and the course and outcome of MS (McDonnell and Hawkins) (Letter); (Weinshenker) (Reply) 1999;53:893
nonepileptic seizures: psychiatric framework, treatment, and outcome (Bowman) (Sept, suppl 2) 1999;53:S84
patient-oriented outcome assessment after temporal lobectomy for refractory epilepsy (Gilliam et al) 1999;53:687
predictive value of ^{1}H MRSI for outcome in temporal lobectomy (Kuzniecky et al) 1999;53:694
psychiatric and neurologic predictors of psychogenic pseudoseizure outcome (Kanner et al) 1999;53:933
residual physical outcome and daily living 3 to 6 years after Guillain-Barré syndrome (Bernsen et al) 1999;53:409
robot training enhanced motor outcome in patients with stroke maintained over 3 years (Volpe et al) 1999;53:1874
Ovarian hyperstimulation syndrome
multiple cerebral infarctions associated with ovarian hyperstimulation syndrome (Yoshii et al) 1999;53:225
Oxcarbazepine
oxcarbazepine in a monotherapy trial for partial seizures: placebo-controlled studies in neurology. where do they stop? (Schachter et al) (Letter); (Chadwick et al) (Reply) 1999;53:2211

P

Pachymeninges
absent pachymeningeal gadolinium enhancement on cranial MRI despite symptomatic CSF leak (Mokri et al) 1999;53:402
Pain management
effect of simple analgesics on quantitative sensation test threshold (Wang et al) 1999;53:1865
gabapentin-induced anorgasmia (Clark and Elliott) 1999;53:2209
lamotrigine adjunctive therapy in painful phenomena in MS: preliminary observations (Cianchetti et al) 1999;53:433
Palliative care
patient choices in ALS: life-sustaining treatment versus palliative care? (Mitsumoto) (Editorial) 1999;53:248
Pallido-nigro-luysian degeneration
mutation in the microtubule-associated protein tau in pallido-nigro-luysian degeneration (Yasuda et al) 1999;53:864
Paramyotonia congenita
lack of sodium channel mutations in an Italian family with paramyotonia congenita (Sampaolo et al) 1999;53:1549
Paraneoplastic disorders
paraneoplastic disorders associated with seminoma (Jaster and Mönkemüller) (Letter); (Wingerchuk et al) (Reply) 1999;53:658
Paraoxonase gene
no association of paraoxonase gene polymorphism with atherosclerosis or Alzheimer's disease (Sodeyama et al) 1999;53:1146
Paraplegia
autosomal dominant spastic paraplegia: refined SPG8 locus and additional genetic heterogeneity (Reid et al) 1999;53:1844
cortical motor reorganization after paraplegia: an EEG study (Green et al) 1999;53:736
genetic localization of a new locus for recessive familial spastic paraparesis to 15q13-15 (Martínez Murillo et al) 1999;53:50
phenotypic analysis of autosomal dominant hereditary spastic paraplegia linked to chromosome 8q (Hedera et al) 1999;53:44
"pure" hereditary spastic paraplegias: the story becomes complicated (Figlewicz and Bird) (editorial) 1999;53:5
Paratonia
facilitory paratonia and frontal lobe functioning (Agid and Lhermitte) (Letter); (Beversdorf and Heilman) (Reply) 1999;53:241
Parkinsonism
autosomal-recessive juvenile parkinsonism in a Jewish Yemenite kindred: mutation of *Parkin* gene (Nisipeanu et al) 1999;53:1602
familial multisystem degeneration with parkinsonism associated with the 11778 mitochondrial DNA mutation (Simon et al) 1999;53:1787
mortality cancer risk in parkinsonian patients: a population-based study (Riggs) (Letter); (Vanacore et al) (Reply) 1999;53:1158
parkinsonism due to predominant involvement of substantia nigra in Japanese encephalitis (Pradhan et al) 1999;53:1781
pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q (Rajput) (Letter); (Mori) (Reply) 1999;53:1375
PET studies of parkinsonism associated with mutation in the α-synuclein gene (Samii et al) 1999;53:2097
Parkinson's disease
autopsy patterns for Parkinson's disease and related disorders in Olmsted County, Minnesota (Maraganore et al) 1999;53:1342
candidate genes and Parkinson's disease: where to next? (Markopoulou and Langston) (Editorial) 1999;53:1382
cardiac uptake of [^{123}]MIBG separates Parkinson's disease from multiple system atrophy (Braune et al) 1999;53:1020
case-control study of the ubiquitin carboxy-terminal hydrolase L1 gene in Parkinson's disease (Maraganore et al) 1999;53:1858
chronic subthalamic nucleus stimulation reduces medication requirements in Parkinson's disease (Moro et al) 1999;53:85
dopamine D_2 receptor gene polymorphism and the risk of levodopa-induced dyskinesias in PD (Oliveri et al) 1999;53:1425
enhanced fatigue during motor performance in patients with PD (Friedman) (Letter); (Ziv and Melamed) (Reply) 1999;53:438
evaluation of surgery for Parkinson's disease (Hallett et al) 1999;53: 1910
immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study (Koller et al) 1999;53:1012
juvenile Parkinson's disease with REM sleep behavior disorder, sleepiness, and daytime REM onset (Rye et al) 1999;53:1868
multicenter trial of ropinirole as adjunct treatment of PD (Jeret) (Letter); (Lieberman) (Reply) 1999;53:658
Parkinson's disease, MOAB, and smoking (Mellick et al) (Letter) 1999; 53:658
Parkinson's disease in twins: a follow-up study (Vieregge et al) 1999; 53:566
pergolide monotherapy in the treatment of early PD: a randomized, controlled study (Barone et al) 1999;53:573
pharmacodynamics of the long-duration response to levodopa in PD (Zappia et al) 1999;53:557
short-term effects of high-dose 17β-estradiol in postmenopausal Parkinson's disease patients: a crossover study (Blanchet et al) 1999;53:91
smoking and Parkinson's disease: the cart before the horse? (Honig) (Letter); (Gorell) (Reply) 1999;53:1158
study of five candidate genes in Parkinson's disease and related neurodegenerative disorders (Nicholl et al) 1999;53:1415
3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease (Korczyn et al) 1999;53:364
Transderm-induced psychosis in Parkinson's disease (Minagar et al) 1999;53:433
Pediatric patients. *See* **Adolescents; Children; Neonates**
Pergolide
pergolide monotherapy in the treatment of early PD: a randomized, controlled study (Barone et al) 1999;53:573
Periodic paralysis
insulin acts in hypokalemic periodic paralysis by reducing inward rectifier K^+ current (Ruff) 1999;53:1556
novel sodium channel mutation in a family with hypokalemic periodic paralysis (Bulman et al) 1999;53:1932
Peripheral neuropathy
amantadine-induced peripheral neuropathy (Shulman et al) 1999;53: 1862
epidural nerve fiber density and sural nerve morphometry in peripheral neuropathies (Herrmann et al) 1999;53:1634
myelin uncompaction in Charcot-Marie-Tooth neuropathy type 1A with a point mutation of peripheral myelin protein-22 (Fabrizi et al) 1999;53:846
prevalence of peripheral neuropathy in injection drug users (Berger et al) 1999;53:592
Perisylvian region
caudal infrasylvian surface in dyslexia: novel magnetic resonance imaging-based findings (Green et al) 1999;53:974
Personality
evidence against the existence of a temporal lobe epilepsy syndrome (Devinsky and Najjar) (Sept, suppl 2) 1999;53:S13
evidence supporting the temporal lobe epilepsy personality syndrome (Blumer) (Sept, suppl 2) 1999;53:S9
Phenotype
phenotypic variation in leukoencephalopathy with vanishing white matter (Rodriguez and Gelot) (Letter); (van der Knaap and Kamphorst) (Reply) 1999;53:1373
phenotypic analysis of autosomal dominant hereditary spastic paraplegia linked to chromosome 8q (Hedera et al) 1999;53:44
Phenytoin
incidence and clinical consequence of the purple glove syndrome in patients receiving intravenous phenytoin (Coplin et al) (Letter); (O'Brien et al) (Reply) 1999;53:1611
Photoparoxysmal response
photosensitive epilepsies and pathophysiologic mechanisms of the photoparoxysmal response (Takahashi et al) 1999;53:926

Photosensitivity
photosensitive epilepsies and pathophysiologic mechanisms of the photoparoxysmal response (Takahashi et al) 1999;53:926
Phrenic nerve
repetitive phrenic nerve stimulation in myasthenia gravis (Zifko et al) 1999;53:1083
Plaque
olfactory dysfunction in multiple sclerosis: relation to longitudinal changes in plaque numbers in central olfactory structures (Doty et al) 1999;53:880
up-regulated $p75^{NTR}$ neurotrophin receptor on glial cells in MS plaques (Dowling et al) 1999;53:1676
Plasma exchange
prognostic factors of Guillain-Barré syndrome after intravenous immunoglobulin or plasma exchange (Visser et al) 1999;53:598
Platelet-activating factors
randomized trial of the platelet-activating factor antagonist lexipafant in HIV-associated cognitive impairment (Schifitto et al) 1999;53:391
Polyneuropathy
aggressive familial amyloidotic polyneuropathy caused by a new variant transthyretin Lys 54 (Togashi et al) 1999;53:637
diagnostic value of myotatic reflexes in axonal and demyelinating polyneuropathy (van Dijk et al) 1999;53:1573
diagnostic value of sural nerve T cells in chronic inflammatory demyelinating polyneuropathy (Bosboom et al) 1999;53:837
fatigue immune-mediated polyneuropathies (Merkies et al) 1999;53:1648
interferon-β1 in chronic inflammatory demyelinating polyneuropathy (Kuntzer et al) 1999;53:1364
matrix metalloproteinase upregulation in chronic inflammatory demyelinating polyneuropathy and nonsystemic vasculitic neuropathy (Leppert et al) 1999;53:62
Pons
asymptomatic central pontine myelinosis (Strub et al) (*NeuroImages*) 1999;53:914
pontine anosognosia for hemiplegia (Evyapan and Kumral) 1999;53:647
Positron emission tomography
[^{11}C](*R*)-PK11195 PET imaging of activated microglia in vivo in Rasmussen's encephalitis (Banati et al) 1999;53:2199
fluoroDOPA PET shows the nondopaminergic as well as dopaminergic destinations of levodopa (Brown et al) 1999;53:1212
globus pallidus deep brain stimulation for generalized dystonia: clinical and PET investigation (Kumar et al) 1999;53:871
glucose and [^{11}C]flumazenil PET abnormalities of thalamic nuclei in temporal lobe epilepsy (Juhász et al) 1999;53:2037
no evidence of hypoxic tissue on ^{18}F-fluoromisonidazole PET following intracerebral hemorrhage (Hirano et al) 1999;53:2179
PET studies of parkinsonism associated with mutation in the α-synuclein gene (Samii et al) 1999;53:2097
transient and falsely lateralizing flumazenil-PET asymmetries in temporal lobe epilepsy (Ryvlin et al) 1999;53:1882
Postpolio syndrome
multicenter, randomized, double-blinded trial of pyridostigmine in postpolio syndrome (Trojan et al) 1999;53:1225
why drugs fail in postpolio syndrome: lessons from another clinical trial (Dalakas) (Editorial) 1999;53:1166
Posture
soleus H-reflex tests in causalgia-dystonia compared with dystonia and mimicked dystonic posture (Koelman et al) 1999;53:2196
Potassium
insulin acts in hypokalemic periodic paralysis by reducing inward rectifier K^+ current (Ruff) 1999;53:1556
Prednisone
gastric tolerance of high dose pulse oral prednisone in multiple sclerosis (Metz et al) 1999;53:2093
Pregnancy
migraine in pregnancy (Aubé) (Sept, suppl 1) 1999;53:S26
stroke and intracranial venous thrombosis during pregnancy and puerperium (Koch and Robyn) (Letter); (Lanska and Kryscio) (Reply) 1999;53:1161
Presynaptic vesicles
striatal presynaptic monoaminergic vesicles are not increased in Tourette's syndrome (Meyer et al) 1999;53:371
Prion diseases. *See also* **Creutzfeldt-Jakob disease**
inherited prion disease with a PrP P105L mutation: clinicopathologic and PrP heterogeneity (Yamada et al) 1999;53:181
multiple prion types in the same brain (Dickson and Brown) (Editorial) 1999;53:1903
Procarbazine
neoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma (Paleologos et al) 1999;53:1141
Progressive supranuclear palsy
cognitive and magnetic resonance imaging aspects of corticobasal degeneration and progressive supranuclear palsy (Soliveri et al) 1999;53:502
mutational analysis of the tau gene in progressive supranuclear palsy (Higgins et al) 1999;53:1421
tau gene A0 allele and progressive supranuclear palsy (Hoenicka et al) 1999;53:1219
Prolactin
transient elevation in plasma prolactin level in rats with temporal lobe status epilepticus (Lin et al) 1999;53:885
Prostaglandins
elevated CSF prostaglandin E_2 levels in patients with probable AD (Montine et al) 1999;53:1495
Protein
humoral response to oligodendrocyte-specific protein in MS: a potential molecular mimic (Bronstein et al) 1999;53:154
Protein C
stroke after zoster ophthalmicus in a 12-year-old girl with protein C deficiency (Cadavid et al) 1999;53:1128
Prothrombin
antibodies to prothrombin in patients with Sneddon's syndrome (Kalashnikova et al) 1999;53:223
Pseudoseizures
pseudoseizures and other nonepileptic paroxysmal disorders in children and adolescents (Andriola and Ettinger) (Sept, suppl 2) 1999;53:S89
psychiatric and neurologic predictors of psychogenic pseudoseizure outcome (Kanner et al) 1999;53:933
Psychiatric issues. *See also* **Depression**
advances in the treatment of behavioral disturbances in Alzheimer's disease (Cummings and Knopman) (Editorial) 1999;53:899
behavioral issues in pediatric epilepsy (Dunn and Austin) (Sept, suppl 2) 1999;53:S96
cognitive deficits in epilepsy and contribution to psychopathology (Perrine and Kiolbasa) (Sept, suppl 2) 1999;53:S49
evidence against the existence of a temporal lobe epilepsy syndrome (Devinsky and Najjar) (Sept, suppl 2) 1999;53:S13
evidence supporting the temporal lobe epilepsy personality syndrome (Blumer) (Sept, suppl 2) 1999;53:S9
juvenile Parkinson's disease with REM sleep behavior disorder, sleepiness, and daytime REM onset (Rye et al) 1999;53:1868
nonepileptic seizures: psychiatric framework, treatment, and outcome (Bowman) (Sept, suppl 2) 1999;53:S84
positive and negative psychiatric effects of antiepileptic drugs in patients with seizure disorders (Ketter et al) (Sept, suppl 2) 1999;53:S53
pseudoseizures and other nonepileptic paroxysmal disorders in children and adolescents (Andriola and Ettinger) (Sept, suppl 2) 1999;53:S89
psychiatric adverse events during vigabatrin therapy (Levinson and Devinsky) 1999;53:1503
psychiatric and neurologic predictors of psychogenic pseudoseizure outcome (Kanner et al) 1999;53:933
psychosis and peri-ictal confusional states (Lancman) (Sept, suppl 2) 1999;53:S33
quality of life assessment in clinical practice (Cramer) (Sept, suppl 2) 1999;53:S49
randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia (De Deyn et al) 1999;53:946
seizure risk associated with psychotropic drugs: clinical and pharmacokinetic considerations (Alldredge) (Sept, suppl 2) 1999;53:S68
Transderm-induced psychosis in Parkinson's disease (Minagar et al) 1999;53:433
Psychosis
psychosis and peri-ictal confusional states (Lancman) (Sept, suppl 2) 1999;53:S33
Transderm-induced psychosis in Parkinson's disease (Minagar et al) 1999;53:433
Psychotropic drugs
seizure risk associated with psychotropic drugs: clinical and pharmacokinetic considerations (Alldredge) (Sept, suppl 2) 1999;53:S68
Ptosis
ptosis, blepharospasm, and apraxia of eyelid opening secondary to putaminal hemorrhage (Verghese et al) 1999;53:652
Puerperium
stroke and intracranial venous thrombosis during pregnancy and puerperium (Koch and Robyn) (Letter); (Lanska and Kryscio) (Reply) 1999;53:1161
Purple glove syndrome
incidence and clinical consequence of the purple glove syndrome in patients receiving intravenous phenytoin (Coplin et al) (Letter); (O'Brien et al) (Reply) 1999;53:1611
Putamen
ptosis, blepharospasm, and apraxia of eyelid opening secondary to putaminal hemorrhage (Verghese et al) 1999;53:652

Pyramidal tract
Wallerian degeneration of the pyramidal tract does not affect stroke rehabilitation outcome (Seitz and Binkofski) (Letter); (Miyai et al) (Reply) 1999;53:1375
Pyridostigmine
multicenter, randomized, double-blinded trial of pyridostigmine in postpolio syndrome (Trojan et al) 1999;53:1225
Pyruvate dehydrogenase
dichloroacetate stabilizes the mutant E1α subunit in pyruvate dehydrogenase deficiency (Morten et al) 1999;53:612

Q

Quality of life
measuring quality of life in a way that is meaningful to stroke patients (Williams et al) 1999;53:1839
neuropsychological and quality of life outcome after thalamic stimulation for essential tremor (Tröste et al) 1999;53:1774
quality of life in multiple sclerosis: measuring the disease effects more broadly (Nortvedt et al) 1999;53:1098
seizure frequency and the health-related quality of life of adults with epilepsy (Leidy) 1999;53:162

R

Radiculopathy
neurologic manifestations of compressive radiculopathy of the first thoracic root (Levin) 1999;53:1149
randomized trial of interferon β-1a in chronic inflammatory demyelinating polyradiculopathy (Hadden et al) 1999;53:57
Reflex sympathetic dystrophy
HLA-DQ1 associated with reflex sympathetic dystrophy (Kemler et al) 1999;53:1350
soleus H-reflex tests in causalgia-dystonia compared with dystonia and mimicked dystonic posture (Koelman et al) 1999;53:2196
Respiratory disease
optic nerve edema as a consequence of respiratory disease (O'Halloran et al) 1999;53:2204
Restless legs syndrome
changes in excitability of motor cortical circuitry in primary restless legs syndrome (Entezari-Taher et al) 1999;53:1201
restless legs syndrome (Gálvez-Jiménez et al) (Letter); (Becker) (Reply) 1999;53:439
Retina
reduced brain creatine in gyrate atrophy of the choroid and retina with hyperornithinemia (Näntö-Salonen) 1999;53:303
Risperidone
randomized trial of risperidone, placebo, and haloperidol for behavioral symptoms of dementia (De Deyn et al) 1999;53:946
RNA
detection and cellular localization of enterovirus RNA sequences in spinal cord of ALS patients (Berger et al) 1999;53:1998
Ropinirole
multicenter trial of ropinirole as adjunct treatment of PD (Jeret) (Letter); (Lieberman) (Reply) 1999;53:658
3-year randomized trial of ropinirole and bromocriptine in early Parkinson's disease (Korczyn et al) 1999;53:364

S

St. Vitus' chorea
relicts of dancing mania: the Dancing Procession of Echternach (Krack) 1999;53:2169
Schwannoma
facial trigeminal synkinesis associated with a trigeminal schwannoma (Rubin et al) 1999;53:635
hyperventilation-induced nystagmus in patients with vestibular schwannoma (Minor et al) 1999;53:2158
Scleromyxedema
encephalopathy in scleromyxedema (Johkura et al) 1999;53:1138
Seizures. *See also* **Epilepsy**
brief AED withdrawal prolongs next seizure (Laowattana et al) 1999;53:1736
childhood-onset epilepsy with and without preceding febrile seizures (Berg et al) 1999;53:1742
do early seizures beget epilepsy? (Theodore and Wasterlain) (Editorial) 1999;53:898
early-life seizures in rats increase susceptibility to seizure-induced brain injury in adulthood (Koh et al) 1999;53:915
effects of neonatal seizures on subsequent seizure-induced brain injury (Schmid et al) 1999;53:1754
focal akinetic seizures as documented by electroencephalography and video recordings (Noachtar and Lüders) 1999;53:427
guideline for discontinuing antiepileptic drugs in seizure-free patients (Wilkins) (Letter); (Franklin et al) (Reply) 1999;53:239
nonepileptic seizures: diagnosis and management (Krumholz) (Sept, suppl 2) 1999;53:S76
nonepileptic seizures: psychiatric framework, treatment, and outcome (Bowman) (Sept, suppl 2) 1999;53:S84
oxcarbazepine in a monotherapy trial for partial seizures: placebo-controlled studies in neurology. where do they stop? (Schachter et al) (Letter); (Chadwick et al) (Reply) 1999;53:2211
placebo-controlled trial of lamotrigine add-on therapy for partial seizures in children (Duchowny et al) 1999;53:1724
pseudoseizures and other nonepileptic paroxysmal disorders in children and adolescents (Andriola and Ettinger) (Sept, suppl 2) 1999;53:S89
psychiatric and neurologic predictors of psychogenic pseudoseizure outcome (Kanner et al) 1999;53:933
risk factors for seizure-related motor vehicle crashes in patients with epilepsy (McAbee and Madison) (Letter); (Drachman) (Letter); (Krauss et al) (Reply) 1999;53:2214
seizure frequency and the health-related quality of life of adults with epilepsy (Leidy) 1999;53:162
seizure risk associated with psychotropic drugs: clinical and pharmacokinetic considerations (Alldredge) (Sept, suppl 2) 1999;53:S68
transient MRI enhancement in a patient with seizures and previously resected glioma: use of MRS (Quan et al) 1999;53:211
Seminoma
paraneoplastic disorders associated with seminoma (Jaster and Mönkemüller) (Letter); (Wingerchuk et al) (Reply) 1999;53:658
Seniors. *See* **Geriatric population**
Sensory function. *See also* **Deafness; Visual function**
effect of simple analgesics on quantitative sensation test threshold (Wang et al) 1999;53:1865
sensory symptoms restricted to proximal body parts in small cortical infarction (Kim) 1999;53:889
Sensory nerves
sensory nerves in skin: painful feet? (Kennedy and Said) (Editorial) 1999;53:1614
Serotonin
increased brain serotonin synthesis in migraine (Chugani et al) 1999;53:1473
Serum
absence of human herpesvirus 6 and 7 from spinal fluid and serum of multiple sclerosis patients (Mirandola et al) 1999;53:1367
serum and CSF neuron-specific enolase in patients with West syndrome (Suzuki et al) 1999;53:1761
Sex. *See also* **Gender; Women**
MS in two studies of US women (Hernán et al) 1999;53:1711
sex differences in the incidence of Alzheimer's and vascular dementia (Andersen et al) 1999;53:1992
sex-related influences on the frequency and age of onset of primary dystonia (Epidemiologic Study of Dystonia in Europe [ESDE] Collaborative Group) 1999;53:1871
Sex hormones
MRI in multiple sclerosis during the menstrual cycle: relationship with sex hormone patterns (Pozzilli et al) 1999;53:622
sex hormones and headache 1999 (menstrual migraine) (Silberstein and Merriam) (Sept, suppl 1) 1999;53:S3
Sexual dysfunction
gabapentin-induced anorgasmia (Clark and Elliott) 1999;53:2209
Siderosis
evidence for preganglionic pupillary involvement in superficial siderosis (Pelak et al) 1999;53:1130
superficial siderosis of the CNS: a late complication of cerebellar tumors (Kassubek et al) (Letter); (Anderson) (Reply) 1999;53:1893
transthyretin amyloidosis and superficial siderosis of the CNS (Mascalchi et al) 1999;53:1498
Silicone breast implants
pathologic findings in nerve and muscle biopsies from 47 women with silicone breast implants (Vogel) 1999;53:293
Situs inversus totalis
structural and functional brain asymmetries in human situs inversus totalis (Kennedy et al) 1999;53:1260
Skin
painful sensory neuropathy: prospective evaluation using skin biopsy (Periquet et al) 1999;53:1641
sensory nerves in skin: painful feet? (Kennedy and Said) (Editorial) 1999;53:1614
Sleep
juvenile Parkinson's disease with REM sleep behavior disorder, sleepiness, and daytime REM onset (Rye et al) 1999;53:1868
silent functional magnetic resonance demonstrates focal activation in REM sleep (Lövblad et al) 1999;53:2193
Smoking
Parkinson's disease, MOAB, and smoking (Mellick et al) (Letter) 1999;53:658
smoking and Parkinson's disease: the cart before the horse? (Honig) (Letter); (Gorell) (Reply) 1999;53:1158
Sneddon's syndrome
antibodies to prothrombin in patients with Sneddon's syndrome (Kalashnikova et al) 1999;53:223
Sodium channels
lack of sodium channel mutations in an Italian family with paramyotonia congenita (Sampaolo et al) 1999;53:1549

novel sodium channel mutation in a family with hypokalemic periodic paralysis (Bulman et al) 1999;53:1932

Soleus H-reflex

soleus H-reflex tests in causalgia-dystonia compared with dystonia and mimicked dystonic posture (Koelman et al) 1999;53:2196

Somatosensory evoked potentials

time course of frontal somatosensory evoked potentials: relation to L-dopa plasma levels and motor performance (Ulivelli et al) 1999;53:1451

South America

current treatment pathways in ALS: a South American perspective (Dubrovsky and Sica) 1999;53:S11

Spasms

case-controlled MRI/MRA study of neurovascular contact in hemifacial spasm (Ho et al) 1999;53:2132

familial trigeminal neuralgia and contralateral hemifacial spasm (Duff et al) 1999;53:216

Spasticity

enhanced spasticity in primary progressive MS patients treated with interferon beta-1b (Frese) (Letter); (Bramanti et al) (Reply) 1999;53:1892

genetic localization of a new locus for recessive familial spastic paraparesis to 15q13-15 (Martínez Murillo et al) 1999;53:50

phenotypic analysis of autosomal dominant hereditary spastic paraplegia linked to chromosome 8q (Hedera et al) 1999;53:44

"pure" hereditary spastic paraplegias: the story becomes complicated (Figlewicz and Bird) (Editorial) 1999;53:5

quantitative assessment of subclinical spasticity in human T-cell lymphotrophic virus type 1 infection (Zunt et al) 1999;53:386

treatment of spasticity with muscle afferent block (Mezaki et al) 1999;53:1156

Spinal cord

arteriovenous malformation of the cervical cord (Ikeda et al) (*NeuroImages*) 1999;53:812

cervical cord and dorsal medullary infarction presenting with retro-orbital pain (de la Sayette et al) 1999;53:632

detection and cellular localization of enterovirus RNA sequences in spinal cord of ALS patients (Berger et al) 1999;53:1998

magnetization transfer imaging of the spinal cord and optic nerve in patients with multiple sclerosis (van Waesberghe and Barkhof) (Sept, suppl 3) 1999;53:S46

Spinal muscle atrophy

preimplantation genetic diagnosis for spinal muscular atrophy type 1 (Fallon et al) 1999;53:1087

Spinocerebellar ataxia

clinical and MRI findings in spinocerebellar ataxia type 5 (Stevanin et al) 1999;53:1355

maculopathy in spinocerebellar ataxia type 7 (Morrow et al) (*NeuroImages*) 1999;53:244

Status epilepticus

de novo status epilepticus due to multiple cerebral hamartomas (Greenfield et al) 1999;53:2237

transient elevation in plasma prolactin level in rats with temporal lobe status epilepticus (Lin et al) 1999;53:885

Stereopsis

perceptual processing of stereopsis in humans: high-field (3.0-tesla) functional MRI study (Kwee et al) 1999;53:1599

Striatum

clinical correlation of striatal ^{1}H MRS changes in Huntington's disease (Sánchez-Pernaute et al) 1999;53:806

striatal biopterin and tyrosine hydroxylase protein reduction in dopa-responsive dystonia (Furukawa et al) 1999;53:1032

Stroke. *See also* **Ischemic stroke**

advances in stroke management: update 1998 (Hacke) (Sept, suppl 4) 1999;53:S1

antiplatelet therapy: foundations for optimal treatment decisions (Albers and Tijssen) (Sept, suppl 4) 1999;53:S25

antiplatelet therapy: views from the experts (Easton et al) (Sept, suppl 4) 1999;53:S32

antiplatelet treatment does not reduce the severity of subsequent stroke (Sivenius et al) 1999;53:825

baseline NIH Stroke Scale score strongly predicts outcome after stroke: a report of the Trial of Organization 172 in Acute Stroke Treatment (TOAST) (Adams Jr. et al) 1999;53:126

catalepsy after stroke (Saposnik et al) 1999;53:1132

cerebral hemodynamic impairment: methods of measurement and association with stroke risk (Derdeyn et al) (Views & Reviews) 1999;53:251

comparison of population-based models of risk factors for TIA and ischemic stroke (Whisnant et al) 1999;53:532

consent issues in the management of cerebrovascular diseases: a position paper of the American Academy of Neurology Ethics and Humanities Subcommittee 1999;53:9

measuring quality of life in a way that is meaningful to stroke patients (Williams et al) 1999;53:1839

MRI white matter hyperintensities: three-year follow-up of the Austrian Stroke Prevention Study (Schmidt et al) 1999;53:132

multiple cerebral infarctions associated with ovarian hyperstimulation syndrome (Yoshii et al) 1999;53:225

reduction of intracerebral hemorrhaging in a rabbit embolic stroke model (Hu et al) 1999;53:2140

risk factors and their management for stroke prevention: outlook for 1999 and beyond (Sacco et al) (Sept, suppl 4) 1999;53:S15

robot training enhanced motor outcome in patients with stroke maintained over 3 years (Volpe et al) 1999;53:1874

stroke after zoster ophthalmicus in a 12-year-old girl with protein C deficiency (Cadavid et al) 1999;53:1128

stroke and intracranial venous thrombosis during pregnancy and puerperium (Koch and Robyn) (Letter); (Lanska and Kryscio) (Reply) 1999;53:1161

thrombolytic stroke therapy: past, present, and future (Zivin) (Views & Reviews) 1999;53:14

Wallerian degeneration of the pyramidal tract does not affect stroke rehabilitation outcome (Seitz and Binkofski) (Letter); (Miyai et al) (Reply) 1999;53:1375

Stuttering

cessation of stuttering after bilateral thalamic infarction (Muroi et al) 1999;53:890

Styloid process

carotid artery dissection due to elongated styloid process (Zuber et al) 1999;53:1886

Subarachnoid hemorrhage

aneurysms in relatives of patients with subarachnoid hemorrhage: frequency and risk factors (Raaymakers and the MARS Study Group) 1999;53:982

Substance abuse

leukoencephalopathy and raised brain lactate from heroin vapor inhalation ("chasing the dragon") (Kriegstein et al) 1999;53:1765

prevalence of peripheral neuropathy in injection drug users (Berger et al) 1999;53:592

suppression of pendular nystagmus by smoking cannabis in a patient with multiple sclerosis (Harte et al) 1999;53:2209

Substantia nigra

bilateral substantia nigra changes on MRI in a patient with encephalitis lethargica (Kun et al) 1999;53:1860

parkinsonism due to predominant involvement of substantia nigra in Japanese encephalitis (Pradhan et al) 1999;53:1781

Subthalamic nucleus

chronic subthalamic nucleus stimulation reduces medication requirements in Parkinson's disease (Moro et al) 1999;53:85

comparative effects of unilateral and bilateral subthalamic nucleus deep brain stimulation (Kumar et al) 1999;53:561

Sulfasalazine

Mayo Clinic-Canadian cooperative trial of sulfasalazine in active multiple sclerosis (Paty) (Letter) 1999;53:437

SUNCT syndrome

possible usefulness of lamotrigine in the treatment of SUNCT syndrome (D'Andrea et al) 1999;53:1609

Superior oblique palsy

superior oblique palsies with brainstem lesions (Thömke and Ringel) 1999;53:1126

Superoxide dismutase

mice lacking cytosolic copper/zinc superoxide dismutase display a distinctive motor axonopathy (Shefner et al) 1999;53:1239

Sural nerve

diagnostic value of sural nerve T cells in chronic inflammatory demyelinating polyneuropathy (Bosboom et al) 1999;53:837

epidural nerve fiber density and sural nerve morphometry in peripheral neuropathies (Herrmann et al) 1999;53:1634

Surgical procedures. *See also specific procedures*

evaluation of surgery for Parkinson's disease (Hallett et al) 1999;53:1910

patient-oriented outcome assessment after temporal lobectomy for refractory epilepsy (Gilliam et al) 1999;53:687

predictive value of ^{1}H MRSI for outcome in temporal lobectomy (Kuzniecky et al) 1999;53:694

safety and factors related to survival after percutaneous endoscopic gastrostomy in ALS (Chiò et al) 1999;53:1123

study of mortality after temporal lobe epilepsy surgery (Hennessy et al) 1999;53:1276

subjective versus objective memory change after temporal lobe epilepsy surgery (Sawrie et al) 1999;53:1511

visual field defects after temporal lobe resection: a prospective quantitative analysis (Hughes et al) 1999;53:167

Syndrome of inappropriate antidiuretic hormone

SIADH as the first symptom of Guillain-Barré syndrome (Hoffmann et al) 1999;53:1365

Synkinesis

facial trigeminal synkinesis associated with a trigeminal schwannoma (Rubin et al) 1999;53:635

Synuclein gene

PET studies of parkinsonism associated with mutation in the α-synuclein gene (Samii et al) 1999;53:2097

T

Tactile function
crossmodal and sensorimotor integration in tactile awareness (Vaishnavi et al) 1999;53:1596

Tapeworms
heavy nonencephalitic cerebral cysticercosis in tapeworm carriers (García et al) 1999;53:1582

Tau gene
mutational analysis of the tau gene in progressive supranuclear palsy (Higgins et al) 1999;53:1421
neurodegenerative diseases of Guam: analysis of *TAU* (Pérez-Tur et al) 1999;53:411

Tau protein
mutation in the microtubule-associated protein tau in pallido-nigro-luysian degeneration (Yasuda et al) 1999;53:864
sensitivity, specificity, and stability of CSF-tau in AD in a community-based patient sample (Andreasen et al) 1999;53:1488

T cells
bradykinin B_1 receptor expression and function on T lymphocytes in active multiple sclerosis (Prat et al) 1999;53:2087
diagnostic value of sural nerve T cells in chronic inflammatory demyelinating polyneuropathy (Bosboom et al) 1999;53:837
does a shift in the T-cell receptor repertoire precede the onset of MS? (Haegert et al) 1999;53:485
interferon beta induces T-helper 2 immune deviation in MS (Kozovska et al) 1999;53:1692

Temporal lobe(s)
APOE-ε4 is associated with less frontal and more medial temporal atrophy in AD (Geroldi et al) 1999;53:1825
cognitive consequences of coexisting temporal lobe developmental malformations and hippocampal sclerosis (Martin et al) 1999;53:709
postencephalitic focal retrograde amnesia after bilateral anterior temporal lobe damage (Tanaka et al) 1999;53:344
visual field defects after temporal lobe resection: a prospective quantitative analysis (Hughes et al) 1999;53:167

Temporal lobe epilepsy
coexistence of temporal lobe and idiopathic generalized epilepsies (Koutroumanidis et al) 1999;53:490
cognitive correlates of ^{1}H MRSI detected hippocampal abnormalities in temporal lobe epilepsy (Martin et al) 1999;53:2052
diffusion mapping applied to mesial temporal lobe epilepsy: preliminary observations (Hugg et al) 1999;53:173
effects of anomalous language representation on neuropsychological performance in temporal lobe epilepsy (Loring et al) 1999;53:260
evidence against the existence of a temporal lobe epilepsy syndrome (Devinsky and Najjar) (Sept, suppl 2) 1999;53:S13
evidence supporting the temporal lobe epilepsy personality syndrome (Blumer) (Sept, suppl 2) 1999;53:S9
glucose and [^{11}C]flumazenil PET abnormalities of thalamic nuclei in temporal lobe epilepsy (Juhász et al) 1999;53:2037
patient-oriented outcome assessment after temporal lobectomy for refractory epilepsy (Gilliam et al) 1999;53:687
predictive value of ^{1}H MRSI for outcome in temporal lobectomy (Kuzniecky et al) 1999;53:694
quantitative MRI in temporal lobe epilepsy: evidence for fornix atrophy (Kuzniecky et al) 1999;53:496
significance of interictal temporal lobe delta activity for localization of the primary epileptogenic region (Koutroumanidis et al) (Letter); (Geyer and Gilliam) (Reply) 1999;53:1892
study of mortality after temporal lobe epilepsy surgery (Hennessy et al) 1999;53:1276
subjective versus objective memory change after temporal lobe epilepsy surgery (Sawrie et al) 1999;53:1511
transient and falsely lateralizing flumazenil-PET asymmetries in temporal lobe epilepsy (Ryvlin et al) 1999;53:1882
transient elevation in plasma prolactin level in rats with temporal lobe status epilepticus (Lin et al) 1999;53:885

Thalamus
bilateral thalamic stimulation for the treatment of essential tremor (Pahwa et al) 1999;53:1447
cessation of stuttering after bilateral thalamic infarction (Muroi et al) 1999;53:890
chronic thalamic stimulation for the tremor of multiple sclerosis (Montgomery Jr. et al) 1999;53:625
neuropsychological and quality of life outcome after thalamic stimulation for essential tremor (Tröste et al) 1999;53:1774

Third nerve palsy
most diabetic third nerve palsies are peripheral (Thömke et al) (Letter); (Keane and Ahmadi) (Reply) 1999;53:894

Thoracic roots
neurologic manifestations of compressive radiculopathy of the first thoracic root (Levin) 1999;53:1149

3,4-DL-Threo-dihydroxyphenylserine
treatment of neurogenic orthostatic hypotension with 3,4-DL-threo-dihydroxyphenylserine (Freeman et al) 1999;53:2151

Thrombolytic therapy
antithrombotic treatment of ischemic stroke among patients with occlusion or severe stenosis of the internal carotid artery: a report of the Trial of Organization 10172 in Acute Stroke Treatment (TOAST) (Adams Jr. et al) 1999;53:122
initial clinical experience with IV tissue plasminogen activator for acute ischemic stroke: a multicenter survey (Tanne et al) 1999;53:424
thrombolysis in acute ischemic stroke: controlled trials and clinical experience (Hacke et al) (Sept, suppl 4) 1999;53:S3
thrombolytic stroke therapy: past, present, and future (Zivin) (Views & Reviews) 1999;53:14

Thrombosis
isolated intracranial hypertension as the only sign of cerebral venous thrombosis (Biousse et al) 1999;53:1537
stroke and intracranial venous thrombosis during pregnancy and puerperium (Koch and Robyn) (Letter); (Lanska and Kryscio) (Reply) 1999;53:1161

Thymoma
myasthenia, thymoma, presynaptic antibodies, and a continuum of neuromuscular hyperexcitability (Vernino et al) 1999;53:1233

Thyroid disorders
association of MS with thyroid disorders (Karni and Abramsky) 1999;53:883
subacute thyroiditis in a patient with MS treated with interferon beta-1a (Kreiss et al) 1999;53:1606

Tinnitus
meningeal metastases from malignant melanoma presenting with gaze-evoked tinnitus (Caraceni et al) 1999;53:2207

Tissue plasminogen activator
initial clinical experience with IV tissue plasminogen activator for acute ischemic stroke: a multicenter survey (Tanne et al) 1999;53:424

Topiramate
topiramate-treated cluster headache (Wheeler and Carranza) 1999;53:234

Tourette syndrome
bilineal transmission in Tourette syndrome (Hanna et al) 1999;53:813
corpus callosum measurements in girls with Tourette syndrome (Mostofsky et al) 1999;53:1345
striatal presynaptic monoaminergic vesicles are not increased in Tourette syndrome (Meyer et al) 1999;53:371
Tourette Syndrome Diagnostic Confidence Index: development and clinical associations (Robertson et al) 1999;53:2108

Transcranial magnetic stimulation
facilitation of picture naming after repetitive transcranial magnetic stimulation (Mottaghy et al) 1999;53:1806
motor cortex localization using functional MRI and transcranial magnetic stimulation (Macdonell et al) 1999;53:1462
transcranial magnetic stimulation identifies upper motor neuron involvement in motor neuron disease (Triggs et al) 1999;53:605

Transient ischemic attacks
comparison of population-based models of risk factors for TIA and ischemic stroke (Whisnant et al) 1999;53:532

Transthyretins
aggressive familial amyloidotic polyneuropathy caused by a new variant transthyretin Lys 54 (Togashi et al) 1999;53:637
transthyretin amyloidosis and superficial siderosis of the CNS (Mascalchi et al) 1999;53:1498

Traumatic brain injury
brain activation during working memory 1 month after mild traumatic brain injury: a functional MRI study (McAllister et al) 1999;53:1300
functional anatomy of neuropsychological deficits after severe traumatic brain injury (Fontaine et al) 1999;53:1963
head trauma and risk of dementia and Alzheimer's disease. The Rotterdam Study (Mehta et al) 1999;53:1959
management of concussion in sports (Jordan) (Letter); (Kelly and Stevens) (Reply) 1999;53:892

Tremor
bilateral thalamic stimulation for the treatment of essential tremor (Pahwa et al) 1999;53:1447
chronic thalamic stimulation for the tremor of multiple sclerosis (Montgomery Jr. et al) 1999;53:625
mirtazapine treats resting tremor, essential tremor, and levodopa-induced dyskinesias (Pact and Giduz) 1999;53:1154
neuropsychological and quality of life outcome after thalamic stimulation for essential tremor (Tröste et al) 1999;53:1774

Trigeminal nerve
facial trigeminal synkinesis associated with a trigeminal schwannoma (Rubin et al) 1999;53:635
familial trigeminal neuralgia and contralateral hemifacial spasm (Duff et al) 1999;53:216
trigeminal neuropathy secondary to perineural invasion of head and neck carcinomas (Boerman et al) 1999;53:213

Trisomy 9p
association of trisomy 9p and band heterotopia (Federico et al) 1999;53:430

Trochlear nerve
isolated trochlear nerve palsy in patients with multiple sclerosis (Jacobson et al) 1999;53:877
Tropical spastic paraparesis
inverse correlation of HTLV-1 viral load in CSF and intrathecal synthesis of HTLV-1 antibodies in TSP/HAM (Puccioni-Sohler et al) 1999;53:1335
Tuberculoma
brainstem tuberculoma mimicking glaucoma (Mak and Cheung) (Letter); (Fong et al) (Reply) 1999;53:1894
Tuberous sclerosis
new developments in the neurobiology of the tuberous sclerosis complex (Crino and Henske) (Views & Reviews) 1999;53:1384
Tumor(s). *See* **Neoplastic diseases;** *specific tumors*
Tumor necrosis factor
changes in serum levels of ICAM and TNF-R correlate with disease activity in multiple sclerosis (Khoury et al) 1999;53:758
primary association of a TNF gene polymorphism with susceptibility to multiple sclerosis (Fernandez-Arquero et al) 1999;53:1361
shedding of TNF receptors in multiple sclerosis patients (Jurewicz et al) 1999;53:1409
TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study (Lenercept Multiple Sclerosis Study Group and University of British Columbia MS/MRI Analysis Group) 1999;53:457
Tyrosine hydroxylase
striatal biopterin and tyrosine hydroxylase protein reduction in dopa-responsive dystonia (Furukawa et al) 1999;53:1032

U

Ubiquitin
case-control study of the ubiquitin carboxy-terminal hydrolase L1 gene in Parkinson's disease (Maraganore et al) 1999;53:1858
Ultrasound
potential source of cerebral embolism in migraine with aura: a transcranial Doppler study (Cheng) (Letter); (Anzola et al) (Reply) 1999;53:2213
vulnerability of nigrostriatal system as detected by transcranial ultrasound (Berg et al) 1999;53:1026
United States
autopsy patterns for Parkinson's disease and related disorders in Olmsted County, Minnesota (Maraganore et al) 1999;53:1342
conceptual approach to diagnostic delay in ALS: a United States perspective (Gelinas) 1999;53:S17
increasing incidence of medically recognized migraine headache in a Unites States population (Rozen et al) 1999;53:1468
MS in two studies of US women (Hernán et al) 1999;53:1711
Urban populations
influence of *APOE* genotype on familial aggregation of AD in an urban population (Devi et al) 1999;53:789

V

Vagus nerve
long-term treatment with vagus nerve stimulation in patients with refractory epilepsy (Morris III et al) 1999;53:1731
reassessment: vagus nerve stimulation for epilepsy: a report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology (Fisher and Handforth) 1999;53:666
Valproic acid
serum leptin changes in epileptic patients who gain weight after therapy with valproic acid (Verrotti et al) 1999;53:230
Varicella zoster virus
varicella zoster virus-associated focal vasculitis without herpes zoster (Rosenblum) (Letter); (Nau) (Reply) 1999;53:242
Vascular disorders. *See also specific disorders*
cerebroretinal vasculopathy mimicking a brain tumor: a case of a rare hereditary syndrome (Weil et al) 1999;53:629
characterization of risk factors for vascular dementia: The Honolulu-Asia Aging Study (Ross et al) 1999;53:337
matrix metalloproteinase upregulation in chronic inflammatory demyelinating polyneuropathy and nonsystemic vasculitic neuropathy (Leppert et al) 1999;53:62
microvasculitis and ischemia in diabetic lumbosacral radiculoplexus neuropathy (Dyck et al) 1999;53:2113
varicella zoster virus-associated focal vasculitis without herpes zoster (Rosenblum) (Letter); (Nau) (Reply) 1999;53:242
Vertigo
modified Epley's procedure for self-treatment of benign paroxysmal positional vertigo (Radtke et al) 1999;53:1358
Vibration
abnormal perception of vibration-induced illusion of movement in dystonia (Rome and Grünewald) 1999;53:1794
Video recordings
focal akinetic seizures as documented by electroencephalography and video recordings (Noachtar and Lüders) 1999;53:427
Vigabatrin
effect of vigabatrin on cerebral blood flow and metabolism (Spanaki et al) 1999;53:1518
psychiatric adverse events during vigabatrin therapy (Levinson and Devinsky) 1999;53:1503
vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects (Kälviäinen et al) 1999;53:922
visual dysfunction in patients receiving vigabatrin: clinical and electrophysiologic findings (Miller et al) 1999;53:2082
Vincristine
neoadjuvant procarbazine, CCNU, and vincristine for anaplastic and aggressive oligodendroglioma (Paleologos et al) 1999;53:1141
Viruses. *See also specific viruses*
gene therapy using viral vectors for acute neurological insults (Sapolsky and Steinberg) (Editorial) 1999;53:1922
Visual fields
vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects (Kälviäinen et al) 1999;53:922
Visual function. *See also* **Nystagmus**
acute isolated monocular blindness and painless carotid artery dissection (Lee et al) 1999;53:1155
cortical activation patterns during voluntary blinks and voluntary saccades (Bodis-Wollner et al) 1999;53:1800
dopamine agonists reorient visual exploration away from the neglected hemispace (Barrett) (Letter); (Geminiani) (Letter); (Grujic) (Reply) 1999;53:1610
ptosis, blepharospasm, and apraxia of eyelid opening secondary to putaminal hemorrhage (Verghese et al) 1999;53:652
reduced cerebral blood flow and impaired visual-spatial function in proximal myotonic myopathy (Meola et al) 1999;53:1042
visual dysfunction in patients receiving vigabatrin: clinical and electrophysiologic findings (Miller et al) 1999;53:2082
visual field defects after temporal lobe resection: a prospective quantitative analysis (Hughes et al) 1999;53:167
Vitamin A
serum vitamin A concentration is elevated in idiopathic intracranial hypertension (Jacobson et al) 1999;53:1114
von Hippel-Lindau disease
VHL gene inactivation in an endolymphatic sac tumor associated with von Hippel-Lindau disease (Kawahara et al) 1999;53:208
von Hippel-Lindau disease: how does one gene cause multiple tumors? (Roach) (Editorial) 1999;53:7

W

Wada procedure
language dominance determined by magnetic source imaging: a comparison with the Wada procedure (Breier et al) 1999;53:938
Website reviews
Webster's Dictionary: Websites for neurologists (Brooke) 1999;53:441
Weight gain
serum leptin changes in epileptic patients who gain weight after therapy with valproic acid (Verrotti et al) 1999;53:230
West syndrome
serum and CSF neuron-specific enolase in patients with West syndrome (Suzuki et al) 1999;53:1761
White matter
phenotypic variation in leukoencephalopathy with vanishing white matter (Rodriguez and Gelot) (Letter); (van der Knaap and Kamphorst) (Reply) 1999;53:1373
Women. *See also* **Gender; Menopause; Menstrual cycle; Menstrual migraine; Pregnancy; Sex**
catamenial epilepsy: clinical aspects (Zahn) (Sept, suppl 1) 1999;53:S34
epilepsy in the menopause (Lee) (Sept, suppl 1) 1999;53:S41
epilepsy in women: the science of why it is special (Morrell) (Sept, suppl 1) 1999;53:S42
hormonal contraception and epilepsy (Guberman) (Sept, suppl 1) 1999;53:S38
management issues for women with epilepsy (Liporace) (Letter); (Galus) (Letter); (Zahn et al) (Reply) 1999;53:656
management of menstrual migraine (Boyle) (Sept, suppl 1) 1999;53:S14
management of migraine and epilepsy throughout the reproductive cycle (Edmeads) (Sept, suppl 1) 1999;53:S1
menstrual cycle effects on cortical excitability (Smith et al) 1999;53:2069
migraine in pregnancy (Aubé) (Sept, suppl 1) 1999;53:S26
migraine in the menopause (Fettes) (Sept, suppl 1) 1999;53:S29
sex hormones and headache 1999 (menstrual migraine) (Silberstein and Merriam) (Sept, suppl 1) 1999;53:S3
use of oral contraceptives in patients with menstrual migraine (Becker) (Sept, suppl 1) 1999;53:S19
Writer's cramp
deficient activation of the motor cortical network in patients with writer's cramp (Ibáñez et al) 1999;53:96

Z

Zoster ophthalmicus
stroke after zoster ophthalmicus in a 12-year-old girl with protein C deficiency (Cadavid et al) 1999;53:1128

Author Index to Volume 53

A

Abbott DF, 1462, 2179
Abbruzzese M, 404
Aberfeld DC, 1889
Abe T, 1633
Abicht A, 1564
Abou-Khalil B, 167, 1736
Abramsky O, 883
Achiron A, 1606
Adams HP Jr., 122, 126
Adams LF, 2069
Adler CH, 1431
Adler RL, 1421
Aere C, 1665
Agid Y, 241, 1197
Agre JC, 1225
Aguglia U, 557, 1425
Ahlskog JE, 411, 795
Ahmadi J, 895
Ahn H, 1155
Aisen ML, 1874
Ajmar F, 404
Akiguchi I, 1671
Akiyoshi H, 1749
Alanen A, 303
Alarcón JOV, 386
Alarcon M, 723
Al-Aweel IC, 1590
Albanese A, 85
Albani F, 1374
Albers GW, 233, S25 (Oct, suppl 4)
Albert M, 1284
Albert S, 1942
Albert SM, 278
Alberts MJ, 1308, 2176
Albin RL, 371
Alfonsi E, 1064
Alfonso G, 50
Alimonti D, 1064
Allaria S, 2206
Alldredge BK, S68 (Sept, suppl 2)
Alliegro MB, 2032
Almqvist EW, 1000
Alpérovitch A, 1948
Alpérovitch A, 1197
Alrawi A, 858
Al-Shehab A, 1076
ALS Percutaneous Endoscopic Gastrostomy Study Group, 1123
Amato AA, 659
Ambrosanio G, 1332
Ameri A, 1537
Andersen AH, 1391
Andersen K, 1992
Andersen O, 1880
Anderson A, 331
Anderson B, 242
Anderson DW, 315, 1342
Anderson NE, 1894
Andersson P-B, 874, 1071, 1397
Andreasen N, 1488
Andreoli V, 1425
Andreone V, 1332
Andreoni M, 2032
Andrews PI, 699
Andriola MR, S89 (Sept, suppl 2)
Ang CW, 2122
Angiolillo A, 1128
Annesi G, 1425
Annis SM, 1983
Annoni G, 1888
Antel JP, 2087
Anthony JC, 321
Antonelli P, 1064
Antonucci T, 1953
Anzola GP, 2213
Aoki M, 1119
Aprile I, 1654
Arahata K, 1119
Arai H, 2208
Arezzo JC, 580, 592
Armitage BA, 1765
Arndt S, 543
Arnold LA, 91, 1205
Arpino C, 2032
Arroyo R, 1361
Arroyo S, 1170
Ascaso C, 1719
Ascherio A, 1711
Ashby P, 730
Ashizawa T, 1164
Ashmead D, 1736
Askanas V, 2184
Aso E, 218
Astarloa R, 1219
Atkinson EJ, 893
Atkinson JLD, 216, 402
Attarian HP, 434
Aubé M, S26 (Sept, suppl 1)
Auger RG, 407, 635, 1233
Augustine AM, 2145
Austin JK, S96 (Sept, suppl 2)
Avila J, 1219
Avison MJ, 1391
Avolio C, 1402
Awada A, 1372
Ay H, 240, 1373
Aylward EH, 2145
Azouvi P, 1963

B

Bacchetti P, 1397
Bäckman L, 1998
Bagley LJ, 49 (Sept, suppl 3)
Baird AE, 1528
Baker KB, 625
Baker RS, 2204
Bakshi R, 1151
Baldereschi M, 1992
Baloh RW, 34, 375
Banati RB, 2199
Banerjee S, 2108
Barabash A, 1219
Barberger-Gateau P, 1953
Bare M, 2073
Barendse GAM, 1350
Barker GJ, 33 (Sept, suppl 3), 751
Barkhof F, 46 (Sept, suppl 3), 448
Barkovich AJ, 270, 1271
Barnett G, 625
Barohn RJ, 1071
Barone P, 573, 1606
Baron R, 548
Baron Y, 548
Barrett AM, 1610, 2017
Barr WB, 260
Bars DL, 1882
Bartalesi F, 2064
Barta PE, 2145
Bartolomeo P, 2023
Bartoloni A, 2064
Bartolucci A, 1983
Baruzzi A, 1374
Basciani F, 230
Bashir K, 765
Basile AS, 1144
Bassetti C, 2193
Bastianello S, 622, 1588
Bates VE, 424
Battistini N, 38, 1451
Battistini S, 38
Baty JD, 956
Bauer B, 357
Baumann P, 297
Beal MF, 1787
Beattie P, 612
Bebin J, 1608
Becher B, 2087
Becker G, 1026
Becker JT, 1292
Becker PM, 439
Becker WJ, S19 (Sept, suppl 1)
Beeson D, 1265
Behan PO, 466
Belden JR, 1312
Belin TR, 1190
Beltramello A, 1825
Benbadis SR, 440
Bendixen BH, 122, 126
Benesch C, 424
Benfield A, 1528
Ben-Menachem E, 1518
Bennett D, 2212
Bennett P, 1415
Bensa S, 57
Benz P, 1026
Berg AT, 1742
Berg D, 1026
Berger A-K, 1998
Berger AR, 592
Berger JR, 2204
Bergeron CB, 1969
Berglund L, 517
Berg MJ, 434
Berg R, 1114
Berkovic SF, 1347, 1462
Bermejo–Pareja F, 573
Bernabei R, 508
Bernardi M, 416
Bernat JL, 284, 1369
Bernsen RAJAM, 409
Bertsch T, 1104
Bethke F, 1892
Bever CT Jr., 1380
Beversdorf DQ, 241
Beyderman L, 2073
Bialy Y, 736
Bianchetti A, 1825
Bianco C, 1335
Bick D, 1087
Bilir E, 496
Billard C, 1724
Biller J, 1839
Billette de Villemeur T, 1197
Binder JR, 424
Binkofski F, 1375
Binnie CD, 490, 1276, 1892
Biousse V, 117, 1537
Bird ED, 1330
Bird TD, 5
Black SH, 1087
Bladin CF, 2179
Blaivas M, 237, 858
Blanchet PJ, 91
Blanchette PL, 337
Bland J, 1051
Blennow K, 1488
Blinkenberg M, 149
Bliwise DL, 1868
Blonder LX, 1391
Blum AS, 1590
Blumberg B, 1676
Blumenkopf B, 167
Blumen SC, 1602
Blumer D, S9 (Sept, suppl 2)
Boatman D, 1813
Bocksberger JP, 946
Bodis–Wollner I, 1800
Boerman RH, 213
Boeve BF, 795, 1579
Bogousslavsky J, 1364
Bohnen NI, 371
Bolognesi M, 404
Bolton CF, 1083
Boltshauser E, 966
Bonavita V, 1549
Bonifati V, 1415
Bonilla E, 44
Bonuccelli U, 1415
Book D, 424
Bordo D, 404
Borenstein Graves A, 1480
Bornstein NM, S32 (Oct, suppl 4)
Boroojerdi B, 1806
Bosboom WMJ, 837
Bosco D, 557
Boshes LD, 12
Bots ML, 1593
Bottacchi E, 1123
Bougniot C, 396
Bour LJ, 2196
Bousser M-G, 117, 1537
Bouvard S, 1882
Bowen JD, 1480
Bower JH, 1342
Bowman ES, S84 (Sept, suppl 2)
Boyle CAJ, S14 (Sept, suppl 1)
Boysen G, S3 (Oct, suppl 4)
Bramanti P, 1893
Brambilla E, 1367
Branca D, 557, 1425
Brandel JP, 1197
Brandt SA, 106
Brashear A, 1439, 2010
Braune S, 1020
Braun JG, 527
Bravi D, 573
Brayne C, 1992
Breier JI, 938
Breitner JCS, 321
Brengman J, 1076
Breteler MMB, 1593, 1937, 1959
Brex PA, 1184
Brice A, 1355
Briemberg HR, 239
Brin MF, 1431, 1439
Brochet B, 12 (Sept, suppl 3)
Brodtmann A, 1347
Broët P, 1719
Brønnum-Hansen H, 473
Bronstein JM, 154
Brooke MH, 441
Brooks DJ, 2199
Brott T, S3 (Oct, suppl 4)
Browne SE, 1787
Browne TR, 1611
Brown GK, 612
Brown MB, 580
Brown P, 1903
Brown RD, 532
Brown RH Jr., 1119, 1239
Brownscheidle CM, 139
Brown WD, 1212
Brügmann M, 1806
Brunereau L, 117
Brunner J, 1564
Brunt ER, 364
Brust JC, 1765
Bryan RN, 189
Bryan WW, 1071
Bucher SF, 1800
Buchwald B, 1246
Buckles VD, 956
Budson AE, 239
Buée L, 411
Buée-Scherrer V, 411

July 13 issue, pp 1–246; July 22 issue, pp 247–442; August issue, pp 443–660; September 11 issue, pp 661–896; September 22 issue, pp 897–1162; September, Supplement 1, pp S1–S48; September, Supplement 2, pp S1–S100; September, Supplement 3, pp S1–S53; October 12 issue, pp 1163–1378; October 22 issue, pp 1379–1612; October, Supplement 4, pp S1–S37; November issue, pp 1613–1898; November, Supplement 5, pp S1–S72; December issue, pp 1899–2246

Bueri JA, 1132
Bugiani O, 404, 2173
Bulman DE, 1932
Buonanno FS, 1373
Burke W, 2215
Bussel B, 1963
Butler MH, 852
Butterworth EJ, 173
Buttinelli C, 1588
Buzzi MG, 1588

C

Cabanis EA, 396, 1091
Cadaldini M, 1609
Cadavid D, 1128
Cairncross JG, 1141
Calabresi P, 1377
Calhoun J, 1596
Calne DB, 2097
Camerlingo M, 112
Campadelli-Fiume G, 1367
Campbell LA, 1888
Campion ME, 893
Campion MK, 139
Canal N, 888
Canciani B, 2173
Capildeo R, 466
Capilldeo R, 1012
Caplan L, S3 (Oct, suppl 4)
Caplan LR, 1312
Capon F, 830
Cappa S, 1042
Cappa V, 1549
Capra R, 1705
Caraceni A, 2207
Carasso RL, 1602
Caravale B, 265
Carbidopa-Levodopa Study Group, 1012
Carey LM, 1462
Carlsson A, 1605
Carpenter MA, 1447
Carpo M, 2206
Carrazana EJ, 234
Carrera P, 26, 38
Carter K, 1660
Carver AC, 284
Casaccia–Bonnefil P, 1676
Casadei VM, 1888
Casale E, 1724
Cascino GD, 1611
Caselli RJ, 201, 795, 1579
Cashman NR, 1225
Casto L, 112
Cattaneo M, 1888
Catt KE, 1292
Cavallaro T, 846
Cavalli G, 416
Cecil KM, 211
Censori B, 112
Ceroni M, 1064
Cesana B, 112
Chadwick D, 2211
Chalela J, 423
Chalk CH, 407
Chamberlain MC, 437
Chan FL, 2132
Chang GY, 652
Chang J-G, 642
Chang KC, 122, 126
Chang L, 782
Chang LJ, 1032
Chan KM, 1271
Chan SHH, 885
Chao M, 1676
Chapman J, 223, 1328
Chase TN, 91
Chatterjee A, 1596
Chaturvedi S, 1473
Chaudhry V, 1660
Chaudhuri A, 466
Chaussain JL, 1197
Chehrenama M, 894
Chelune GJ, 260
Cheng PW, 2132
Cheng TO, 2213
Chen W-T, 1887
Chen Y, 331
Cheung RTF, 1894, 1894
Chiappa KH, 605
Chiarelli F, 230
Chillrud S, 1765
Chin CT, 1271
Chiò A, 1123
Chokron S, 2023
Chokroverty S, 1889
Christodoulou K, 1076
Christophidis N, 197
Christov C, 1683
Chrousos GA, 177
Chugani DC, 1473, 2037
Chugani HT, 1473, 2037
Churchwell J, 723
Ciacci C, 1606
Cianchetti C, 433
Ciarmiello A, 1332
Cittadella R, 1425
Civitelli D, 1425
Clarberg A, 1488
Clark CM, 1000
Clarke WR, 122, 126
Clark JD, 2209
Coffey CE, 189
Cohen DJ, 2108
Cohen O, 1606
Cohen RA, 819
Cole AJ, 915
Coleman LT, 715
Coles AJ, 751
Colleluori A, 1042
Collet J-P, 1225
Collins MP, 1641
Collins S, 656
Colonnese C, 1588
Colosimo C, 1415
Combs-Cantrell D, 2211
Combs-Cantrell DT, 2212
Comella CL, 1431, 1439
Comi G, 1 (Sept, suppl 3), 888, 1705
Commenges D, 1953
Compston DAS, 751
Conejero L, 1361
Conneally PM, 245, 1164
Conolly ES, 421
Consortium on Dementia with Lewy Bodies, 902
Constantinou JEC, 938
Contant CF, 813
Contin M, 1374
Cookfair DL, 139
Cook S, 1676
Copeland JRM, 1992
Coplin WM, 424, 1611
Corbett JJ, 1114
Cornblath DR, 1634, 1660
Cortelli P, 1374
Cosman F, 437
Costagliola D, 1197
Cotelli M, 1042
Counihan T, 1377
Couratier P, 1059
Couropmitree NN, 1330
Couture R, 2087
Cowan T, 485
Cramer JA, S49 (Sept, suppl 2), 2212
Créange A, 1683
Creel G, 50
Crerar MM, 1352
Crews BC, 1495
Crino PB, 1384
Crisci C, 1370
Crispin D, 669
Crook R, 411
Cros D, 605
Cross A, 1378
Croxen R, 1265
Cruts M, 1593
Crystal HA, 1974
Cucinotta D, 416
Cumming A, 418
Cumming P, 1374
Cummings JL, 899
Cunha L, 825
Cupples LA, 1330
Curatolo J, 1347
Curatolo JM, 1462
Curb JD, 337
Curcio M, 26
Currier RD, 1608
Curti D, 1064
Cutting L, 1345
Cyrus PA, 2010
Cysticercosis Working Group in Perú, 1582
Cysyk B, 2073

D

D., 2032
Dagher A, 871
Dahiyat MT, 418
Dahl N, 2190
d'Aignaux JH, 1197
Dalakas MC, 1166
D'Aleo G, 1893
Daley S, 424
Dallapiccola B, 830
Dalla Volta G, 2213
Damon D, 1953
D'Andrea G, 1609
Dartigues JF, 1953, 1992
da Silva EA, 2037
Dautzenberg PLJ, 946
Davidsson P, 1488
Davis PH, 122, 126
Dawson JM, 1051
Day J, 891
Dayno JM, 424
Dean A, 1518
De Angelis LM, 438
Dearlove AM, 1844
de Baets M, 1246
deBelleroche J, 1064
De Bleecker JL, 435
De Boer L, 837
De Camilli P, 852
DeCarli C, 1825
Deckert-Schlüter M, 220
Defazio G, 1402
DeFries JC, 723
Deiber M-P, 96
de Jager AEJ, 409
DeJesus OT, 1212
De Keyser J, 1628
DeKosky ST, 228, 1292
de la Concha EG, 1361
Delacourte A, 411
de la Sayette V, 632
Delattre JY, 1719
del Barrio Alba A, 806
Del Bene ML, 278
Del Brutto OH, 1582, 1895
Delong D, 1308
DeLong DM, 2176
Delrahim S, 1190
De Maria AF, 895
de Martino M, 230
Denckla MB, 1345
Dennett X, 2127
Derdeyn CP, 251
De Ronchi D, 416
D'Errico A, 1498
Deslys JP, 1197
Desport JC, 1059
De Stefano N, 430
Devi G, 789
Devinsky O, S13 (Sept, suppl 2), 1503
Dewey ME, 1992
De Wilde P, 213
de Yébenes JG, 806, 1219
Deymeer F, 1076
Deyn PPD, 946
Di Bella P, 1893
Dichgans M, 233
Dickson DW, 795, 1903, 1974
Diels CM, 1874
Diener H-C, 825, S32 (Oct, suppl 4)
Digre KB, 1114
Di Iorio G, 1549
DiMauro S, 44, 1352
Diomedi M, 430
DiPatre PL, 375
Diringer MN, 351
Disbrow E, 548
DiStefano L, 1032
Djouhri H, 117
Dobko T, 2097
Dobyns WB, 270
Dodge HH, 228
Dodick DW, 216, 402
Donahue SP, 167
Donnan G, S3 (Oct, suppl 4)
Donnan GA, 2179
Donoghue S, 466
Dorfmann A, 1087
Dormont D, 1197
Dorrucci M, 2032
Dotti MT, 430
Doty RL, 880
Dousset V, 12 (Sept, suppl 3)
Dowler R, 709
Dowling P, 1676
Dowson A, 988
Drachman DA, 2214
Drury I, 237
D'Souza I, 864
D'Souza J, 2212
Dubovsky EC, 1128
Dubuis O, 1584
Duchowny M, 1724
Ducimetière P, 1948
Ducruet T, 1225
Dudel C, 629
Duff JM, 216
Dufouil C, 1948
Dulli D, 424
Dumas M, 2064
Duncan JS, 2199
Dunn DW, S96 (Sept, suppl 2)
Duong DH, 421
Duquette P, 2087
Dürr A, 1355
D'Urso R, 622
Dutch Guillain-Barré Study Group, 598
Dyck PJ, 1865, 2113
Dyck PJB, 2113
Dykstra DD, 1439

E

Easton JD, S32 (Oct, suppl 4)
Ebers GC, 1932
Ebmeier KP, 644
Edelman RR, 1528, 2193
Edelsteinn L, 1874
Edmeads J, S1 (Sept, suppl 1)
Edmonds ZV, 1190
Edwards DF, 351
Egan GF, 2179
Eggenberger ER, 877
Einhäupl K, S32 (Oct, suppl 4)
Ekesbo A, 1605
Ekes R, 1151
Eldevik OP, 44
Elixhauser A, 162
Ellefson RD, 1114
Elliott J, 2209
Elliott JL, 1071
Ellis CM, 1051
Ellison GW, 154, 1190
Ellis RJ, 1144
Elwes RDC, 490, 1276, 1892
Emslie-Smith AM, 1233
Endres M, 2082
Engel AG, 1076
Engel U, 801
Engel WK, 2184
Enns R, 2093
Ensoli B, 2032
Entezari-Taher M, 1201
Epidemiologic Study of Dystonia in Europe(ESDE) Collaborative Group, 1871
Epstein LG, 391
Erba G, 434
Erbguth FJ, 1850
Erdem S, 1641

Erickson SM, 434
Eriksson S, 946
Erne B, 62, 1364
Ernst T, 782
Espey MG, 1144
Ettinger AB, S1 (Sept, suppl 2), S89 (Sept, suppl 2)
EURODEM Incidence Research Group, 1992
European Atrial Fibrillation Trial(EAFT) Study Groups, 1319
European Inflammatory Neuropathy Cause, 1648
European Stroke Prevention Study 2 Working Group, 825
European Study Group on Atypical Parkinsonism, 1415
EVA Study Group, 1948
Evers S, 357
Evyapan D, 647
Exconde RE, 891

F

Fabbrini G, 1415
Faber R, 1159
Fabinyi GC, 1462
Fabrigoule C, 1953
Fabrizi GM, 846
Factor SA, 1431, 1439
Failla G, 2064
Fakhouri M, 1473
Fakhoury T, 167, 1736
Falaschi P, 622
Fallon L, 1087
Fang J, 91
Farina E, 50
Farlow MR, 2010
Farrer MJ, 1858
Fassbender K, 1104
Fassetta G, 852
Faught E, 496, 687, 694, 709, 1511, 2052, 2211, 2212
Fazekas F, 132, 448
Fazilat S, 1518
Fazio F, 1042
Feasby TE, 1905
Federico A, 430
Feinberg DM, 241
Ferini–Strambi L, 1154
Ferlini A, 1498
Fernandez-Arquero M, 1361
Ferracci F, 852
Ferrante RJ, 1239
Ferrari M, 26, 38
Ferrari MD, 537
Ferrer JM, 861
Ferri C, 888, 1888
Ferriero DM, 1271
Fettes I, S29 (Sept, suppl 1)
Field LK, 1087
Fields JA, 1774
Fieschi C, S3 (Oct, suppl 4), 1876
Figlewicz DA, 5
Figueredo MA, 1361
Filipek PA, 723
Filippi M, 1 (Sept, suppl 3), 18 (Sept, suppl 3), 40 (Sept, suppl 3), 52 (Sept, suppl 3), 448, 622, 1705
Filla A, 1606
Filley CM, 723
Finch L, 1225
Fink JK, 44
Finocchiaro E, 1123
Fischer JS, 139
Fisher E, 1698
Fisher RS, 666, 2211, 2212
Flanigan KM, 1180
Flashman LA, 1300
Floeter MK, 664
Flood DG, 1239
Floridia D, 1893
Florio C, 1332
Floyd S, 852
Foley DJ, 337
Foley KM, 284
Foltys H, 1806
Fong GCY, 1894
Fontaine A, 1963
Fontaine B, 1091
Forbes C, 825
Forbes R, 466
Forsell Y, 1998
Forti P, 416
Franceschi M, 1888
Frank JA, 29 (Sept, suppl 3)
Franklin G, 239
Franssen H, 837, 1573
Fratiglioni L, 1998
Frederiksen JL, 473
Freeman K, 592
Freeman R, 2151
Freimer ML, 1641
Frese A, 357, 1892
Frey KA, 371
Frey M, 933
Friedman JH, 438
Frisoni GB, 1825
Frontoni M, 622
Fuchs K, 801
Fugger EF, 1087
Fuh JL, 962, 1887
Fuhrer R, 1953
Fuhr P, 62, 914
Fujii A, 2182
Fujii Y, 1599
Fujiwara T, 926
Fukuyama H, 1833
Furie KL, 240
Furukawa Y, 1032
Furuya H, 2187
Fusco C, 1332
Futagi Y, 1761

G

Gabizon R, 1328
Gadag V, 485
Gaillard WD, 1518
Galaburda A, 723
Galetta SL, 877, 1130
Gallino G, 2207
Galluzzi G, 50
Galus MA, 656
Gálvez-Jiménez N, 439
Gambardella A, 557, 1425
Gambassi G, 508
Gamboa H, 2064
Ganguli M, 228
García HH, 1582
García–Segura JM, 806
Garrè C, 404
Gash DM, 1458
Gasser T, 233, 855
Gavazzi A, 1888
Gawne–Cain M, 751
Gazzaniga MS, 243, 974
Gazzola P, 895
Gee L, 1397
Gelfi C, 26, 38
Gelot A, 1373
Geltinger M, 1087
Geminiani G, 1610
Gennarelli M, 830
Gent M, S32 (Oct, suppl 4)
Gerhardt GA, 1458
Geroldi C, 1825
Gervil M, 995
Geyer JD, 1892
Gherardi RK, 1683
Ghezzi A, 1705
Ghiglieri O, 1451
Giaccone G, 2173
Giannini F, 38
Gidal B, S3 (Sept, suppl 2)
Giduz T, 1154
Gigli GL, 430
Gillen DA, 1865
Gilliam F, 496, 687, 694, 709, 1511, 1892, 2052
Gilligan AK, 1347
Gilman J, 1724
Giovannoni G, 20
Girkin CA, 2082
Girotti F, 502
Giugni E, 1588
Giuliani F, 1402
Gjedde A, 1374
Glabus MF, 644
Gleeson JG, 270
Godbold JH, 1523
Godoy M, 1219
Goerres GW, 2199
Goldberger AL, 1590
Goldblatt D, 245
Goldman J, 1765
Goldman ME, 1523
Goldman WP, 956
Goldstein AM, 1260
Goldstein DS, 1205
Goldstein G, 2145
Goldstein J, 1542
Gómez-Isla T, 2003
Gómez-Tortosa E, 1284, 2003
Gonzalez RG, 1373
Good JL, 894
Goodkin DE, 139, 874, 1397
Goodman AD, 743
Gordon B, 1813, 2073
Gorelick PB, S15 (Oct, suppl 4)
Gorell JM, 1158
Gorter JW, 1319
Goto M, 1761
Gottfries J, 1488
Gourevitch MN, 592
Gout O, 396, 1091
Goyal M, 1542
Grace GM, 1665
Graff–Radford NR, 201
Graff-Radford N, 795
Grafman J, 639
Graf P, 1000
Graf WD, 446, 1724
Granella F, 1609
Granger C, 1225
Grauer MT, 895
Grau JM, 241
Graus F, 1719
Gray L, 2176
Greco A, 1876
Greenberg BD, 2069
Greenberg SM, 1135
Greene DA, 580
Greenfield LJ Jr., 237
Green JB, 736
Green RL, 974
Griffin JW, 1634
Griggs RC, 2, 1899
Grigoletto F, 315
Grimaldi LME, 26, 478, 888, 1367, 1888
Grimes DA, 1969
Grisold W, 1083
Grisoli M, 502
Griswold M, 2193
Grossman RI, 1 (Sept, suppl 3), 8 (Sept, suppl 3), 23 (Sept, suppl 3), 49 (Sept, suppl 3), 52 (Sept, suppl 3), 448, 1130
Group TINCAT, 1648
Growdon JH, 1284
Growdon WB, 2003
Grubb RL Jr., 251
Grujic Z, 1610
Grünewald RA, 1794
Grygar C, 62
Gualdi GF, 430
Guazzi GC, 38
Guberman A, S38 (Sept, suppl 1)
Guerin SJ, 1300
Guillon B, 117
Guindani M, 2213
Gulanski B, 2010
Gunn RN, 2199
Gupta RK, 1781
Gusella JF, 1330
Gütlich M, 1032
Gutmann L, 894
Guttmann CRG, 758

H

Haass A, 895
Habgood J, 1064
Hacke W, S1 (Oct, suppl 4), S3 (Oct, suppl 4)
Hackney DB, 211
Hadden RDM, 57
Haegert DG, 485
Hagenah J, 566
Hahn AF, 1932
Halket E, 561
Hall AJ, 2064
Hallett M, 96, 1910
Halpern M, 657
Handforth A, 666
Hanna DR, 1611
Hanna PA, 813
Hansen LA, 1570
Hansen MD, 122, 126
Hanson M, 439
Hansson GK, 1880
Hardy J, 411
Hardy JA, 1858
Hardy MA, 1000
Hardy R, 308
Harper CM, 1233
Harrell LE, 1983
Harris LE, 1839
Harris MR, 245
Hart J, 1813
Hartmann A, 421
Harton GL, 1087
Hart PE, 2209
Hartung H-P, 20, 132
Harvey AS, 715
Harzheim M, 220
Hasegawa H, 864
Hasegawa O, 1138
Hashimoto R, 344
Haslwanter T, 2158
Hatanaka N, 894
Hattori N, 1602
Hauer P, 1634
Haur LS, 1860
Hausdorff JM, 1590
Hauw JJ, 1197
Havlik R, 337
Hawkins CP, 466
Hawkins SA, 893
Hayashi A, 1160
Hayashi YK, 1119
Haycock JW, 1032
Hayden MR, 1000
Hazama F, 864
Heaney DC, 657
Heaton RK, 1144
Heberlein I, 566
Hedera P, 44
Hedley-Whyte ET, 2003
Heilman KM, 241, 2017, 2028
Heinänen K, 303
Heiss W-D, S3 (Oct, suppl 4)
Helmer C, 1953
Hennerici M, 1104
Hennessy MJ, 490, 1276, 1892
Henschel K, 1151
Henske EP, 1384
Henson JW, 1260
Herczegfalvi A, 1564
Hering R, 220
Herman A, 1355
Hermann B, S3 (Sept, suppl 2)
Hermann BP, S1 (Sept, suppl 2), 260
Hermansen F, 1374
Hernán MA, 1711
Herndon RM, 139
Herrmann DN, 1634
Herskovitz S, 592
Hertfelder H-J, 220
Hetherington H, 694
Hetta J, 2190
Higgins JJ, 1421
Higuchi M, 2208
Hilgevoord AAJ, 2196
Hiller L, 1415
Hill G, 521

Hillis AE, 1813
Hilsden RJ, 2093
Hirano T, 2179
Hirayama K, 890
Hirono N, 413
Hirose S, 1749
Hirota N, 1156
Hirsch LJ, 669, 1896
Hodgson TL, 2209
Hoenicka J, 1219
Hoffman EP, 50
Hoffmann KL, 2176
Hoffmann O, 1365
Hofman A, 1593, 1937, 1959, 1992
Hofmann E, 1026
Hof PR, 411
Hogancamp WF, 1107
Hogan N, 1874
Hohlfeld R, 1622
Holden JE, 1212
Holinski–Feder E, 801
Hollander D, 1225
Hollingsworth H, 351
Holloway RG, 1905
Holme E, 79
Holmes CS, 1205
Holmes GL, 1754
Holmes KK, 386
Holm S, 149
Holsboer F, 772
Ho MF, 1119
Honeycutt NA, 2145
Hong CJ, 962
Hong J, 1692
Honig LS, 1158
Hopf HC, 894
Horany K, 1076
Horiuchi S, 619
Hornykiewicz O, 1032
Horowitz DR, 1523
Horsfield MA, 40 (Sept, suppl 3), 1051
Horváth R, 1564
Ho S, 709
Hoshino S, 1160
Ho SL, 1894, 2132
Howell JMC, 1352
Hsu W-C, 642
Hu B, 2140
Huber S, 62
Huber W, 1806
Hu C-J, 642
Hugg J, 496, 694, 2052
Hugg JW, 173
Hughes M, 2028
Hughes P, 62
Hughes RAC, 57, 466
Hughes TS, 167
Hunder GG, 1579
Hungs M, 1806
Husar W, 1676
Husstedt I-W, 357
Hutchison WD, 871
Hutsler JJ, 974
Hutton JT, 1012
Hutton M, 411
Hyland K, 91, 1205
Hyman BT, 1284, 2003

I

Iannaccone S, 1154
Ibáñez V, 96
Iba-Zizen MT, 396
Ida M, 1160
Idiaquez J, 1610
Ikeda K, 812, 894
Ikeda T, 1180
Ikezoe K, 2187
Imamura T, 413
Imbesi F, 1064
Inaba A, 181
Inzelberg R, 1602
Iriarte J, 933
Irizarry MC, 1284
Ishii K, 413
Italian CTS Study Group, 1654
Italian HIV-Seroconversion Study, 2032
Itoh Y, 181, 236, 1146
Ito M, 1749
Ives J, 2193
Ives JR, 1590
Iwasaki Y, 812, 894
Iwata H, 1749

J

Jackson GD, 715, 1462
Jacobs BC, 2122
Jacobs L, 1698
Jacobs LD, 139
Jacobson DM, 877, 1114
Jacova C, 1000
Jakob PM, 2193
Jaksch M, 855
Jamil F, 1511
Janardhan V, 1151
Jani A, 1352
Janjua FN, 813
Jankovic J, 813, 1431, 2102
Janßen G, 1564
Jaster JH, 658
Jayakumar PN, 32A
Jayaweera DT, 1365
Jen J, 34
Jenkins JA, 644
Jenkins MA, 819
Jensen CV, 149
Jeret JS, 658
Johkura K, 1138
Johns DR, 1787
Johnson CC, 1158
Johnson MA, 2082
Johnson SC, 1300
Johnston JM, 228
Johnston LH, 1868
Joh T, 1660
Jolesz FA, 758
Jones CR, 1201
Jones DK, 1051
Jones T, 2199
Joosten J, 213
Jordan BD, 892
Jorge RE, 543
Joshi S, 421
Jost W, 1026, 1564
Joynt RJ, 1896
Jubelt B, 1225
Juhász C, 2037
Jurewicz AM, 1409

K

Kaanders HAM, 213
Kahana E, 1328
Kahana I, 1328
Kaji M, 437
Kaji R, 1156
Kalashnikova LA, 223
Kalmijn S, 1959
Kälviäinen R, 922
Kamata T, 181
Kammann E, 331
Kamphorst W, 1373
Kanazi GE, 245
Kaneko S, 1749
Kanner AM, 933, S26 (Sept, suppl 2)
Kanno T, 617
Kapeller P, 132
Kaplan RF, 819
Kaprio J, 995
Karanjia PN, 424
Karcagi V, 1564
Karni A, 883
Karpati G, 1352
Karp B, 96
Kasner SE, 423, 424
Kassubek J, 1893
Kaste M, S32 (Oct, suppl 4)
Katayama K, 2182
Kato T, 619, 1761
Kattah JC, 177
Katz JS, 1071
Kaufer DI, 1292
Kawahara N, 208
Kawai J, 864
Kawamata T, 864
Kawanami T, 619
Kawashima S, 1671
Kayano T, 181
Kaye EM, 249
Keane JR, 652, 895
Kean MJ, 715
Keel JC, 2069
Keime-Guibert F, 1719
Kelkar P, 891
Kelly JP, 892
Kemler MA, 1350
Kennard C, 2209
Kennedy DN, 723, 1260
Kennedy WR, 1614
Keran C, 284
Kett DH, 1365
Ketter TA, S53 (Sept, suppl 2)
Khachaturian A, 321
Khan T, 439
Khoury SJ, 758
Kieburtz K, 391
Kieltyka J, 1774
Kieseier BC, 20
Kikinis R, 758
Kilbourn MR, 371
Killian JM, 1692
Kim JS, 889, 1155
Kim M, 2017
Kimmel DW, 659
Kim SH, 2073
Kimura H, 2182
Kimura J, 1156, 1671, 1833
Kindy MS, 1391
Kinkel PR, 1151
Kinkel RP, 139, 625
Kinoshita M, 812, 894
Kiolbasa T, S39 (Sept, suppl 2)
Kippes CM, 868
Kira J, 2187
Kirino T, 208, 654
Kirk A, 527
Kish SJ, 1032
Kissel JT, 1641
Kitagaki H, 413
Kitamoto T, 181
Klein C, 566
Klopstock T, 855
Klunk W, 1292
Knopman D, 899
Kobayashi H, 50
Kobayashi K, 1749
Koch CA, 1161
Koelman JHTM, 2196
Koeppe RA, 371
Koga M, 2122
Kohara N, 1156
Kohno S, 617
Koh S, 915
Kokmen E, 795
Koller M, 1431, 1439
Koller WC, 1012, 1447, 1774
Kolodner K, 988
Komatsumoto S, 1138
Komu M, 303
Komure O, 864
Kondo I, 1180
Konishi J, 1833
Kopylev L, 1518
Korczyn AD, 223, 364, 1328
Kornberg AJ, 2127
Koroshetz WJ, 1373
Koski CL, 894
Kossoff S, 2216
Koutroumanidis M, 490, 1892
Kowall NW, 1239
Kozovska ME, 1692
Krack P, 2169
Kraft E, 1135
Kragh–Sorensen P, 1992
Kramer L, 2212
Krauss G, 2073
Krauss GL, 2082, 2215
Krebs HI, 1874
Kreiss Y, 1606
Kremer B, 1000
Kriegstein AR, 1765
Kreutzberg GW, 2199
Krishnamurthy KB, 1590
Krumholz A, S76 (Sept, suppl 2), 2215
Kryscio RJ, 1161, 1391, 1458
Kuban KCK, 1205
Kubota K, 1376
Kuh D, 308
Kuhl DE, 371
Kuivaniemi H, 297
Kulisevsky J, 573
Kumar R, 561, 871
Kume H, 208
Kümpfel T, 772
Kumral E, 647
Kunkel RS, 868
Kun LN, 1860
Kuno S, 864
Kuntzer T, 1364
Kuo C-C, 1888
Kurimoto M, 1104
Kurita H, 654
Kuriyama M, 2182
Kurlan R, 2108
Kuroiwa Y, 1138
Kuzniecky R, 496, 687, 694, 709, 1511, 2052
Kuzniecky RI, 173
Kwan E, 1312
Kwee IL, 1599
Kwon SU, 1155
Kyriallis K, 1076

L

Laakso M, 825
Laakso MP, 1825
Labiner D, 656
Labuda M, 1854
Laccone F, 801
Lafont S, 1953
Lago A, 861
Lahiri DK, 2010
Lai F, 331
Lajaunie M, 139
Lallone RL, 154
Lamberti P, 1415
Lamictal Pediatric Partial Seizure Study Group, 1724
Lamont BH, 435
Lancman M, S33 (Sept, suppl 2)
Landi F, 508
Landis DMD, 650
Landolfi J, 438
Landsberg L, 2151
Lang AE, 561, 871, 1969
Langan Y, 1276
Lang CJG, 1370
Lange KW, 1026
Langston JW, 1382
Lanska DJ, 655, 1161, 1891
Laowattana S, 1736
Lapane KL, 508
Larsen JP, 364
Larson EB, 1480
Larsson C, 1265
Lassmann H, 220
Lau CS, 1894
Launer LJ, 537, 1992
Lavebratt C, 1254
Lavin PJM, 167
Lawlor BA, 946
Laxer KD, 2211, 2212
Lebowitz BD, 315
Leckman JF, 2108
Le Couter DG, 658
Le DA, 1373
Ledbetter DH, 270
Lee C-C, 642
Lee D, 1660
Lee G, 2028
Lee GP, 260
Lee J-C, 1698
Lee K, 2028
Lee K-Y, 642

Lee MA, S41 (Sept, suppl 1)
Lee M-L, 1473
Leeper HA, 1665
Lee SK, 1155
Lee WB, 2204
Lefly D, 723
Leidy NK, 162
Leigh PN, 1051
Leigh RJ, 244
Leira E, 122
Leira EC, 126
Leisti J, 297
Lempert T, 1358
Lenercept Multiple Sclerosis Study Group, 457
Lenkinski RE, 211
Lennon VA, 1233
Leong LLY, 2132
Leonido–Yee M, 782
Leppert D, 62
Leproux F, 632
Lesser RP, 2073
Leston JE, 543
Leta R, 1628
Letellier P, 632
Letenneur L, 1953, 1992
Lettry–Trouillat R, 1364
Leventer RJ, 715
Levi G, 1876
Levine SR, 424
Levin KH, 1149
Levinson DF, 1503
Levinson G, 1087
Lévy C, 117
Levy HL, 1205
Levy LM, 639
Levy SR, 1742
Lew MF, 1431, 1439
Lhermitte F, 241
Libenson MH, 265
Liberman JN, 988
Liblau R, 396, 1091
Li C, 880
Licastro F, 1888
Li CY, 337
Li DKB, 448
Lieberman AN, 658
Li FY, 1265
Li G, 2215
Liguori M, 1402
Li LSW, 2132
Li LYJ, 891
Lincoln SJ, 1858
Lindor NM, 216
Linfante I, 1332
Lin YY, 885
Liow K, 1518
Liporace J, 656
Lipton RB, 988, 1974
Li S, 1692
Litt M, 34
Litvan I, 1292, 1910
Liu C, 2140
Liu F, 375
Liu GT, 877
Liu H-C, 642, 962
Liuzzi GM, 1402
Livrea P, 1402
Lobo A, 1992
Lochmüller H, 1564
Loftus WC, 974
Logtenberg T, 837
Lolli F, 1498
Lo Monaco M, 1654
Longstreth WT Jr., 386
Looi JCL, 670
Lopez IA, 375
López-Navidad A, 1369
Lopez OL, 1292, 2217
Loring DW, 260, 2028
Lo SK, 2132
Lövblad KO, 1528, 2193
Loveless JM, 1421
Lovestone S, 1907
Lowenthal A, 825
Lozano AM, 561, 871
Lubetzki C, 1091
Lublin F, 1893
Luca AD, 2032
Lucas J, 201
Lucchinetti CF, 407, 1615
Lucke JF, 189
Lücking CH, 1020, 1893
Lüdemann P, 1892
Lüders HO, 427, 2045
Ludin H-P, 566
Luijckx GJ, 1246
Lundberg PO, 2190
Lundbom N, 303
Lu S-R, 1887
Lynch T, 1765
Lyon-Caen O, 396, 1091
Lyons EA, 1611
Lyons K, 1774
Lyons KL, 1447

M

Maassen EM, 213
Maccario J, 1197
Macdonald DR, 1141
MacDonald ME, 1330
Macdonell RAL, 1347, 1462
Mackay MT, 2127
MacLeod MJ, 418
MacManus D, 751
MacManus DG, 466
Madison A, 2214
Maeda M, 2182
Maeda S, 637
Maggio WW, 938
Magoni M, 2213
Mainero C, 622
Maioli F, 416
Majors AW, 71
Mak E, 2097
Makris N, 1260
Mak W, 1894
Malagù S, 573
Malaspina A, 1064
Malischke LM, 1212
Mallory GB Jr., 1542
Mallory M, 1570
Mamoli A, 112
Mamourian AC, 1300
Manasco P, 1724
Mander A, 197
Manning EL, 1458
Mannix LK, 868
Mannon LJ, 880
Mansbach HH, 424
Mäntyjärvi M, 922
Manz HJ, 177
Manzur KL, 743
Maraganore DM, 795, 1342, 1858
Marchioni E, 26
Marconi R, 573, 1415
Marczinek K, 801
Marder K, 391, 789
Mariani C, 50, 1888
Markesbery WR, 1458, 1495
Markopoulou K, 1382, 2097
Markowitz M, 657
Marler JR, S3 (Oct, suppl 4)
Marnett LJ, 1495
Marres HAM, 213
Marrosu MG, 433
Marson DC, 1983
MARS Study Group, 982
Martens-Davidson A, 139
Martin C, 1361
Martinelli F, 888
Martinelli P, 1374
Martinelli V, 1705
Martinez–Lage JM, 1992
Martin-Miguel C, 1892
Martin R, 496, 687, 694, 709
Martin RC, 1511, 2052
Martin W, 1000
Martocchia A, 622
Masaki KH, 337
Mascalchi M, 1498
Masdeu JC, 892
Mas JL, 1886
Masliah E, 1570
Mast H, 421
Matheson J, 2193
Mathur A, 1781
Maton BM, 2045
Matsuda C, 1119
Matsui T, 2208
Matsumine H, 1602
Matsumoto JY, 635
Matsumoto N, 270
Matsushita M, 181, 236, 1146
Matsuura E, 2187
Matsuzawa H, 1599
Matthews PM, 612
Mauguière F, 1882
Mauskopf J, 657
Mavromatis I, 1076
Mayer RF, 894
Mayer SA, 2216
Mayeux R, 517, 789
Mayordomo F, 861
McAbee G, 2214
McAllister TW, 1300
McArthur JC, 391, 1634
McBride MC, 434
McCann SJ, 658
McCarron MO, 1308, 2176
McCormick WC, 1480
McCurry SM, 1480
McDermott MP, 391, 743
McDonald WI, 448
McDonnell GV, 893
McDonnell SK, 1342, 1468, 1858
McFarland HF, 448
McFerrin J, 2184
McGeer PL, 411
McGowan JC, 3 (Sept, suppl 3), 23 (Sept, suppl 3), 49 (Sept, suppl 3)
McInturff B, 1983
McKay WJ, 2179
McKeith IG, 902
McMahon W, 2108
McNamara JO, 699
McNamara M, 2003
Meador K, 687
Meador KJ, 260, 2028
Means E, 162
Meco G, 1159, 1415
Meddings JB, 2093
Meder JF, 1886
Meekins G, 1201
Mehta KM, 1959
Meier D, S3 (Oct, suppl 4)
Meiklejohn D, 418
Meineri P, 1123
Mejico L, 177
Melamed E, 439
Melberg A, 79, 2190
Mellick GD, 658
Mendell JR, 1641
Menkes D, 605
Menon RS, 1665
Meola G, 1042
Merkies ISJ, 1648
Merriam G, S3 (Sept, suppl 1)
Mesenbrink P, 2212
Metz LM, 2093
Meulstee J, 598
Meyer B-U, 106
Meyer MR, 321
Meyer P, 371
Mezaki T, 1156
Mezei M, 1000
Mian AY, 915
Michele GD, 1606
Michel U, 1584
Middleton L, 1076
Mielke O, 1104
Miernicki M, 1660
Mietus JE, 1590
Miglioretti DL, 2073
Miletich RS, 1151
Millar WS, 1765
Miller DE, 139
Miller DH, 33 (Sept, suppl 3), 448, 466, 751, 1184, 1893
Miller EN, 782
Miller GM, 402
Miller K, 1397
Miller KM, 62
Miller NR, 2082
Miller RG, 1225
Milling C, 652
Milone M, 1076
Minagar A, 433, 1862
Minghetti L, 1876
Ming X, 1676
Minor LB, 2158
Minoshima S, 371
Minshew NJ, 2145
Minthon L, 1488
Mirabella M, 830
Mirandola P, 1367
Miró O, 241
Mishima K, 208
Miszkiel KA, 1184
Mitsudome A, 1749
Mitsumoto H, 71, 248
Miyai I, 1376
Miyajima H, 617
Miyazawa Y, 344
Mizuno Y, 1602
Mizusawa H, 181, 236, 1146
Mochimaru F, 225
Mohrenweiser HW, 830
Mohr JP, 421
Moiola L, 1705
Mokri B, 402
Molinuevo JL, 1719
Molyneux PD, 751
Monini P, 2032
Mönkemüller KE, 658
Montano S, 386
Montermini L, 1854
Montesanti R, 1425
Montgomery EB Jr., 625
Montine TJ, 1495
Montouris GD, 2211, 2212
Monza D, 502
Morawetz R, 687, 694, 709, 1511
Morbin M, 846
Morgese G, 230
Mori E, 413
Mori H, 1375
Moro E, 85
Morrell M, 656
Morrell MJ, S42 (Sept, suppl 1)
Morresi S, 230
Morris GL, 2211, 2212
Morris GL III, 1731
Morris HR, 411
Morris JC, 956
Morris–Rosendahl DJ, 801
Morrow JD, 1495
Morrow MJ, 244
Morten K, 1265
Morten KJ, 612
Mortier W, 1564
Morton-Bours EC, 233
Mor V, 508
Moseley IF, 466, 1184
Moseley ML, 1854
Moser DJ, 819
Moshé SL, 1168
Moslemi A-R, 79
Moster ML, 877
Mostofsky SH, 1345
Mottaghy FM, 1806
Mouradian MM, 91
Moxley RT, 1042
Mubaidin A, 1076
Muehlhauser F, 1104
Mueller WM, 1731
Müller-Felber W, 1564
Multiple Sclerosis Collaborative Research Group, 139, 1698
Munsat TL, 1225
Munschauer FE III, 139
Murillo FM, 50
Muroi A, 890
Murphy PL, 278
Murray JJ, 1431, 1439
Murray TJ, 485
Murry KR, 1611

Musch DC, 858
Muthane UB, 32A
Muzik O, 1473, 2037
Myers G, 1377
Myers LW, 154, 1190
Myers R, 2199
Myers RH, 1330
Myhr K-M, 1098
Myllylä R, 297
Myllylä V, 297
Mylonas I, 1076

N

Nadel A, 2010
Naegeli C, 1364
Nagahama Y, 1833
Nagai R, 619
Nagamatsu K, 2187
Nagaraja HN, 1641
Nagasaka T, 637
Nagy F, 2037
Nagy Z, 364
Najjar S, S13 (Sept, suppl 2)
Najm IM, 2045
Nakada T, 1599
Nakamura S, 1671
Nakamura Y, 218
Nakano I, 344
Nakano S, 1671
Nalbantoglu J, 1352
Nänto–Salonen K, 303
Nashef L, 1276
Nash SM, 1641
Nash TE, 777
Natelson BH, 1340
Nations SP, 1071
Naumann M, 659, 1850
Nau R, 242, 1584
Neary D, 1159
Nelson DR, 71
Nelson SF, 34
Nennesmo I, 2190
Neocleous V, 1076
Neri G, 430
Nesi B, 416
Neuhauser H, 1358
Neurological AIDS Research Consortium, 391
Newell K, 605, 1284, 2003
Newsom–Davis J, 1265
Ng TC, 71, 2045
Nicastri E, 2032
Nicholl DJ, 1415
Nichols M, 2028
Nickles RJ, 1212
Nicoletti A, 2064
Nicoletti G, 557, 1425
Nicolle MW, 1083, 1932
Niehaus L, 106
Nieto JCR, S26 (Sept, suppl 2)
Nigro V, 1549
Niimura K, 1473
Nikoskelainen E, 922
Nishizawa S, 1833
Nisipeanu P, 1602
Nixon RA, 331
Noachtar S, 427, 629
Nobile-Orazio E, 2206
Nochlin D, 1888
Noetzel MJ, 446
Nolte D, 801
Noori NE, 375
Nordgren RA, 974
Nordgren RE, 974
Norell JE, 2113
Norton MC, 321
Nortvedt MW, 1098
Nose H, 1160
Noseworthy JH, 444, 659
Notermans NC, 1573
Nousiainen I, 922
Novak V, 1641
Novelli G, 830
Novis SAP, 1335
Nutt J, 34
Nygaard T, 1219
Nygaard TG, 1032
Nyland HI, 1098

O

Oakes TR, 1212
Obayashi T, 344
Obeid T, 1372
Obert M, 1893
O'Brien C, 1431
O'Brien PC, 893, 1107
O'Brien TJ, 1611
Ochsner F, 1364
O'Connor P, 485
O'Craven KM, 1260
Oda Y, 1633
O'Donnell HC, 1135
O'Duffy JD, 1579
O'Fallon WM, 532
O'Halloran HS, 2204
Ohno K, 1076
Ohshima K, 1854
Oizomi K, 437
Ojemann L, 2211, 2212
Okamura N, 2208
Okeda R, 181
Oldfors A, 79
Olek MJ, 1711
Olesen J, 995
Oliveira C, 1335
Oliveri RL, 557, 1425
Onaya T, 637
Once Weekly Interferon for MS Study Group (OWIMS), 679
Ongerboer de Visser BW, 2196
Onorato J, 605
Onstead L, 411
Ooki N, 225
Oppenheimer S, 1896
Orange JB, 1665
Orav EJ, 758
Orgogozo JM, 1953
O'Riordan JI, 1184
Orrico D, 846
Osborne D, 201
Osinaga R, 2064
Østbye T, 521
Otomo E, 181, 236, 1146
Ott A, 1593, 1937, 1959, 1992
Ottman R, 789
Overman J, 1447
Özdemir C, 1076

P

Pact V, 1154
Padua L, 1654
Padua R, 1654
Pahwa R, 1447, 1774
Palace J, 466
Pal DK, 2058
Paleologos NA, 1141
Pambakian ALM, 2209
Panda K, 32A
Pandey N, 1781
Pandolfo M, 1854
Pandya S, 743
Pan JT, 885
Pantzaris M, 1076
Paolicelli D, 1402
Paolillo A, 751
Papanicolaou AC, 938
Papka M, 1377
Papponen H, 297
Paradisi F, 2064
Paridi D, 502
Pari G, 1352
Parisi JE, 795
Parker RA, 1528
Parra J, 933
Parry GJ, 891
Partanen J, 922
Partanen K, 922
Pasqua AA, 1425
Pasqualetti P, 1451
Passero S, 1451
Patel SC, 424
Patronas NJ, 777
Paty DW, 437, 448
Pauli RM, 50
Pauls DL, 2108
Paulson OB, 149
Paul SR, 2082
Pavone L, 478
Pearl PL, 1128
Pearlson GD, 2145
Pearson PA, 2204
Pedersen NL, 1254
Pedley TA, 906
Pedrol E, 241
Pegoraro E, 50
Pelak VS, 1130
Pellecchia MT, 1606
Pellock JM, 1724
Penco S, 404
Pennington BF, 723
Perani D, 1042
Percy AK, 1617
Pérez M, 1219
Pérez-Tur J, 411, 1219
Pergolide Monotherapy Study Group, 573
Periquet MI, 1641
Perra L, 433
Perretti A, 1606
Perrine K, 260, S39 (Sept, suppl 2)
Perry EK, 902
Perry JD, 2082
Perry RH, 902
Pessin MS, 1312
Petajan JH, 1201
Petersen HC, 473
Petersen RC, 411, 795
Peterson EL, 1158
Petersson A-S, 1880
Petersson S, 1254
Petrie MD, 743
Petrovitch H, 337
Petty GW, 532
Pezzotti P, 2032
Phelan EM, 715
Piatti M, 26, 38
Pickering S, 1447
Piepgras DG, 402
Pierre–Louis S, 933
Pifl C, 1032
Pihlajamäki M, 1825
Pilz DT, 270
Pioro EP, 71
Pirini MG, 1498
Planchenault T, 1683
Plant GT, 1184
Plasmati R, 1498
Plassman BL, 321
Plaster NM, 1180
Plastino M, 557
Poewe WH, 364
Poirier J, 1854, 2087
Polizzi A, 478
Polkey CE, 490, 1276, 1892
Poloni TE, 1064
Pols HAP, 1937
Pombo-de-Oliveira MS, 1335
Pongratz D, 1564
Poorkaj P, 864
Poron F, 1683
Post RM, S53 (Sept, suppl 2)
Powers WJ, 251
Pozzilli C, 622, 1588
Pradhan S, 1781
Prasad AN, 265
Pras E, 1606
Prat A, 2087
Preier M, 1026
Prestigiacomo CJ, 421
Preux PM, 1059
Price K, 1032
Price R, 386
Primavera A, 895
Privitera. M, 2211
Probst A, 62
Proietti A, 622
Pruitt AA, 211
Ptáček LJ, 1180
Puca AA, 1549
Puccioni-Sohler M, 1335
Pullicino P, 2215
Pulst SM, 1787
Puoti G, 2173

Q

Quality Standards Subcommittee, 239
Quan D, 211
Quattrini A, 1154
Quattrone A, 557, 1425

R

Raaymakers TWM, 982
Rabheru K, 946
Radice D, 502
Radtke A, 1358
Radziwill AJ, 1364
Raininko R, 2190
Rajaram L, 1480
Rajput AH, 1032, 1375
Ramaekers V, 1564
Ramsden DB, 1415
Randazzo AP, 433
Rand JH, 1523
Ranum LPW, 1854
Raphaël J-C, 1683
Rapin I, 1168
Raschetti R, 1159
Rasmussen A, 946
Ratcliff G, 189
Ravaglia G, 416
Raval S, 1676
Raymond LA, 1000
Read SJ, 2179
Reaume AG, 1239
Rebeck GW, 331
Rebrova O, 223
Reggio A, 2064
Reid E, 1844
Reifenberger G, 629
Reiman EM, 201
Reiners K, 1026
Reinhardt M, 1020
Reis IL, 639
Remy P, 1963
Reñé R, 1719
Reshetnyak T, 223
Reuter U, 1365
Reynolds C, 730
Reynolds MD, 228
Rey RC, 1132
Rezza G, 2032
Rhodes M, 1844
Rhoney DH, 1611
Ricamato A, 736
Ricci E, 50, 830
Riccio P, 1402
Richard IH, 1, 247, 443, 661
Richards M, 308
Richert JR, 139
Richert ND, 29 (Sept, suppl 3)
Riedel A, 1020
Riekkinen P Sr., 825, 922
Riess O, 801
Rifici C, 1893
Riggs JE, 1158
Righetti PG, 26, 38
Riise T, 1098
Ringel K, 1126
Ringel SP, 284, 2216
Rios M, 1335
Risner M, 1724
Ristori G, 1588
Riva R, 1374
Rivera VM, 1692
Rizzuto N, 846
Roach ES, 7
Roberts AD, 1212
Roberts LJ II, 1495
Robertson MM, 2108
Roberts TPL, 548
Robinson A, 1225
Robinson RG, 543
Robyn JA, 1161
Rocca MA, 1705
Rocca WA, 1342, 1468, 1858

Rocchi R, 38
Rodnitzky RL, 1439
Rodriguez BL, 337
Rodriguez D, 1373
Rodriguez E, 1087
Rodriguez M, 893, 1615
Rognoni F, 1064
Romas SN, 517
Rome S, 1794
Romito LMA, 85
Roos K, 1162
Röricht S, 106
Rosa G, 830
Roselli M, 2064
Roselli R, 85
Rosenbaum DM, 652
Rosenberg GA, 1380
Rosenberg J, 239
Rosenblum WI, 242
Rosenmann H, 1328
Ross BD, 249
Ross GW, 337
Rossi G, 2173
Rossini PM, 1451
Rossi S, 1451
Ross ME, 270
Rossol S, 1104
Rost N, 573
Rothwell JC, 664
Rovaris M, 40 (Sept, suppl 3)
Rowland LP, 278
Rozen TD, 1468
Rozzini L, 2213
Rubin DI, 635
Rubinow DA, 2069
Rubinsztein DC, 1844
Rubio A, 1361
Rüdel R, 1564
Rudick RA, 139, 1698
Ruff RL, 1556
Ruggieri M, 478, 1402
Ruggieri S, 364, 1588
Rupprecht R, 772
Ruprah M, 2209
Russell MB, 995
Ryan S, 2204
Rybicki BA, 1158
Rye DB, 1868
Ryvlin P, 1882

S

Sabatini U, 1588
Sabuda D, 2093
Sacco RL, S15 (Oct, suppl 4), S32 (Oct, suppl 4)
Sachdev PS, 670
Sachinidis JI, 2179
Sacktor N, 391
Sadato N, 96
Sahenk Z, 1641
Sahrmann S, 956
Said G, 62, 1614
Sailer M, 1893
Sakamoto N, 1854
Salani G, 1888
Salazar AM, 139
Salazar E, 2064
Salvetti M, 1588
Salvi F, 1498, 1705
Samii A, 2097
Samijn JPA, 1648
Sampaolo S, 1549
Samson Y, 1963
Sánchez–Pernaute R, 806
Sander HW, 605, 892, 1889
Sander JWAS, 657, 1170
Sandor P, 2108
Sandoval E, 1610
Sanges G, 1549
Sangiuolo F, 830
Sanjak M, 743
Sannino V, 1549
Sansone V, 1042
Santacroce MP, 1402
Santoro L, 1606
Santos TC, 915
Saperstein DS, 1071
Sapolsky RM, 1922
Saposnik G, 1132
Sarris BM, 1367
Sasahara M, 864
Sasaki H, 2208
Sasaki T, 208
Satoh S, 181
Satoi H, 1671
Sato Y, 437
Saunders AM, 2176
Sautereau D, 1059
Savoiardo M, 502
Sawrie S, 687, 2052
Sawrie SM, 1511
Sawyer J, 988
Saxton JA, 189
Saykin AJ, 1300
Scala R, 1606
Scammell T, 2193
Scarlato G, 2206
Scerrati M, 85
Schachter SC, 2211, 2212
Schaefer PW, 1135, 1373
Schalling M, 1254
Schara U, 1564
Scharf S, 197
Schaumburg HH, 592
Scheffer IE, 1462
Schein RMH, 1365
Scheithauer BW, 1579
Schelfhout VJ, 435
Schellenberg GD, 864, 1480
Schenone A, 404
Schielke E, 1365
Schiffer D, 1123
Schifitto G, 391
Schlaug G, 239, 1528
Schlegel U, 220
Schlotter B, 1564
Schlüter G, 801
Schmidley JW, 2216
Schmid R, 1754
Schmidt H, 132
Schmidt PJ, 2069
Schmidt R, 132
Schmidt S, 220
Schmitt FA, 1391, 1458
Schmitz PIM, 409, 598, 1648, 2122
Schneider O, 1584
Schnitzer R, 1020
Schoener C, 1087
Schomer DL, 1590
Schon F, 2209
Schriever S, 629
Schueller MJ, 1212
Schulman J, 1087
Schultz LR, 424
Schutzer SE, 1340
Schwartz RL, 2017
Schwid SR, 444, 743, 1162
Sciacca FL, 888
Scoggan KA, 1932
Scolari S, 2207
Scott AM, 2179
Scott P, 424
Scott RW, 1239
Searl JP, 1447
Seelos KC, 1800
Segawa H, 654
Seidel U, 1564
Seidenberg M, S3 (Sept, suppl 2)
Seifert T, 20
Seino M, 926
Seitz RJ, 1375
Seitz RS, 154
Selmaj KW, 1409
Selman W, 650
Semah F, 440
Semprini S, 830
Serdaroğlu P, 1076
Servidei S, 830
Sessa E, 1893
Sette G, 1876
Sevilla MT, 861
Seysedadr M, 1660
Sferrazza B, 1154
Sgadari A, 508
Shah J, 2037
Shaikh ZA, 1151
Shajahan PM, 644
Shanske S, 1352
Shapiro MF, 1190
Shapiro S, 1225
Sharma K, 1862
Sharrack B, 57, 466
Sharshar T, 1683
Shashank S, 1781
Shatin D, 1190
Shavit S, 223
Shaw CM, 1888
Shaw D, 418
Shebert RT, 659
Shefner JM, 1239
Shetty R, 32A
Shewmon DA, 1371
Shield LK, 2127
Shimadzu M, 1032
Shimizu S, 890
Shindo K, 637
Shinnar S, 1742
Shinohara Y, 225
Shio H, 1833
Shiozaki T, 1833
Shiozawa Z, 637
Shoji S, 1160
Shoubridge E, 1352
Shrinidhi J, 1330
Shulman LM, 433, 1862
Shungu DC, 1765
Shyu HY, 962
Sica REP, 1132
Sicks JD, 532
Siddique T, 411
Sidell KR, 1495
Siegel H, 1518
Siewert B, 1528
Silberfarb AW, 974
Silberstein S, S3 (Sept, suppl 1)
Sileo C, 112
Silverman JM, 2217
Silver NC, 33 (Sept, suppl 3)
Sime E, 561
Simell O, 303
Simmons A, 1051
Simonati A, 846
Simon DK, 1787
Simonetti F, 2207
Simonian N, 139
Simon J, 1698
Simon JH, 139, 448, 723
Simos PG, 938
Singer C, 1439
Singer HS, 1345
Singleton JR, 1201
Sipilä I, 303
Sisson ME, 1087
Sivenius J, 825
Siwek DF, 1239
Skalabrin EJ, 233
Skoog I, 321
Slevin JT, 1458
Sloan R, 874, 1397
Slooter AJC, 1593, 1959
Small S, 391
Smets P, 825
Smirne S, 1154
Smith AG, 1201
Smith CD, 1391, 1458
Smith MJ, 2069
Snow B, 1000
Sodeyama N, 236, 1146
So EL, 1611
Sofia V, 2064
Soininen H, 1825
Solimena M, 852
Soliveri P, 502
Solomon GD, 868
Sonesson C, 1605
Sora E, 736
Sorbi S, 1888
Sørensen PS, 149
Sørensen TL, 473
Sossi V, 2097
Soto O, 605
Soudain SE, 57
Spadafora P, 1425
Spanaki MV, 1518
Sparing R, 1806
Sparling MB, 1300
Speck O, 782
Speelman JD, 2196
Spila-Alegiani S, 1159
Spinazzola A, 830
Spinner RJ, 216
Spiro AJ, 241
Spranger M, S3 (Oct, suppl 4)
Squier W, 1265
St. Clair D, 418
Stabler G, 1397
Stafstrom CE, 1754
Stang PE, 1468
Stat. D, 2032
Stebbins G, 933
Steck AJ, 62, 914, 1364
Steele JC, 411
Steenhuis R, 521
Stefan A, 1367
Steffens DC, 321
Steinberg GK, 1922
Steinlin M, 966
Stengel LM, 1151
Stenirri S, 26, 38
Stern Y, 789, 1942
Stevanin G, 1355
Stevens JC, 892
Stewart T, 1397
Stewart WF, 988
Stievenart JL, 1091
Stijnen T, 1992
Stocchi F, 1415
Stoessl AJ, 2097
Stögbauer F, 1892
Stolk RP, 1937
Stolp-Smith KA, 893
Storey TW, 915
Stowe R, 1292
Straits–Tröster KA, 1774
Straumann D, 2158
Strauss E, 260
Streefland C, 1628
Stroke Prevention In Reversible Ischemia Trial(SPIRIT), 1319
Strong MJ, 1665
Strub MU, 914
Stucka R, 1564
Styger M, 966
Suarez GA, 635
Suematsu N, 181, 236, 1146
Suhr B, 357
Su MS, 885
Sung S-M, 642
Sun Y, 1087
Susuki K, 1138
Sutton JP, 1787
Suzuki T, 1376
Suzuki Y, 1761
Svenningsson A, 1880
Swanson JW, 1468
Swingler R, 466
Swoboda KJ, 1205
Syngeniotin A, 1462
Systematic Assessment of Geriatric Drug Use via Epidemiology (SAGE) Study Group, 508

T

Tagliavini F, 2173
Taioli F, 846
Tajima K, 619
Takagi A, 1160
Takahashi Y, 617, 926
Takashima M, 181
Taly AB, 32A
Tamaoka A, 1160
Tanaka C, 864
Tanaka Y, 344
Tandan R, 1225
Tandon P, 1754
Tan E-K, 2102
Tang M, 789
Tang M-X, 517, 1942

Tanimukai S, 864
Taniwaki T, 2187
Tanne D, 424
Tanno Y, 890
Tariq M, 1265
Task Force on Surgery for Parkinson's Disease, 1910
Tassinari CA, 1498
Tawata M, 637
Taylor MD, 1212
Tedroff J, 1605
Tembl JI, 861
Tempera G, 2064
Teng EL, 962
Tenser RB, 1893
Terwindt GM, 537
Tessa C, 1498
Testa D, 502
Testa FM, 1742
Thatcher RW, 736
the 053 Study Group, 364
Then Bergh F, 772
Theodore W, 898
Theodore WH, S53 (Sept, suppl 2), 1518
Thibodeau SN, 201
Thomas CE, 974
Thomas R, 2193
Thömke F, 894, 1126
Thompson AJ, 1184, 1893
Thornton CA, 743, 1042
Ticho BS, 1260
Tijssen JGP, S25 (Oct, suppl 4), S32 (Oct, suppl 4)
Tjia H, 1860
Tochon-Danguy HJ, 2179
Togashi S, 637
Tollar LL, 1932
Tolosa E, 1012
Tomasetti P, 430
Tonali P, 85, 830, 1654
Töpper R, 1806
Toppinen T, 297
Toribe Y, 1761
Tourbah A, 396, 1091
Tournier-Lasserve E, 3
Townsend JJ, 1130
Toyka KV, 659, 1246
t-PA Stroke Survey Group, 424
Trabucchi M, 1825
Tramo MJ, 243, 974
Treib J, 895
Trenerry MR, 260
Trenkwalder C, 772
Triggs WJ, 605
Trobe JD, 858
Trojan DA, 1225
Trojano M, 1402
Tromp G, 297
Trosch R, 1439
Tröster AI, 1774
Tröster AI, 1447
Truong TC, 1059
Truwit CL, 270
Tsai C-H, 642
Tsai W-Y, 1942
Tsang KL, 2132
Tschanz JT, 321
Tsingis M, 1076
Tsujino S, 1352
Tubridy N, 466
Tucha O, 1026
Tucker T, 244
Tuhrim S, 1523
Turkheimer FE, 2199
Twijnstra A, 382
Tycko B, 789
Tzourio C, 1948

U

Uchino M, 1180
Uecker A, 201
Uehara K, 225
Uehara Y, 1633
Ueki K, 208, 654
Uesaka Y, 1160
Ugoni A, 197
UK Antegren Study Group, 466
Ulivelli M, 1451
Ulrich V, 995
Umberger GH, 1458
University of British Columbia MS/MRI Analysis Group, 457
Upton–Rice M, 1239
Uyama E, 1180

V

Vagus Nerve Stimulation Study Group E01–E05, 1731
Vaishnavi S, 1596
Vajda F, 197
Valind S, 2190
Vallat JM, 1059
Vanacore N, 1159, 1415
Van Broeckhoven C, 1593
van Buchem MA, 23 (Sept, suppl 3)
Van den Berg LH, 837
van den Berg-Loonen EM, 1350
van der Knaap MS, 1373
van der Meché FGA, 409, 598, 1648, 2122
Vanderstichele H, 1488
van de Vusse AC, 1350
van de Wetering BJM, 2108
van Dijk GW, 1573
van Doorn PA, 598, 1648, 2122
van Duijn CM, 1593, 1959
van Gijn J, S32 (Oct, suppl 4), 1573
van Harskamp F, 1937
van Kleef M, 1350
Vanmechelen E, 1488
van Oene MD, 1932
van Oostenbrugge RJ, 382
van Overbeeke J, 213
Van Son MJ, 837
van Waesberghe JHTM, 46 (Sept, suppl 3)
Vazquez B, 2211, 2212
Veglia F, 888, 1888
Veldman H, 837
Vereczkey-Porter K, 424
Verghese J, 652, 1974
Verma A, 1365
Vernino S, 1233
Verro P, 424
Verrotti A, 230
Verstraete AG, 435
Vezina LG, 1128
Viaño J, 806
Vick NA, 1141
Vickrey B, 162
Vickrey BG, 284, 662, 1190
Vidal L, 1219
Vieira–Saecker AMM, 801
Viereggе P, 566, 1415
Vigil P, 1361
Viikinsalo M, 687, 1511
Vilchez JJ, 861
Villari N, 1498
Vinters HV, 375
Viselli F, 1588
Visser LH, 598
Vogel H, 293
Volpe BT, 1874
Volpe NJ, 1130
von Beust G, 801
von Brevern M, 1358
von Kummer R, S3 (Oct, suppl 4)
Vonsattel JP, 1330
von Spiegel T, 220
Voss H, 357
Vrièze FW-D, 411

W

Wada K, 1749
Wada Y, 181
Wadsworth M, 308
Wahlgren NG, S3 (Oct, suppl 4)
Wakata N, 894
Walczak AK, 1409
Wald J, 44
Walker MF, 1576
Wallace JD, 1431, 1439
Wall M, 1114
Walot I, 782
Walsh CA, 270
Walther EU, 1622
Wang AK, 1865
Wang B, 1373
Wang PN, 962
Wang SJ, 962, 1887
Wang Y, 2045
Warach S, 1528, 2193
Waring SC, 411
Wasay M, 1151
Wassermann EM, 2069
Wasterlain CG, 898
Watanabe H, 637
Watanabe T, 890
Waters N, 1605
Watson C, 2037
Watts RL, 1868
Waubant E, 874, 1397
Weaver A, 201
Weaver JB, 1300
Webber WRS, 2073
Weber BHF, 801
Weber JR, 1365
Weber WEJ, 1350
Weidenheim KM, 241
Weigell–Weber M, 801
Weil S, 629
Weinberger J, 1523
Weinberger M, 1839
Weiner HL, 758
Weiner WJ, 433, 1862
Weinrib L, 2087
Weinrich M, 1175
Weinshenker BG, 893, 1107
Weirich–Schwaiger H, 801
Weiser R, 573
Wekstein DR, 1458
Wells RD, 1854
Welsh-Bohmer KA, 321
Wende K, 139
Wendlandt J, 1345
Wernette K, 371
Werz MA, 650
Westerveld M, 260
Wheeler SD, 234
Wheless JW, 938
Whisnant JP, 532
Whitaker JN, 765
Whiteford ML, 1844
White LR, 337
Whitman GT, 375
Whitney KD, 699
Whyte J, 988
Wick M, 233
Wiebers DO, 532
Wiegartz P, S3 (Sept, suppl 2)
Wijdicks EFM, 1369
Wilczak N, 1628
Wilkins DE, 239
Wilkinson H, 819
Wilkinson SB, 1447, 1774
Williams AC, 1415
Williams LS, 1839
Williamson EM, 2209
Williams SCR, 1051
Willian MK, 162
Willmer–Hulme A, 1431, 1439
Willmore LJ, 938, 2211, 2212
Winblad B, 1488, 1998
Windebank AJ, 407
Wingerchuk DM, 659, 1107
Witteman JCM, 1593
Witt M, 782
Woessner R, 895
Wokke JHJ, 837, 1573
Wolfe GI, 1071
Wolf PA, S15 (Oct, suppl 4)
Wolinsky JS, 448
Womble G, 1724
Wong JG, 1367
Wong M, 1542
Wong WC, 2132
Wong W-K, 642
Woodard A, S3 (Sept, suppl 2)
Woolson RF, 122, 126
Woo S-I, 1570
Wszolek ZK, 2097
Wu X, 1523
Wu YW, 1271
Wu ZA, 885
Wyse BW, 321

Y

Yagi K, 926
Yamada KA, 1542
Yamada M, 181, 236, 1146
Yamada T, 2187
Yamaji S, 413
Yamamoto T, 890
Yamamoto Y, 864
Yamauchi H, 1833
Yanagawa H, 218
Yanofsky N, 1300
Yano K, 337
Yan RS-H, 605
Yasha TC, 32A
Yasuda M, 864
Yates KO, 2145
Yen SH, 885
Yerby M, 656
Yian SY, 1860
Yoneda M, 2182
Yonekawa O, 617
Yoshii F, 225
Yoshikawa H, 1633
Yoshimura T, 2187
Young C, 466
Young J, 2151
Young MS, 605
Yousem DM, 880
Yousry TA, 629
Yue Q, 34
Yu H, 34
Yuki N, 2122
Yu X, 1570

Z

Zahn C, 239, 656, S34 (Sept, suppl 1)
Zaidat OO, 650
Zamba E, 1076
Zang YCQ, 1692
Zappalà G, 315
Zappia M, 557, 1425
Zazulia AR, 351
Zee DS, 1576, 2158
Zeiler B, 1026
Zenarestat Study Group, 580
Zhang JZ, 1692
Zhang Z, 1458
Zhu SW, 1335
Zifko UA, 1083
Zimmerman LE, 177
Zinn AB, 244
Ziv I, 439
Zivin JA, 14, 2140
Zollino M, 430
Zouridakis G, 938
Zuber M, 1886
Zuddas A, 433
Zühlke C, 801
Zunt JR, 386
Zysk G, 1584